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Abstract 
Brucellosis is a widespread neglected zoonotic disease. It can cause severe and 
prolonged illness in people, as well as impacting on animal health and 
productivity. Brucellosis is endemic in much of sub-Saharan Africa (SSA). The 
global burden of brucellosis is suspected to be highest in SSA, where there are 
many livestock-keeping communities. Cattle, sheep and goats are common 
maintenance hosts of zoonotic Brucella spp. Pastoralist communities in frequent 
contact with these livestock species are at increased risk of infection. This study 
was performed to improve our understanding of the epidemiology of brucellosis 
in Tanzania through: a risk factor analysis for human acute brucellosis cases; 
trialling an active surveillance approach to identify additional cases through 
household screening in a high-risk population; and latent class analyses to 
evaluate diagnostic test performance in different animal hosts. 
 
In Chapter 2, questionnaire data were collected from febrile patients attending 
a rural hospital in the Ngorongoro Conservation Area (NCA), Tanzania. Risk 
factors associated with acute brucellosis were: having herded cattle, sheep 
and/or goats in the past 12 months; and decreasing age in years. In Chapter 3, 
active surveillance in the form of screening household members of febrile 
patients for exposure to Brucella spp. was implemented in the NCA. Screening 
household members of febrile patients with acute brucellosis led to 
identification of additional acute cases. However, the study did not find a 
significant association between the Brucella spp. exposure of household 
members and the household member who sought care at hospital. In Chapter 4, 
Bayesian latent class analyses were used to evaluate the Rose Bengal plate test 
(RBT) and the competitive enzyme-linked immunosorbent assay (cELISA) for the 
diagnosis of livestock brucellosis in northern Tanzania. Sensitivity was variable 
across livestock models, RBT sensitivity was comparable to cELISA in the bovine 
model and greater than cELISA in ovine and caprine models. RBT and cELISA 
specificity was essentially comparable in all livestock models. Conducting 
parallel RBT and cELISA testing optimised diagnostic test performance in all 
livestock models. 
 
These novel findings can inform the development and implementation of 
effective, evidence-based brucellosis prevention and control measures in SSA. 
Improved knowledge of acute human brucellosis risk factors is important in 
understanding temporally relevant risks associated with active infection and is a 
vital tool in developing interventions that prevent transmission. Active 
surveillance by screening household members requires further study but may 
prove too resource-intensive for routine implementation in Tanzania. However, 
it can provide valuable data on disease burden for the population that do not 
reach a healthcare facility, as well as assist in targeting prevention and control 
measures towards high-risk populations. In livestock, a parallel RBT and cELISA 
diagnostic testing approach, potentially implemented at the herd/flock level, 
would be more effective than using either test alone or serial approaches. Using 
these data, identification of a national sampling and testing approach can guide 
the development of a surveillance strategy which is a crucial step towards 
improving our understanding of brucellosis burden across livestock-keeping 
settings in Tanzania and wider SSA. 
  
  3 
Table of Contents 
Abstract ...................................................................................... 2 
List of tables ................................................................................ 8 
List of figures .............................................................................. 12 
Acknowledgements ....................................................................... 15 
Author’s declaration ...................................................................... 16 
Abbreviations .............................................................................. 17 
Chapter 1 Brucellosis in Tanzania: An introduction to a neglected zoonosis . 19 
1.1 The neglected zoonoses .................................................................. 19 
1.2 A short history of brucellosis ............................................................ 21 
1.3 The global burden of brucellosis ........................................................ 21 
1.3.1 Brucellosis in low- to middle-income countries ................................... 22 
1.4 Causative agent ............................................................................. 23 
1.5 Infection in humans ....................................................................... 25 
1.6 Infection in animals ........................................................................ 26 
1.7 Diagnosis ..................................................................................... 27 
1.7.1 Direct diagnostic tests ................................................................ 28 
1.7.2 Indirect diagnostic tests .............................................................. 28 
1.7.3 Active brucellosis versus Brucella spp. exposure ................................. 30 
1.8 Treatment ................................................................................... 31 
1.9 Brucellosis in pastoral sub-Saharan Africa ............................................ 32 
1.9.1 Human brucellosis in Tanzania ....................................................... 32 
1.9.2 Livestock brucellosis in Tanzania .................................................... 34 
1.10 Control strategies ........................................................................ 36 
1.10.1 Control in sub-Saharan Africa ...................................................... 37 
1.11 Overview of thesis aims ................................................................. 39 
Chapter 2 Risk factors for acute brucellosis in febrile patients from a 
pastoralist community ................................................................... 41 
2.1 Introduction ................................................................................. 41 
2.1.1 Study aims .............................................................................. 44 
2.2 Methods ...................................................................................... 45 
2.2.1 Study site and population ............................................................. 45 
2.2.2 Febrile hospital-based surveillance study .......................................... 46 
2.2.3 Febrile hospital study: Eligibility and enrolment ................................. 46 
  4 
2.2.4 Febrile hospital study: Blood sample collection & processing .................. 47 
2.2.5 Definition: Acute brucellosis case ................................................... 48 
2.2.6 Febrile hospital study: Participant questionnaire ................................ 48 
2.2.7 Risk factor analysis: Questionnaire data cleaning ................................ 49 
2.2.8 Risk factor analysis: Multiple correspondence analysis .......................... 50 
2.2.9 Risk factor analysis: Literature-informed logistic regression ................... 50 
2.2.10 Risk factor analysis: Exploring candidate variable relationships .............. 51 
2.2.11 Risk factor analysis: Lasso regression ............................................. 51 
2.2.12 Research clearance and ethics ..................................................... 52 
2.3 Results ........................................................................................ 53 
2.3.1 Risk factor analysis data set ......................................................... 53 
2.3.2 Multiple correspondence analysis ................................................... 55 
2.3.3 Literature-informed logistic regression ............................................ 59 
2.3.4 Exploring the relationship between sex, age and herded livestock candidate 
variables ........................................................................................ 64 
2.3.5 Lasso regression ........................................................................ 64 
2.4 Discussion .................................................................................... 65 
2.5 Conclusion ................................................................................... 71 
Chapter 3 Human brucellosis active surveillance: Screening household 
members of febrile hospital patients ................................................. 73 
3.1 Introduction ................................................................................. 73 
3.1.1 Study aims .............................................................................. 77 
3.2 Methods ...................................................................................... 78 
3.2.1 Study area ............................................................................... 78 
3.2.2 Febrile hospital study ................................................................. 78 
3.2.3 Definitions: Acute brucellosis case and Brucella spp. exposure ................ 78 
3.2.4 Febrile hospital participant sampling and RBT testing ........................... 79 
3.2.5 Definitions: Brucellosis positive and brucellosis negative febrile hospital 
participants .................................................................................... 80 
3.2.6 Household classification .............................................................. 80 
3.2.7 Definitions: BPH and BNH households .............................................. 81 
3.2.8 Household selection ................................................................... 81 
3.2.9 Selection of household members .................................................... 81 
3.2.10 Household participant sampling .................................................... 83 
3.2.11 Sample processing and laboratory diagnostics ................................... 84 
3.2.12 Power analysis ........................................................................ 84 
3.2.13 Statistical analyses ................................................................... 85 
  5 
3.2.14 Research clearance and ethics ..................................................... 86 
3.3 Results ........................................................................................ 87 
3.3.1 Febrile hospital study participants .................................................. 87 
3.3.2 Household participant characteristics .............................................. 88 
3.3.3 Aim 1: Determining if new acute brucellosis cases could be identified 
amongst the household members of febrile hospital participants with acute 
brucellosis ...................................................................................... 89 
3.3.4 Aim 2: Estimating the prevalence of Brucella spp. exposure amongst the 
household members of febrile hospital study participants ............................. 90 
3.3.5 Aim 3: Evaluating evidence of association between Brucella spp. exposure 
status of household participants and febrile hospital participants ................... 94 
3.3.6 Aim 4: Comparing the age and sex distributions of febrile hospital study and 
household member study participants ..................................................... 94 
3.3.7 Aim 5: Comparing the age and sex distributions of RBT-defined Brucella spp. 
exposed febrile hospital study and household member study participants .......... 96 
3.4 Discussion .................................................................................... 99 
3.5 Conclusion ................................................................................. 103 
Chapter 4 Evaluating the performance of serological tests in detecting animal 
brucellosis in Tanzania ................................................................. 104 
4.1 Introduction ............................................................................... 104 
4.1.1 Study aims ............................................................................. 108 
4.2 Methods .................................................................................... 109 
4.2.1 Study area .............................................................................. 109 
4.2.2 Study design ........................................................................... 109 
4.2.3 Sample collection ..................................................................... 112 
4.2.4 Rose Bengal plate test ............................................................... 112 
4.2.5 Competitive enzyme-linked immunosorbent assay .............................. 112 
4.2.6 Subpopulation classifications ....................................................... 113 
4.2.7 Statistical analyses: Bayesian Hui-Walter model ................................. 113 
4.2.8 Statistical analyses: Model assumptions ........................................... 114 
4.2.9 Statistical analyses: Prior distributions ............................................ 116 
4.2.10 Statistical analyses: Model implementation ..................................... 121 
4.2.11 Statistical analyses: Model sensitivity analyses ................................. 121 
4.2.12 Statistical analyses: Model diagnostics ........................................... 123 
4.2.13 Statistical analyses: Positive and negative predictive values ................ 123 
4.3 Results ...................................................................................... 125 
4.3.1 Livestock data ......................................................................... 125 
  6 
4.3.2 Bovine final model: Specifications ................................................. 125 
4.3.3 Bovine final model: Estimates and diagnostics ................................... 128 
4.3.4 Ovine final model: Specifications .................................................. 133 
4.3.5 Ovine final model: Estimates and diagnostics .................................... 135 
4.3.6 Caprine final model: Specifications ................................................ 137 
4.3.7 Caprine final model: Estimates and diagnostics ................................. 139 
4.3.8 Final model estimates for all livestock models .................................. 141 
4.4 Discussion .................................................................................. 143 
4.5 Conclusion ................................................................................. 149 
Chapter 5 Discussion ................................................................... 151 
5.1 The current brucellosis prevention and control strategy in Tanzania ........ 151 
5.2 The importance and application of identified risk factors for human 
brucellosis ...................................................................................... 152 
5.3 The importance and feasibility of active surveillance techniques ............. 153 
5.4 The importance of evaluating diagnostic test performance and next steps . 155 
5.5 Brucellosis knowledge gaps ............................................................ 156 
5.6 Future research .......................................................................... 157 
5.7 Suggestions for the implementation of brucellosis prevention and control in 
Tanzania and SSA ............................................................................. 158 
5.7.1 An ideal brucellosis prevention and control strategy ........................... 158 
5.7.2 Considerations for a successful brucellosis prevention and control strategy 159 
Appendices ............................................................................... 162 
Appendix 1: Hospital Febrile Surveillance Participant Information and Consent 
Form ............................................................................................. 163 
Appendix 2: Febrile Participant Questionnaire ......................................... 170 
Appendix 3: Household Surveillance Participant Information and Consent Form 182 
Appendix 4: Bovine brucellosis Bayesian latent class model sensitivity analysis 
diagnostic plots ................................................................................ 189 
Bovine model: Model with uniform prior set and conditional dependence ......... 190 
Bovine model: Model with uniform prior set and conditional independence ....... 192 
Bovine model: Model with relaxed prior set and conditional dependence .......... 194 
Bovine model: Model with relaxed prior set and conditional independence ....... 196 
Bovine model: Model with strict prior set and conditional dependence ............ 198 
Bovine model: Model with strict prior set and conditional independence .......... 200 
Appendix 5: Bayesian latent class model code: Bovine final model with conditional 
independence .................................................................................. 202 
  7 
Appendix 6: Ovine brucellosis Bayesian latent class model sensitivity analysis 
diagnostic plots ................................................................................ 204 
Ovine model: Model with uniform prior set and conditional dependence .......... 205 
Ovine model: Model with uniform prior set and conditional independence ........ 207 
Ovine model: Model with relaxed prior set and conditional dependence ........... 209 
Ovine model: Model with relaxed prior set and conditional independence ........ 211 
Ovine model: Model with strict prior set and conditional dependence ............. 213 
Ovine model: Model with strict prior set and conditional independence ........... 215 
Appendix 7: Ovine final model diagnostic plots ........................................ 217 
Appendix 8: Bayesian latent class model code: Ovine final model with conditional 
dependence .................................................................................... 221 
Appendix 9: Caprine brucellosis Bayesian latent class model sensitivity analysis 
diagnostic plots ................................................................................ 223 
Caprine model: Model with uniform prior set and conditional dependence ........ 224 
Caprine model: Model with uniform prior set and conditional independence ...... 226 
Caprine model: Model with relaxed prior set and conditional dependence ........ 228 
Caprine model: Model with relaxed prior set and conditional independence ...... 230 
Caprine model: Model with strict prior set and conditional dependence ........... 232 
Caprine model: Model with strict prior set and conditional independence ......... 234 
Appendix 10: Caprine final model diagnostic plots .................................... 236 
Appendix 11: Bayesian latent class model code: Caprine final model with 
conditional dependence ..................................................................... 240 
List of references ....................................................................... 242 
 
  
  8 
List of tables 
Table 1.1: Twelve recognised Brucella species, their biovars, preferential hosts 
and pathogenicity in humans* ............................................................ 24 
Table 1.2: Human and animal brucellosis suitable serological tests and test type 
classifications* .............................................................................. 30 
Table 1.3: Summary of human brucellosis seroprevalence studies in Tanzania .. 33 
Table 1.4: Summary of livestock brucellosis seroprevalence studies in Tanzania35 
Table 2.1: The number and proportion of febrile hospital participants (n=228) 
with evidence of a bloodstream infection by blood culture identified during the 
febrile hospital study ...................................................................... 53 
Table 2.2: Eigenvalues and proportion of variance explained by the first 5 
dimensions of multiple correspondence analysis ...................................... 55 
Table 2.3: Risk factor candidate variables contributing to the first three 
dimensions of multiple correspondence analysis (MCA), including factor levels, 
candidate variable description and period of reference ............................. 57 
Table 2.4: Literature- or epidemiologic opinion-informed candidate risk factor 
variables selected for inclusion in logistic regression analyses, including factor 
levels, candidate variable description and period of reference .................... 60 
Table 2.5: Univariable logistic regression results for ten literature- and 
epidemiologic opinion-informed candidate variables and the number and 
proportion of acute brucellosis cases at each candidate variable factor level ... 61 
Table 2.6: Multivariable logistic regression results for maximal and final models 
investigating association between ten literature- and epidemiologic opinion-
informed candidate variables and febrile hospital participant acute brucellosis 
case status .................................................................................. 63 
Table 2.7: Febrile hospital participants relationship between sex and herded 
livestock risk factor candidate variables ............................................... 64 
Table 2.8: Lasso regression coefficient estimates (Coef.) for non-zero candidate 
risk factor variables ........................................................................ 64 
Table 3.1: Brucellosis status as defined by diagnostic test outcome for 
brucellosis positive febrile hospital participants (BPH) .............................. 88 
Table 3.2: Household participant characteristics for brucellosis positive and 
brucellosis negative febrile hospital participant households (BPHH and BNHH), 89 
  9 
Table 3.3: Seroprevalence at the individual household participant-level and 
household-level as indicated by the Rose Bengal plate test (RBT) and the serum 
agglutination test (SAT) ................................................................... 91 
Table 3.4: Generalised linear mixed-effect model evaluating association 
between Brucella spp. exposure status of household participants and febrile 
hospital participants ....................................................................... 94 
Table 3.5: Multivariable generalised linear model evaluating the relationship 
between febrile hospital participant versus household member participant 
(reference population) study populations and the covariables sex and age in 
years ......................................................................................... 96 
Table 3.6: Maximal and final generalised linear models evaluating relationship 
between RBT-defined Brucella spp. exposed participants in the febrile hospital 
study versus household member study (reference population) and the covariables 
sex and age (years) ........................................................................ 98 
Table 4.1: Sensitivity (Se) and specificity (Sp) mean estimates using the Rose 
Bengal plate test (RBT) for cattle in Africa .......................................... 117 
Table 4.2: Sensitivity (Se) and specificity (Sp) mean estimates using the 
competitive enzyme-linked immunosorbent assay (cELISA) for cattle in Africa 117 
Table 4.3: Sensitivity (Se) and specificity (Sp) mean estimates using the Rose 
Bengal plate test (RBT) for small ruminants ......................................... 118 
Table 4.4: Sensitivity (Se) and specificity (Sp) mean estimates of the competitive 
enzyme-linked immunosorbent assay (cELISA) for small ruminants .............. 118 
Table 4.5: Prior distribution diagnostic test parameter estimates for sensitivity 
and specificity of the Rose Bengal plate test (RBT) and the competitive enzyme-
linked immunosorbent assay (cELISA) used for cattle, sheep and goat models 119 
Table 4.6: Brucellosis seroprevalence estimates for cattle in Tanzania generated 
using the Rose Bengal plate test (RBT) and/or the competitive enzyme-linked 
immunosorbent assay (cELISA) ......................................................... 120 
Table 4.7: Brucellosis seroprevalence estimates for sheep and goats in Tanzania 
using the Rose Bengal plate test (RBT) and/or the competitive enzyme-linked 
immunosorbent assay (cELISA) ......................................................... 120 
Table 4.8: Beta distributions (dbeta) used to define priors for sensitivity (Se) and 
specificity (Sp) of Rose Bengal plate test (RBT) and competitive enzyme-linked 
immunosorbent assay (cELISA) parameters for the bovine model ................ 122 
  10 
Table 4.9: Beta distributions (dbeta) used to define priors for sensitivity (Se) and 
specificity (Sp) of Rose Bengal plate test (RBT) and competitive enzyme-linked 
immunosorbent assay (cELISA) parameters for the ovine model ................. 122 
Table 4.10: Beta distributions (dbeta) used to define priors for sensitivity (Se) 
and specificity (Sp) of Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) parameters for the caprine model ...... 122 
Table 4.11: Rose Bengal plate test (RBT) and competitive enzyme-linked 
immunosorbent assay (cELISA) positive test results for cattle, sheep and goats in 
exclusive pastoralist and non-exclusive pastoralist subpopulations from two 
cross-sectional studies in northern Tanzania ........................................ 125 
Table 4.12: Deviance information criterion (DIC) scores for each combination of 
bovine model with uniform, relaxed and strict literature-informed prior sets, and 
conditional dependence (with covariance) or conditional independence (without 
covariance) ................................................................................ 127 
Table 4.13: Mean posterior parameter estimates and 95% Bayesian Credibility 
Intervals (BCI) for the final bovine model using the relaxed prior set* and 
assuming conditional independence .................................................. 128 
Table 4.14: Positive and negative predictive values for RBT, cELISA, in-series and 
in-parallel diagnostic approaches in an exclusive pastoralist subpopulation for 
the final bovine model .................................................................. 129 
Table 4.15: Deviance information criterion (DIC) scores for each combination of 
ovine model with uniform, relaxed and strict literature-informed prior sets, and 
conditional dependence (with covariance) or conditional independence (without 
covariance) ................................................................................ 135 
Table 4.16: Mean posterior parameter estimates and 95% Bayesian Credibility 
Intervals (BCI) for the final ovine model using the relaxed prior set* and 
assuming conditional dependence ..................................................... 136 
Table 4.17: Positive and negative predictive values for RBT, cELISA, in-series and 
in-parallel diagnostic approaches in an exclusive pastoralist subpopulation for 
the final ovine model .................................................................... 136 
Table 4.18: Deviance information criterion (DIC) scores for each combination of 
caprine model with uniform, relaxed and strict literature-informed prior sets, 
and conditional dependence (with covariance) or conditional independence 
(without covariance) .................................................................... 139 
  11 
Table 4.19: Mean posterior parameter estimates and 95% Bayesian Credibility 
Intervals (BCI) for the final caprine model using the relaxed prior set* and 
assuming conditional dependence ..................................................... 140 
Table 4.20: Positive and negative predictive values for RBT, cELISA, in-series and 
in-parallel diagnostic approaches in an exclusive pastoralist subpopulation for 
the final ovine model .................................................................... 140 
 
 
 
 
  
  12 
List of figures 
Figure 1.1: Three key reasons why zoonotic disease burden is greatest for 
impoverished communities ............................................................... 20 
Figure 2.1: The Endulen Hospital (white X) location within the Ngorongoro 
Conservation Area (blue shading) within Arusha Region and adjacent to Simiyu 
Region (beige shading), and the location of Arusha and Simiyu Regions within a 
regional map of Tanzania (grey shading) ............................................... 45 
Figure 2.2: Flowchart of febrile hospital study screening, eligibility, enrolment 
and brucellosis data collection figures ................................................. 54 
Figure 2.3: The proportion of contribution of the top ten candidate variable 
factors to the construction of three multiple correspondence analysis orthogonal 
dimensions .................................................................................. 56 
Figure 3.1: Examples of negative and positive agglutination using the Rose 
Bengal plate test (RBT) ................................................................... 79 
Figure 3.2: Flow diagram showing identification of BPHs and BNHs, BPHHs and 
BNHHs and household members for the household member study ................. 82 
Figure 3.3: Flow diagram of household member study household identification 
process ....................................................................................... 88 
Figure 3.4: Mean seroprevalence estimates and 95% confidence intervals for 
human brucellosis studies conducted in agro-pastoral and/or pastoral areas of 
Tanzania ..................................................................................... 92 
Figure 3.5: Flow diagram of household member study participant enrolment and 
brucellosis test results .................................................................... 93 
Figure 3.6: Age and sex distribution of febrile hospital study participants (left 
panel) and age and sex distribution of household member study participants 
(right panel) ................................................................................ 95 
Figure 3.7: Age and sex distribution of febrile hospital study RBT-defined 
Brucella spp. exposed participants (left panel) and age and sex distribution of 
household member study RBT-defined Brucella spp. exposed participants (right 
panel) ........................................................................................ 97 
Figure 4.1: Arusha, Kilimanjaro, and Manyara Regions (green shading) in 
Tanzania ................................................................................... 111 
Figure 4.2: Sensitivity, specificity and prevalence mean estimates and ranges for 
each combination of bovine model with uniform, relaxed and strict literature-
  13 
informed prior sets, and conditional dependence (with covariance) or 
conditional independence (without covariance) .................................... 126 
Figure 4.3: In-series and in-parallel sensitivity and specificity mean posterior 
estimates and 95% Bayesian credibility intervals (BCI) for each combination of 
bovine model with uniform, relaxed and strict literature-informed prior sets, and 
conditional dependence (with covariance) or conditional independence (without 
covariance) ................................................................................ 127 
Figure 4.4: Density plots for each parameter of the final bovine model ........ 130 
Figure 4.5: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the final bovine model ................................................. 131 
Figure 4.6: Trace plots showing MCMC chain convergence for each parameter of 
the final bovine model .................................................................. 132 
Figure 4.7: Sensitivity, specificity and prevalence mean estimates and ranges for 
each combination of ovine model with uniform, relaxed and strict literature-
informed prior sets, and conditional dependence (with covariance) or 
conditional independence (without covariance) .................................... 133 
Figure 4.8: In-series and in-parallel sensitivity and specificity mean posterior 
estimates and 95% Bayesian credibility intervals (BCI) for each combination of 
ovine model with uniform, relaxed and strict literature-informed prior sets, and 
conditional dependence (with covariance) or conditional independence (without 
covariance) ................................................................................ 134 
Figure 4.9: Sensitivity, specificity and prevalence mean estimates and ranges for 
each combination of caprine model with uniform, relaxed and strict literature-
informed prior sets, and conditional dependence (with covariance) or 
conditional independence (without covariance) .................................... 137 
Figure 4.10: In-series and in-parallel sensitivity and specificity mean posterior 
estimates and 95% Bayesian credibility intervals (BCI) for each combination of 
caprine model with uniform, relaxed and strict literature-informed prior sets, 
and conditional dependence (with covariance) or conditional independence 
(without covariance) .................................................................... 138 
Figure 4.11: Sensitivity, specificity and prevalence posterior mean estimates and 
ranges for the final bovine model with relaxed priors and conditional 
independence (without covariance) and the final ovine and final caprine models 
with relaxed prior sets and conditional dependence (with covariance) ......... 141 
  14 
Figure 4.12: In-series and in-parallel sensitivity and specificity posterior mean 
estimates and 95% Bayesian credibility intervals (BCI) for the final bovine model 
with relaxed priors and conditional independence (without covariance) and the 
final ovine and final caprine models with relaxed prior sets and conditional 
dependence (with covariance) ......................................................... 142 
 
  
  15 
Acknowledgements 
I would like to extend my sincerest gratitude to the following individuals and 
organisations: 
 
Jo Halliday for sharing her time and expertise so generously and for being a 
patient, intelligible and approachable teacher. Dan Haydon for his time, for 
helping in un-muddying statistics and for his confidence in me. Gabriel Shirima 
for helping to initiate the research and for sharing his knowledge of brucellosis. 
 
The British research councils: BBSRC, DFID, ESRC, MRC, NERC and DSTL for 
funding this research. Mary Ryan and John Claxton for their continual and 
efficient assistance throughout the PhD programme. The numerous people in the 
research team at the Institute of Biodiversity, Animal Health and Comparative 
Medicine that offered their advice and time, especially: Sarah Cleaveland, Simon 
Babayan, Annette MacLeod, Will de Glanville and Paul Johnson. Mark Bronsvoort 
and Stella Mazeri at the University of Edinburgh for their guidance and support 
in Bayesian modelling. Those at the Animal and Plant Health Agency that 
supported data collection and laboratory analyses, including: Adrian Whatmore, 
Roland Ashford and Lorraine Perrett. 
 
All those at the Kilimanjaro Christian Medical Centre, Kilimanjaro Clinical 
Research Institute, Nelson Mandela African Institute of Science and Technology 
and other Tanzanian organisations that helped me directly or indirectly in 
completing both field and laboratory research, including: Blandina Mmbaga, 
John Crump, Matt Rubach, Kate Thomas, Philoteus Sakasaka, Elizabeth 
Kasagama, Nelson Amani, Ephrasia Hugho, Frank Michael, Francis Karia, Robert 
Chuwa, Shama Cash-Goldwasser, Manuela Carugati, Dassa Nkini and Kezia Oola. 
Folorunso Fasina and Niwael Mtui-Malamsha at the Food and Agriculture 
Organization for welcoming me and sharing their broad expertise. 
 
Karin Orsel, Frank Van der Meer, Elias Nyanza and Jeremiah Seni from the 
University of Calgary for their kind and thorough introduction to the Ngorongoro 
Conservation Area. Nestory Mkenda and Father Albano for welcoming and 
accommodating the entire field team at the Endulen Hospital. All Endulen 
Hospital staff for being ready to assist with anything. The field team: Kadogo 
Lerimba for passing the seemingly impassable, Laizer Lokida for his foresight and 
inexhaustible enthusiasm, Joseph Peshut for picking up the reigns with ease, 
Chris Kiboya for making an exception to early starts and treating all participants 
with unfaltering care, Salehe Mganzila for his flexibility and reliability, Olterere 
Salimu for his honesty and attention to detail, Mary Lonyori for her unwavering 
dedication, and Abdul Lukambagire for extending his advice, friendship and 
sweets. The community of the Ngorongoro Conservation Area, who have 
invariably left an indelible mark on my life, and to whom I am unquestionably 
indebted. Their willing and generosity have been inspirational. 
 
My Tanzanian family for their unfaltering kindness and guidance. My Mum and 
Dad for their unconditional love and continual support in everything I do. Saitoti 
for arriving into our lives, bringing happiness to us all and new perspective. 
Finally, Saniniw for his endless optimism and belief in my ability, for always 
holding everything together and for the supu. Ashe naleng pi  
  16 
Author’s declaration 
I declare that this thesis is my own original work. The content of this thesis has 
not been submitted as part of any other degree or professional qualification. 
  
  17 
Abbreviations 
 
AGID Agar Gel Immunodiffusion Test 
AIC Akaike Information Criterion 
aOR Adjusted Odds Ratio 
APHA Animal and Plant Health Agency 
BCI Bayesian Credibility Interval 
BMAT Brucella Microagglutination Test 
BNH Brucellosis Negative Febrile Hospital Participant 
BNHH Brucellosis Negative Febrile Hospital Participant Household 
BPAT Buffered Plate Agglutination Test 
BPH Brucellosis Positive Febrile Hospital Participant  
BPHH Brucellosis Positive Febrile Hospital Participant Household 
CDC Centers for Disease Control and Prevention 
cELISA Competitive Enzyme-linked Immunosorbent Assay 
CFT Complement Fixation Test 
CI Confidence Interval 
DF Degrees of Freedom 
DIC Deviance Information Criterion 
ELISA Enzyme-linked Immunosorbent Assay 
EMA-i Events Mobile Application 
FAO Food and Agriculture Organization of the United Nations 
FPA Fluorescence Polarisation Assay 
GLM Generalised Linear Model 
GLMM Generalised Linear Mixed-effect Model 
KCRI Kilimanjaro Clinical Research Institute 
LCA Latent Class Analysis 
LMICs Low- and Middle-Income Countries 
LRT Likelihood Ratio Test 
MCA Multiple Correspondence Analysis 
MCMC Markov Chain Monte Carlo 
MDGs Millennium Development Goals 
NCA Ngorongoro Conservation Area 
NPV Negative Predictive Value 
  18 
NTD Neglected Tropical Disease 
NZD Neglected Zoonotic Disease 
OD Optical Density 
OIE World Organisation for Animal Health 
OPD Outpatient Department 
OPS O-polysaccharide 
OR Odds Ratio 
PCR Polymerase Chain Reaction 
PPV Positive Predictive Value 
RBT Rose Bengal Plate Test 
RIV Rivanol Test 
SACIDS Southern African Centre for Infectious Disease Surveillance 
SAT 
SD 
Serum Agglutination Test 
Standard Deviation 
SDGs Sustainable Development Goals 
SE Standard Error 
WHO World Health Organization 
 
  19 
Chapter 1 Brucellosis in Tanzania: An introduction to a 
neglected zoonosis 
 
1.1 The neglected zoonoses 
In 2000, eight Millennium Development Goals (MDGs) were agreed upon at the 
United Nations Millennium Summit. One of the eight MDGs was “to combat HIV 
and AIDS, malaria and other diseases”. The designation of “other diseases” 
included a group termed the neglected tropical diseases (NTDs) (Molyneux et al., 
2005). More recently, 2015 brought the classification of 17 Sustainable 
Development Goals (SDGs), a facet of the 2030 Agenda for Sustainable 
Development adopted by the United Nations Member States. The third SDG 
focuses on Good Health and Well-Being, referring to combatting AIDS, malaria 
and “other diseases” including NTDs by 2030. The NTDs are severe, chronic 
conditions that are among the most common infections of people living in 
extreme poverty (Hotez et al., 2007; Hotez and Kamath, 2009), and have been 
referred to as the “true allies of impoverishment” (Molyneux, 2008). The burden 
of NTDs is often underestimated, which negatively impacts funding opportunities 
for their control and research (Maudlin et al., 2009). Of the NTDs, the zoonoses 
are the most neglected (Molyneux et al., 2011). Zoonoses are defined as diseases 
that are transmitted between humans and other vertebrates (WHO et al., 2006). 
Despite being the cause of more than 60% of all infectious disease in humans 
(Taylor et al., 2001), zoonoses are neglected for four main reasons: lack of 
robust data on disease burdens in endemic regions; lack of widespread 
knowledge among clinicians and policy makers concerning zoonotic human 
disease; lack of laboratory diagnostic capacity; and limited reporting systems 
that are often fragmented with little communication between public and animal 
health sectors (Molyneux et al., 2011). Ultimately these issues perpetuate the 
inability to accurately estimate disease burden and lead to limited disease 
awareness and political interest in zoonotic disease research and control 
(Molyneux et al., 2011). 
 
The greatest burden of neglected zoonotic diseases (NZDs) is found in 
marginalised, impoverished communities (Grace et al., 2012). This is for three 
key reasons (see Figure 1.1): 1 - an association between people living in poverty 
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and being in close contact with infected animals and/or consuming infected 
animal products, meaning that these communities are at high-risk of infection; 2 
– these communities are least likely to receive appropriate treatment due to 
reduced access to healthcare facilities and laboratory diagnostics leading to poor 
prognosis; 3 – impoverished communities that rely on livestock suffer a double 
burden from zoonoses as there is an impact on both human health and livestock 
health and productivity, leading to a greater vulnerability to zoonotic illness 
(WHO et al., 2006). There is a need for a robust evidence-base estimating the 
burden of the different NZDs on people and animals, especially in marginalised 
livestock-keeping communities, so that the importance of the different NZDs is 
perceived by political and funding bodies (WHO et al., 2006). 
 
 
Figure 1.1: Three key reasons why zoonotic disease burden is greatest for 
impoverished communities, reproduced from WHO et al., 2006 
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1.2 A short history of brucellosis 
Brucellosis is a neglected zoonotic disease that has been recorded in different 
societies throughout history (Godfroid et al., 2005). In fact, brucellosis may 
predate Homo sapiens, as it has been hypothesised as the cause of skeletal 
lesions identified in the excavated remains of a 2.4 to 2.8 million year old 
hominid (Australopithecus africanus) found in South Africa (D’Anastasio et al., 
2009). During the time of Hippocrates circa 460 BC, a clinical syndrome was 
described suggestive of brucellosis, including: long-lasting fevers; joint ache; 
and tumours (Hippocrates, 400BC; Pappas et al., 2008). Vertebral lesions 
consistent with brucellosis have also been discovered in Roman-era human 
remains from the volcanic eruption of Mount Vesuvius, 79 AD (Capasso, 1999), as 
well as the discovery of carbonised cheese with cocco-like forms morphologically 
and dimensionally similar to the brucellosis causative agent (Capasso, 2002).  
 
In 1887, David Bruce was the first to isolate Micrococcus melitensis from the 
spleen samples of British soldiers in Malta, who were said to have died from 
undulant fever ((Bruce, 1887), cited by (Rossetti et al., 2017)). A decade later, a 
veterinarian named L. F. Benhard Bang discovered Bang’s bacillus, a bacterium 
resulting in abortion in cattle and the causative agent of Bang’s disease (Bang, 
1897). In 1905, Themistocles Zammit isolated M. melitensis from goat’s milk in 
Malta, indicating zoonotic transmission of the pathogen ((Zammit, 1905), cited 
by (Godfroid et al., 2005)). Throughout history, the disease has been referred to 
by a number of descriptive names such as: intermittent typhoid; Mediterranean 
fever; Corps disease; and Malta fever (Madkour, 2001). In 1918, microbiologist 
Alice Evans deciphered the link between Bang’s disease and Malta fever, 
proposing the renaming of the genus to Brucella and terming the zoonotic 
disease “brucellosis” (Evans, 1918; Madkour, 2001; Seleem et al., 2010). 
 
1.3 The global burden of brucellosis 
Brucellosis is now regarded as the most common zoonosis worldwide (Franco et 
al., 2007). It is reported across Europe, the Americas, Asia, Australasia and 
Africa (Pappas et al., 2006). The evolution of the global epidemiology of 
brucellosis is influenced by a host of anthropogenic factors including: 
socioeconomic and political change; implementation of control and eradication 
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programmes; advances in brucellosis detection and reporting systems; illegal 
importation of infected animals and animal products; and increased 
international tourism to brucellosis endemic areas (Pappas, 2010; Pappas et al., 
2006). Deviation in such factors may help to explain the high variability in 
incidence of human brucellosis reported between, and even within countries 
(Dean et al., 2012b). 
 
High-income countries have lower reported brucellosis incidence than low- and 
middle-income countries (LMICs), although specific low economic status 
communities in high-income countries can still exhibit an increased brucellosis 
incidence (Dean et al., 2012b). The World Health Organisation (WHO) estimate 
the global burden of human brucellosis at 264,073 (95% uncertainty interval: 
100,540 - 6,187,148) disability-adjusted life years for 2010 (Havelaar et al., 
2015). This is regarded as a conservative estimate that likely underestimates the 
true disease burden, particularly as robust data on disease incidence and 
prevalence are scarce for many regions including: Latin America; Asia-Pacific; 
Eastern Europe; and sub-Saharan Africa (Dean et al., 2012b). 
 
1.3.1 Brucellosis in low- to middle-income countries 
Brucellosis is considered to be widespread in LMICs (Rubach et al., 2013) and the 
burden of disease is reported to be large (Doganay and Aygen, 2003; Franco et 
al., 2007). However, the true burden for both human and animal brucellosis in 
LMICs is not well quantified (Godfroid et al., 2011). This is especially true 
concerning impoverished rural communities where robust brucellosis data are 
generally lacking (Perry et al., 2002). It has been estimated that close to 1 
billion impoverished people are involved in livestock-keeping in LMICs (Grace et 
al., 2012; Staal et al., 2009), and approximately 100-200 million people 
participate in pastoral production systems (Racloz et al., 2013; Rass, 2006). 
Pastoralism can be defined as “the use of grassland grazing for the purpose of 
livestock production” (Racloz et al., 2013). These pastoral production systems 
can be subset according to the level of mobility in livestock keeping: highly 
nomadic; transhumant or semi-nomadic; and agro-pastoral (Racloz et al., 2013). 
Brucellosis is endemic and an important disease in many pastoral systems, 
causing a high risk of human infection and substantial production losses in 
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bovine, caprine and ovine populations (McDermott et al., 2013; Mcdermott and 
Arimi, 2002).  
 
It is important to consider that brucellosis can be present in both rural and 
urban settings (Racloz et al., 2013). Human contacts with livestock may be less 
in urban settings as compared to rural, however infection risk is still present 
through activities such as consumption of raw animal products (Makita et al., 
2008). There are now more people that live in close contact with animals than 
ever before (Plumb et al., 2007). Future projected increases in the human 
population will result in increased global demand for animal products especially 
in LMICs (Delgado et al., 2001; Herrero et al., 2012). This means that brucellosis 
and other zoonoses may increase in prevalence in some populations, particularly 
those populations with frequent livestock contacts (Plumb et al., 2013) and no 
enhancements in the livestock production system. This is especially true for 
marginalised pastoralist communities where increased livestock product 
demands, coupled with little to no livestock vaccination and minimal hygienic 
measures may result in increased brucellosis transmission for both livestock-
keepers and consumers. 
 
The estimated impact of brucellosis on livestock productivity is not well 
understood (Roth et al., 2003). However, areas with higher brucellosis 
prevalences are assumed to have higher productivity losses (McDermott et al., 
2013). The economic production impacts of brucellosis in livestock species in 
LMICs has been reported most frequently for cattle (McDermott et al., 2013). A 
report from the Food and Agriculture Organization of the United Nations (FAO) 
has estimated that brucellosis in cattle of SSA reduces milk and meat offtake 
potential by 5%-10% and 12%-35%, respectively, in traditional extensive 
production systems and by 4%-7% and 10%-21%, respectively, in smallholder 
production (Mangen et al., 2002). 
 
1.4 Causative agent 
The causative agents of brucellosis in humans and animals are Gram-negative, 
facultative intracellular bacteria of the genus Brucella (Godfroid et al., 2005). 
There are six classical species of Brucella including: B. melitensis; B. abortus; B. 
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suis; B. canis; B. ovis; B. neotomae, and six more recently recognised species: B. 
ceti; B. pinnipedialis; B. microti; B. inopinata; B. papionis; and B. vulpis 
(Whatmore et al., 2016). A list of identified Brucella spp., their associated 
biovars (i.e. strains of the same Brucella species that differ physiologically), 
preferential hosts and human pathogenicity are given in Table 1.1. The Brucella 
species that most commonly cause human infection are B. melitensis, followed 
by B. abortus and B. suis (Pappas, 2010). The most virulent Brucella spp. are 
those with domesticated animal hosts (Moreno, 2014). B. melitensis is the most 
virulent form of the disease in humans (Doganay and Aygen, 2003), followed by: 
B. suis biovars 1, 3 and 4; B. abortus; and B. canis (Moreno, 2014). However,  
 
Table 1.1: Twelve recognised Brucella species, their biovars, preferential 
hosts and pathogenicity in humans* 
Brucella species Biovars Preferential hosts Human pathogenicity 
B. melitensis 1 – 3 Sheep, Goat High 
B. abortus 1 – 6, 9  Cattle High 
B. suis 1, 3 Pig High 
 2 Wild boar, Hare No 
 4 Reindeer, Caribou High 
 5 Rodents No 
B. canis - Dog Moderate 
B. ovis - Ram No 
B. neotomae - Desert wood rat No 
B. ceti - Cetaceans Low 
B. pinnipedialis - Pinnipeds Unknown 
B. microti - Soil, Vole Unknown 
B. inopinata - Unknown High 
B. papionis - Baboon Unknown 
B. vulpis - Fox Unknown 
*Adapted from Godfroid et al., 2011 
 
disease virulence also varies geographically according to the endemic Brucella 
spp. and biovars (Ariza et al., 2007). 
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The global burden of the different Brucella spp. is not well known, although B. 
melitensis and B. abortus are considered to cause the majority of human 
infections (Franco et al., 2007). In the USA the species causing the majority of 
human infections is reported to be B. melitensis, thought to be largely caused by 
the consumption of imported contaminated dairy products, B. abortus is less 
prevalent (Pappas et al., 2006). In western Europe, human brucellosis is mainly 
constrained to the Mediterranean basin (Pappas et al., 2006). In countries such 
as Greece and Spain, reported human brucellosis cases are largely caused by B. 
melitensis infection (Taleski et al., 2002; Valdezate et al., 2007). In many LMICs, 
the human burden of the different Brucella spp. is not clear, which is largely 
due to a lack of capacity to isolate and speciate Brucella spp. bacteria (Ducrotoy 
and Bardosh, 2017). In Egypt, B. melitensis and B. abortus have been identified 
by culture in hospital patients, with B. melitensis being the predominant species 
(Jennings et al., 2007). There are few studies in SSA that have successfully 
speciated the pathogen in humans (Ducrotoy et al., 2017). B. melitensis has 
been identified by culture for hospital patient populations in countries including: 
Kenya; Somalia; South Africa; and the Gambia (Oomen, 1976; Valenza et al., 
2006; Wheat et al., 1995; Wojno et al., 2016) and B. abortus in Kenya and 
Zimbabwe (Bevan, 1930; Oomen, 1976). These examples of both B. melitensis 
and B. abortus human infections in SSA suggest that cattle, sheep and goats have 
a role as livestock maintenance hosts and in the transmission of brucellosis to 
humans in this region. 
 
1.5 Infection in humans 
The main transmission routes for human brucellosis are direct contacts with 
infected animals and their secretions, including via skin abrasion, inhalation, eye 
conjunctiva or through consumption of infected animal products (Doganay and 
Aygen, 2003). Examples of human to human transmission are rare and this route 
of transmission is considered to be negligible (Corbel, 1997). The incubation 
period can range from days to several months (Robinson, 2003). Mortality rate 
are low for brucellosis (Grace et al., 2012). However, Brucella spp. infection in 
humans is more severe than in animals (Moreno, 2014). Furthermore, human 
brucellosis has been described as “the disease that rarely kills anyone, but often 
makes a patient wish they were dead” (Seleem et al., 2010), and “major among 
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the zoonoses in the illness and misery it causes” (Meyer, 1954). The clinical 
manifestations of brucellosis are variable and non-distinct, meaning clinical 
diagnosis alone is inaccurate (Rubach et al., 2013). Acute illness may include 
fluctuating fever (Aygen et al., 2002), as well as other debilitating conditions 
such as myalgia, arthralgia and back pain (Dean et al., 2012a). Brucella spp. 
infection in women during pregnancy increases the risk of spontaneous 
miscarriage during the first two gestational trimesters, preterm delivery (birth 
before 37 weeks of pregnancy), and foetal disease transmission (Arenas-Gamboa 
et al., 2016). Acute disease may resolve spontaneously (Wright, 1998), or if left 
untreated, can progress to chronic infection leading to serious complications and 
permanent sequelae (Corbel, 2006). It is estimated that as many as 30% of 
undiagnosed acute brucellosis cases may become chronic (Berbari and Wilson, 
2001). Epididymo-orchitis has been found to effect 1 in 10 male brucellosis 
patients, and severe neurological complications and endocarditis have been 
reported to effect 4 and 1 case per 100 brucellosis patients, respectively (Dean 
et al., 2012a). Several chronic cases have been reported as lasting more than 30 
years (Cutler et al., 2005). 
 
As a febrile illness that lacks differentiating clinical signs, in regions endemic to 
diseases such as malaria and typhoid fever, brucellosis is at high risk of being 
misdiagnosed and mistreated (Araj, 2010). In a study of 528 patients clinically 
diagnosed with malaria in northern Tanzania, only 14 (1.6%) tested positive for 
malaria, whereas 118 (26.2%) of these patients were positive for a bacterial 
zoonosis (Crump et al., 2013). In the same study, 16 (3.5%) of 453 patients that 
underwent laboratory testing were diagnosed with brucellosis (Crump et al., 
2013). 
 
1.6 Infection in animals 
There are many wild and domestic animal natural hosts of the genus Brucella. 
Brucella spp. have been identified in a range of wildlife hosts such as: wild boar 
(Sus scrofa); bison (Bison bison); elk (Cervus elaphus); ibex (Capra ibex); African 
buffalo (Syncerus caffer); blue wildebeest (Connochaetes taurinus); giraffe 
(Giraffa camelopardalis); and White’s tree frog (Litoria caerulea) (Alexander et 
al., 2012; Fyumagwa et al., 2009; Godfroid et al., 2013b; Whatmore et al., 
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2015). B. abortus and B. suis have been isolated from a wide range of wildlife 
species, whereas isolation of B. melitensis is less common (Godfroid et al., 
2013b). However, the most important reservoir hosts for human transmission are 
considered to be cattle, sheep, goats and pigs (Corbel, 2006). The 
epidemiological characteristics of the different Brucella spp. are variable 
(Godfroid et al., 2005). Broadly, cattle act as the maintenance host for B. 
abortus, sheep and goats are the maintenance hosts for B. melitensis, and pigs 
are the maintenance host for B. suis (OIE, 2018). However, understanding the 
different Brucella spp. transmission pathways is complicated by the ability of 
Brucella spp. to spillover into non-preferential hosts, for example B. suis and B. 
melitensis can be found in cattle and B. abortus in small ruminants (Godfroid et 
al., 2013a, 2011). Animal to animal transmission of Brucella spp. is via: contact 
with infected aborting animals, aborted foetus or secretions; contact with 
contaminated grazing areas or animal enclosures following parturition; sexual 
transmission and artificial insemination from infected animals (Aune et al., 
2011; Corbel, 2006; Jergefa et al., 2009; Muma et al., 2006; Osoro et al., 2015). 
Animal infection is most frequently by ingestion, but may also include 
transmission by skin abrasion, inhalation, inoculation of conjunctiva or vaginal 
mucosa (Corbel, 2006; Druett et al., 1956; Stuart et al., 1987; Thorne and 
Morton, 1978). Clinical manifestation in domestic reservoir hosts is variable and 
may include: abortion; reduced fertility; carpal hygromas; and chronically 
lowered milk yields (Grace et al., 2012; WHO et al., 2006). Abortion typically 
happens during the second half of gestation, and in 75% to 90% of cases abortion 
occurs once, during the first pregnancy following acute infection (Godfroid et 
al., 2013b). These variable clinical signs of infection are non-distinctive and 
therefore diagnosis requires laboratory confirmation (Ducrotoy et al., 2017). 
 
1.7 Diagnosis 
Both human and animal brucellosis should be confirmed by laboratory 
diagnostics. There are a range of tests available that can be defined as either: 
‘direct’ in that they attempt to detect the presence of Brucella bacteria in the 
sample; or ‘indirect’ whereby the test detects the host response to a Brucella 
spp. infection, such as an antibody response (Ducrotoy and Bardosh, 2017; 
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Godfroid et al., 2010). Each testing approach has its own advantages and 
disadvantages. 
1.7.1 Direct diagnostic tests 
The gold standard laboratory method for diagnosis of definitive Brucella spp. 
infection in humans and animals is isolation of the bacterium by culture. Blood is 
the most common culture sample in human brucellosis, whereas blood, vaginal 
fluid, parturition products and milk are common culture samples in animal 
brucellosis (Corbel, 2006). In humans, the isolation success rate can be up to 86% 
during periods of fever, however during periods of no fever or if antibiotics have 
been administered, the success rate can be low (Ducrotoy and Bardosh, 2017). 
Isolation success for animals can be over 80% (Ducrotoy et al., 2018). However, 
manipulation of isolated bacteria is slow, expensive and hazardous. Brucella 
spp. infection is one of the most commonly acquired laboratory infections and 
requires Biosafety Level 3 laboratory facilities (OIE, 2018). 
 
Polymerase chain reaction (PCR) diagnostics have been developed to detect 
Brucella DNA in human and animal samples, such as serum, whole blood and 
foetal tissue (Al Dahouk et al., 2013; Fekete et al., 1992; OIE, 2018). PCR 
techniques have a high specificity but are generally regarded as having a lower 
sensitivity than culture (Godfroid et al., 2010). PCR greatly reduces testing times 
as compared to culture (Zerva et al., 2001). However, varying protocols and 
poor test reproducibility complicate the routine application of PCR diagnostics 
(Ducrotoy and Bardosh, 2017).  
 
Overall, application of culture or PCR techniques are rarely able to be routinely 
implemented in the LMICs where they are most needed. This is due to: the need 
for specialised laboratory facilities; unavailability of laboratory technicians with 
required expertise in implementation and interpretation of results; and the cost 
per test (Ducrotoy and Bardosh, 2017). 
 
1.7.2 Indirect diagnostic tests 
The most commonly applied laboratory diagnostic method for brucellosis is 
serology (Araj, 2010). Brucellosis serology for detection of immunological 
response to B. melitensis, B. abortus and B. suis infection exploits the fact that 
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the cell surfaces contain O-polysaccharide (OPS) (Nielsen, 2002). Evidence for 
exposure to OPS can then be identified by tests based on either whole cell 
antigen or smooth lipopolysaccharide preparation for these three Brucella spp. 
(Nielsen, 2002). However, in the detection of other important species such as B. 
canis and B. ovis rough lipopolysaccharide specific serology must be used, as the 
immune response specific to these Brucella spp. means that they do not cross-
react with smooth lipopolysaccharide tests (Araj, 2010). 
 
Human and animal serological tests can be broken down into the following 
classifications: agglutination tests; primary binding assays; precipitation tests; 
and complement fixation tests (Nielsen, 2002). The serum agglutination test 
(SAT) is a well validated, common reference test in the diagnosis of human 
brucellosis (Al Dahouk et al., 2013; Araj, 2010). In cattle, sheep and goats the 
Rose Bengal plate test (RBT) is often used as a screening test, and requires 
confirmation by an additional serological test such as a complement fixation test 
(CFT) or an enzyme-linked immunosorbent assay (ELISA) (Godfroid et al., 2013a). 
There are a wide range of diagnostic tests that have been developed for 
brucellosis (Moreno, 2014), with different degrees of test validation data 
available for various study species and populations. Serological tests suitable for 
the detection of human and animal brucellosis, as defined by WHO and OIE, are 
given in Table 1.2. 
 
Serological tests are relatively fast to perform and for the most part require 
minimal equipment, making serology the most commonly applied technique in 
brucellosis endemic areas (de Glanville et al., 2017). However, it is important to 
consider some of the limitations of serology also. One such example is that the 
OPS cell surface found in some of the key zoonotic Brucella spp. is similar to 
that of other bacteria such as Yersinia enterocolitica 0:9, resulting in reduced 
test specificity due to the potential for false positive results given by test cross-
reactivity (Kittelberger et al., 1995). There is also no one recommended 
serological test and no standardised reference antigen, consequently the source 
of the antigen used can affect the test result (Araj, 2010). Additionally, 
serological tests cannot identify Brucella to the species-level (Godfroid et al., 
2013a). 
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Table 1.2: Human and animal brucellosis suitable serological tests and test 
type classifications* 
Serological test Test 
classification 
Human 
brucellosis 
(WHO)  
Animal 
brucellosis 
(OIE) 
Rose Bengal plate test 
(RBT) 
Agglutination ü 
 
ü 
 
Serum agglutination test 
(SAT) 
Agglutination ü 
 
ü 
 
Coombs antiglobulin test Agglutination ü 
 
 
Buffered plate 
agglutination test (BPAT) 
Agglutination  ü 
 
Enzyme-linked 
immunosorbent assay 
(ELISA) 
Primary 
binding assay 
ü 
 
ü 
 
Fluorescence 
polarisation assay (FPA) 
Primary 
binding assay 
 ü 
 
Complement fixation 
test (CFT) 
Complement 
fixation 
ü 
 
ü 
 
*Adapted from Corbel et al., 2006 & OIE, 2018 
 
1.7.3 Active brucellosis versus Brucella spp. exposure 
The various categories of brucellosis diagnostic tests mentioned above differ in 
their ability to detect active infection versus evidence of Brucella spp. 
exposure. In the case of culture, a positive culture result can be interpreted as 
definitive evidence of an active brucellosis infection, acute or chronic (Mantur 
et al., 2008). A PCR positive on the other hand shows evidence of Brucella spp. 
DNA presence only. This makes clinical interpretation of PCR results difficult, as 
active and historic infections are not easily distinguished and persistence of 
Brucella spp. DNA is variable and not well understood (Al Dahouk et al., 2013). 
The interpretation of serology is also complex, in that a seropositive result is not 
able to differentiate between active infection and historic exposure to Brucella 
spp., unless antibody titres are quantified (Al Dahouk and Nöckler, 2011). 
Additionally, it is possible to show an antibody response to Brucella spp. 
exposure without manifestation of clinical signs of infection (Zhen et al., 2013). 
 
The ability to differentiate between active infection versus evidence of historic 
exposure is especially important when diagnosing and treating human 
brucellosis. The Centers for Disease Control and Prevention (CDC) have defined 
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the criteria required for the identification of both probable and confirmed acute 
human brucellosis (CDC, 2010). The CDC case definition for probable acute 
human brucellosis is “a clinically compatible illness, with a Brucella total 
antibody titre of ≥160 by SAT or BMAT in at least one serum sample, or detection 
of Brucella DNA in a clinical specimen by PCR”. The CDC case definition for 
confirmed acute brucellosis is “a clinically compatible illness, with culture and 
identification of the Brucella spp., or evidence of a four-fold or greater rise in 
Brucella antibody titre between acute- and convalescent-phase sera obtained ≥2 
weeks apart” (CDC, 2010). 
 
1.8 Treatment 
Treatment of human brucellosis is by dual antibiotic therapy. WHO 
recommendations for the treatment of uncomplicated brucellosis in adults and 
children over seven years old is primarily by: a tetracycline, ideally doxycycline 
100 mg orally every 12 hours for six weeks; plus an amino-glycoside such as, 
streptomycin 1 g intramuscularly per day for two to three weeks, or gentamicin 
5 mg per kg intravenously or intramuscularly per day for seven to ten days 
(Corbel, 2006). In children aged seven years and below, the recommended 
treatment is primarily by: trimethoprim/sulfamethoxazole 8/40 mg per kg orally 
every 12 hours for six weeks; plus streptomycin 30 mg per kg intramuscularly per 
day for three weeks, or gentamicin 5 mg per kg intravenously or intramuscularly 
per day for seven to ten days (Corbel, 2006). 
 
The treatment of brucellosis is non-trivial and protracted. Treatment with 
doxycycline and amino-glycosides can cause adverse effects such as abdominal 
pain and light sensitivity (Roushan et al., 2006). Intravenous or intramuscular 
administration of amino-glycosides require repeat visits to a healthcare facility. 
This means that in geographically remote areas, up to a three-week inpatient 
admission is required. Little to nothing is known about patient compliance with 
brucellosis treatment (Pappas et al., 2005), such as completion of treatment 
rates for orally administered doxycycline over extended periods. 
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1.9 Brucellosis in pastoral sub-Saharan Africa 
The population of sub-Saharan Africa (SSA) was estimated at over 1.07 billion 
people in 2018 (The World Bank, 2019). Brucellosis is endemic across SSA, 
and is a major threat to the region (Moreno, 2014). Much of the global burden of 
brucellosis is found in SSA (Racloz et al., 2013), particularly in countries with 
extensive pastoral areas (Njeru et al., 2016b). At least 50 million people in SSA 
are estimated to be involved in pastoralism (Rass, 2006). East Africa holds the 
highest density of livestock kept in pastoral and agro-pastoral systems (Rass, 
2006). The persistence of brucellosis in these pastoral areas is due to factors 
such as: reduced access to public services; small and dispersed human 
populations; large distances; severe environmental conditions; insufficient 
governance; multi-species herd/flock composition; and limited regional 
epidemiological knowledge (Plumb et al., 2013; Racloz et al., 2013).  
 
1.9.1 Human brucellosis in Tanzania 
Human brucellosis seroprevalence estimates have varied widely, from 0.0% to 
36.5% in Tanzania (Assenga et al., 2015; Bouley et al., 2012; Carugati et al., 
2018; Chipwaza et al., 2015; Crump et al., 2013; Kunda et al., 2007; Orsel et 
al., 2015; Shirima et al., 2010; Shirima and Kunda, 2016; Swai and Schoonman, 
2009). Various recent studies in wider East Africa, estimate human brucellosis 
seroprevalence between 1.3% and 17.0% (Kiambi, 2012; Migisha et al., 2018; 
Miller et al., 2016; Nakeel et al., 2016; Nanyende, 2010; Njeru et al., 2016a; 
Omballa et al., 2016; Osoro et al., 2015; Tumwine et al., 2015). Variation in 
seroprevalence estimates across studies can be explained by a number of factors 
including varied study design, study setting and study population, diagnostic 
tests used and brucellosis case definition. For a comparison of the different 
human brucellosis study details in Tanzania see Table 1.3. 
 
Studies investigating febrile hospital patient populations have reported 
seroprevalence estimates between 2.9% and 36.5% in Tanzania (Bouley et al., 
2012; Carugati et al., 2018; Chipwaza et al., 2015; Orsel et al., 2015). Of those 
hospital-based febrile surveillance studies, the studies that have identified acute 
brucellosis using the CDC case definition have estimated seroprevalence of 
confirmed acute brucellosis to range from 2.9% to 3.5%  
  
 
Table 1.3: Summary of human brucellosis seroprevalence studies in Tanzania, RBT is Rose Bengal plate test, BPAT is buffered plate 
agglutination test, cELISA is competitive enzyme-linked immunosorbent assay, Riv is rivanol precipitation test, BMAT is Brucella 
microagglutination test 
Study area Study population Study 
design 
Sample 
size 
Study 
population 
seroprevalence 
(%) 
Diagnostic test CDC-defined 
brucellosis 
case status 
Reference 
Pastoral & agro-
pastoral,  
northern Tanzania  
Patients with: fever; 
headache; arthralgia; 
malaise; backache; or 
anorexia 
Cross-
sectional 
1586 6.2 cELISA Exposure (Kunda et al., 
2007) 
Urban & rural, 
northern Tanzania 
High-risk occupational 
groups 
Cross-
sectional 
199 5.5 RBT Exposure (Swai and 
Schoonman, 
2009) 
Pastoral & agro-
pastoral,  
northern Tanzania 
Pastoralist & agro-
pastoralist households 
Cross-
sectional 
460 8.3 cELISA Exposure (Shirima et 
al., 2010) 
Urban, 
northern Tanzania 
Febrile patients Prospective 
cohort 
454 3.5 BMAT Confirmed 
acute 
(Bouley et 
al., 2012) 
Agro-pastoral, 
western Tanzania 
Agro-pastoralist 
households 
Cross-
sectional 
340 0.6 
0.6 
RBT & BPAT  
RBT & Riv 
Exposure (Assenga et 
al., 2015) 
Agro-pastoral, 
central-eastern 
Tanzania 
Febrile patients aged 
2-13 years 
Cross-
sectional 
370 7.0  
11.4 
IgM-ELISA  
IgG-ELISA 
Exposure (Chipwaza et 
al., 2015) 
Pastoral,  
northern Tanzania 
Febrile and/or 
suspected malaria 
patients 
Cross-
sectional 
159 5.7 
36.5 
Slide card agglutination  
IgM-ELISA & IgG-ELISA 
Exposure (Orsel et al., 
2015) 
Agro-pastoral, 
northern Tanzania 
Agro-pastoralist 
households 
Cross-
sectional 
82 0.0 RBT or cELISA Exposure (Shirima and 
Kunda, 2016) 
Urban,  
northern Tanzania 
Febrile patients Prospective 
cohort 
1095 2.9 BMAT Confirmed 
acute 
(Carugati et 
al., 2018) 
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(Bouley et al., 2012; Carugati et al., 2018). All other studies of human 
brucellosis in Tanzania (see Table 1.3) can be classified as evidence of exposure 
to Brucella spp. (past or present), due to choice of diagnostic test. A febrile 
surveillance study at a rural hospital in Arusha Region estimated seroprevalence 
at 36.5% using IgM and IgG ELISA and 7.0% using a slide card agglutination test 
(Orsel et al., 2015). This study was conducted in a semi-nomadic pastoral area 
where it is expected that brucellosis is endemic (Njeru et al., 2016b). However, 
the difference in seroprevalence estimates between tests from the same study is 
non-negligible, which highlights the importance of the application of 
standardised diagnostic tests and test antigens in generating population 
representative seroprevalence estimates. Lack of comparability across studies 
and variation in prevalence estimates complicates the already difficult task of 
understanding the true burden of human brucellosis in Tanzania and across 
LMICs. Examples of febrile hospital-based studies in East Africa that meet the 
CDC acute brucellosis case definition are few. The available East African studies 
estimate acute brucellosis prevalence of febrile hospital patients to range 
between 4.3% and 15.4% (Kiambi, 2012; Migisha et al., 2018; Njeru et al., 
2016a). In comparison, it would appear that studies in Tanzania have a 
comparatively low acute brucellosis detection rate. However, study design must 
again be considered, such as the study definition for a brucellosis case. The 
acute brucellosis estimate range for East Africa includes studies using both 
probable and confirmed acute brucellosis to define a case, which may explain 
some of the variation as compared to the estimate range for Tanzania, which 
has used evidence of confirmed acute brucellosis only. 
 
1.9.2 Livestock brucellosis in Tanzania 
Livestock brucellosis seroprevalence studies have been conducted in Tanzania 
across a range of livestock-keeping systems, see Table 1.4 for study descriptions. 
Seroprevalence has been reported to range from 3.0% to 18.0% in cattle, 0.0% to 
23.1% in sheep and 0.0% to 13.8% in goats (Assenga et al., 2015; Chitupila et al., 
2015; Jiwa et al., 1996; John et al., 2010; Lyimo, 2013; Mathew et al., 2015; 
Mellau et al., 2009; Sagamiko et al., 2018; Shirima et al., 2010; Shirima and 
Kunda, 2016; Swai and Schoonman, 2010; Weinhaupl et al., 2000). As in humans, 
these variable livestock seroprevalence estimates are likely influenced by a  
   
 
Table 1.4: Summary of livestock brucellosis seroprevalence studies in Tanzania, RBT is Rose Bengal plate test, cELISA is competitive 
enzyme-linked immunosorbent assay, BMAT is Brucella microagglutination test, iELISA is indirect enzyme-linked immunosorbent assay, 
and SAT is serum agglutination test 
Location in 
Tanzania 
Livestock-keeping 
system 
Sampling Species Sample 
size 
Seroprevalence 
(%) 
Diagnostic 
tests 
Reference 
Northern Commercial Cross-sectional Cattle 13078 10.8 SAT (Jiwa et al., 1996) 
Eastern  Pastoral & smallholder Cross-sectional Cattle 2563 12.5 SAT (Weinhaupl et al., 
2000) 
Northern Pastoral Cross-sectional Cattle 
Goats 
Sheep 
200 
87 
13 
10.0, 6.0 
11.5, 13.8 
7.7, 23.1 
RBT, BMAT 
RBT, BMAT 
RBT, BMAT 
(Mellau et al., 
2009) 
Northern Pastoral & agro-pastoral Matched case-
control 
Cattle 
Goats 
Sheep 
Unknown 
Unknown 
Unknown 
3.0 
4.6 
3.4 
RBT & cELISA 
RBT & cELISA 
RBT & cELISA 
(John et al., 2010) 
Northern Pastoral & agro-pastoral Cross-sectional Cattle 
Small ruminants 
Unknown 
Unknown 
Total=2723 
4.9 
6.5 
cELISA 
cELISA 
(Shirima et al., 
2010) 
Northern Pastoral 
Smallholder 
Cross-sectional 
Cross-sectional 
Cattle 
Cattle 
246 
409 
7.3 
4.1 
RBT 
RBT 
(Swai and 
Schoonman, 2010) 
Eastern Smallholder Cross-sectional Cattle 450 18.4 cELISA (Lyimo, 2013) 
Western Agro-pastoral Cross-sectional Cattle 
Goats 
1103 
248 
6.8 
1.6 
RBT & cELISA 
RBT & cELISA 
(Assenga et al., 
2015) 
Western Agro-pastoral Cross-sectional Cattle 410 5.6 RBT & cELISA (Chitupila et al., 
2015) 
Southern Commercial Cross-sectional Cattle 
Goats 
Sheep 
200 
50 
35 
18.0 
2.0 
5.7 
RBT & iELISA 
iELISA 
iELISA 
(Mathew et al., 
2015) 
Northern Agro-pastoral Cross-sectional Cattle 
Small ruminants 
288 
125 
5.6 
0.0 
RBT & cELISA 
RBT & cELISA 
(Shirima and 
Kunda, 2016) 
Southern Agro-pastoral & 
commercial 
Cross-sectional Cattle 1211 9.3 RBT & cELISA (Sagamiko et al., 
2018) 
  36 
 
 
number of factors including the different study populations, the use of different 
diagnostic tests and even variability in the quality of the test antigen used 
where the same or a similar test has been used across different studies. 
Seroprevalence estimates generated using OIE recommended tests for livestock 
populations in East Africa are: 3.5% to 21.9% in cattle; 7.3% to 8.6% in sheep; 
and 2.0% to 17.0% in goats (Makita et al., 2011b; Miller et al., 2016; Nakeel et 
al., 2016; Nanyende, 2010; Osoro et al., 2015). Brucella spp. seroprevalence  
estimates for cattle and goat species in Tanzania to date do not differ greatly 
from estimates reported for wider East Africa. However, in sheep 
seroprevalence has been estimated to be higher in Tanzania than for other 
studies of East Africa (Mellau et al., 2009). This estimate may be a true 
representation of the prevalence of brucellosis in the pastoral study site. 
Equally, the elevated estimate may be a consequence of study design. Two 
diagnostic tests were run in parallel in the study, the RBT estimated a 
seroprevalence three times lower than the 23.1% seroprevalence estimated by 
the BMAT (Mellau et al., 2009). This variation in seroprevalence in the same 
study is an argument for the use of both a screening and confirmatory or 
complementary diagnostic test in order to generate more robust seroprevalence 
estimates. 
 
1.10 Control strategies 
In order to control human brucellosis, it is necessary to identify and control the 
Brucella spp. found in the animal reservoir hosts (Bamaiyi, 2016; Seleem et al., 
2010). Therefore, control programmes in high-income countries largely focus on 
animal and livestock-keeper interventions, which have resulted in reduced 
animal incidence and few reported human cases (Seleem et al., 2010; WHO et 
al., 2006). These animal and livestock-keeper interventions can include: 
adequate vaccination of susceptible animals; use of suitable brucellosis 
diagnostics; control of livestock movements; test and slaughter of infected 
animals; livestock-keeper compensation for culled animals; and certification and 
financial incentives for disease-free herd status (Moreno, 2014; Saegerman et 
al., 2010). 
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Human brucellosis is controlled, with only sporadic infections, across North 
America, Australia, New Zealand and parts of northern Europe, including the UK 
(Cutler et al., 2005; Moreno, 2014). Countries achieving control or even 
eradication of brucellosis are still susceptible to disease re-emergence due to 
livestock movements (Cutler et al., 2005). Therefore, ongoing surveillance, 
including abortion reporting, as well as pre- and post-import testing is 
important, although can be difficult to maintain when incidence is low (England 
et al., 2004; Maudlin et al., 2009). 
 
Zoonotic disease control becomes more complicated in areas where there is an 
interface with wildlife hosts (Grace et al., 2012). A well-known example of this 
is in the Greater Yellowstone Ecosystem where elk and bison represent the last 
reservoir hosts for B. abortus in the USA, which results in periodic reinfection in 
livestock hosts (Scurlock and Edwards, 2010). 
 
1.10.1 Control in sub-Saharan Africa 
In SSA, brucellosis control has been infrequently attempted outside southern 
Africa (Mcdermott and Arimi, 2002; OIE, 2013). The approaches that have been 
successful for brucellosis control in high-income countries are not necessarily the 
approaches that will work in SSA. Control programmes in these settings require 
infrastructure such as: capacity building in the form of educating communities 
about brucellosis risks; active surveillance and reporting; and sufficient 
laboratory facilities, effective diagnostic tests and trained technicians (Seleem 
et al., 2010).  
 
Furthermore, test and slaughter of livestock, one of the key control approaches 
in high-income countries, cannot be considered a realistic approach in SSA (WHO 
et al., 2006). Firstly, because the resources to compensate livestock-keepers for 
culled animals are not available, which would severely impair compliance with 
such a strategy. Secondly, there are more than 165 million impoverished people 
participating in some form of livestock-keeping in SSA (Grace et al., 2012; 
Herrero et al., 2012), and these livestock-keepers are often dependent on their 
animals not only as a source of income but also as an important source of 
nutrition (Rubach et al., 2013). Convincing these communities to have 
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potentially asymptomatic animals slaughtered, as well as to not consume the 
meat from these animals would be extremely difficult to implement and 
regulate. 
 
Restricting and monitoring livestock movements is another key aspect of 
brucellosis control that is challenging to implement in SSA. This is particularly 
true for potentially high-brucellosis risk nomadic communities that move in 
remote areas and may cross international borders (Corbel, 2006). There is a risk 
that livestock movements could even increase due to the introduction of a 
brucellosis control strategy, where testing animals for brucellosis can lead to the 
distress sale (i.e. urgent sale often at a compromised price) of test-positive 
livestock (Renukaradhya et al., 2002). 
 
Vaccination of livestock is viewed as a feasible approach to the control of 
brucellosis in SSA (WHO et al., 2006). Before a vaccination campaign can be 
developed, the Brucella species causing human infections must be identified, so 
that the correct animal host species can be targeted for vaccination. However, 
characterised isolates for human infections in SSA are not common (Ducrotoy et 
al., 2017). Representative data on the true burden of brucellosis is also 
important in guiding vaccination campaign decision making. Additionally, the 
implementation of a sustainable approach to vaccination must be carefully 
considered, as an approach that is not maintained successfully can have serious 
consequences for both public health and livestock production (Godfroid et al., 
2013a). This has been demonstrated in Greece, where successful national 
vaccination of small ruminants using Rev-1 was discontinued (Minas et al., 2004). 
This was followed by a rapid increase in livestock and human brucellosis 
incidence which required implementation of an emergency mass vaccination 
campaign (Minas et al., 2004). If sufficient evidence about the epidemiology of 
brucellosis in an area can be collected and sustainable funding can be allocated 
to a vaccination campaign, then additional aspects of vaccination need to be 
carefully considered. These aspects include: the demographic group to be 
targeted; type of vaccine to use; the route of vaccination (conjunctival or 
subcutaneous); and the frequency of vaccination (Ducrotoy et al., 2017). 
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An additional approach in brucellosis control that has been endorsed for SSA is 
the implementation of specific hygiene measures, such as the pasteurisation of 
dairy products (Doganay and Aygen, 2003). The aim of improved hygiene 
measures is to reduce exposures to infected animals and their products (Corbel, 
2006). Effecting change in traditional consumption and livestock-keeping 
practices of local communities will likely be extremely challenging. Therefore, 
control strategies that are developed considering the specific needs and 
perceptions of the community are vital (Marcotty et al., 2009). 
 
Finally, due to the zoonotic nature of brucellosis a One Health approach must be 
taken with regard to its control (Hattendorf et al., 2017). The control of 
brucellosis is a complex task involving a wide range of stakeholders. There must 
be an inclusive and holistic multi-sectoral approach to any brucellosis control 
intervention to maximise its impact (Godfroid et al., 2013a).  
 
1.11 Overview of thesis aims 
Brucellosis is an epidemiologically complex disease that causes incapacitating 
long-lasting illness and diminishes livestock productivity. For impoverished 
communities in LMICs, without the control of NZDs such as brucellosis the cycle 
of disease and poverty will continue (Molyneux et al., 2011). In SSA where the 
global brucellosis burden is estimated to be greatest (Racloz et al., 2013), the 
availability of robust data is crucial in understanding the true burden of the 
disease (Dean et al., 2012b). Novel representative data on brucellosis burden 
can be used to inform the development of effective evidence-based disease 
prevention and control strategies (Corbel, 2006). 
 
The broad aim of this thesis is to improve our understanding of identified 
knowledge gaps in the epidemiology of brucellosis in Tanzania and wider SSA. 
The knowledge gap that Chapter 2 aims to address is the need for more detailed 
epidemiological data, particularly in areas suspected to be at high risk of 
brucellosis in Tanzania. This chapter describes identification of the risk factors 
associated with acute human brucellosis in a pastoralist community of Tanzania. 
Representative data on acute brucellosis risk factors can help to identify the 
demographic at highest risk of recent active infection, which is vital in the 
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effective prioritisation of disease control interventions. This is the first study of 
risk factors for acute brucellosis in a pastoralist community in Tanzania, and one 
of few in East Africa. The knowledge gap that Chapter 3 aims to address is the 
need for surveillance approaches that assist in providing a true representation of 
brucellosis burden in Tanzania. This chapter describes investigation into the use 
of community-based active surveillance in the form of screening household 
members of febrile hospital patients in a pastoralist community. It is recognised 
that only a proportion of the population in SSA will access a healthcare facility 
when suffering from febrile illness (Panzner et al., 2016). Therefore, 
community-based approaches can play a very important role in brucellosis 
surveillance. The key aims of this study are to determine if additional acute 
brucellosis cases can be identified in household members of febrile patients and 
to evaluate if there is any evidence of grouping of Brucella spp. exposure status 
between household members and febrile hospital patients. This is the first study 
to implement this form of active surveillance for brucellosis in Tanzania. Similar 
studies in SSA are not evident. The knowledge gap that Chapter 4 aims to 
address is the need for a validated and standardised brucellosis diagnostic test 
approach in Tanzania. This chapter describes evaluation of brucellosis diagnostic 
test performance in cattle, sheep and goats, as well as estimating disease 
prevalence in different livestock-keeping communities. In the absence of a gold 
standard test, diagnostic test performance data are vital in evaluating the 
probability of available brucellosis tests to correctly identify Brucella spp. 
exposures. The key aim of this study is to generate robust estimates for 
individual test performance and testing protocols in cattle, sheep and goats. 
This is the first study to evaluate RBT and cELISA diagnostic test performance in 
Tanzania for cattle, it is likely the first study in SSA for sheep and goats. The 
results from each of these chapters can be used to improve estimates of the true 
burden of brucellosis in SSA and inform the implementation of an evidence-
based brucellosis prevention and control strategy for Tanzania. 
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Chapter 2 Risk factors for acute brucellosis in febrile 
patients from a pastoralist community 
 
Sections of this chapter have been published: Bodenham, R.F., Lukambagire, 
A.S., Ashford, R.T., Buza, J.J., Cash-Goldwasser, S., Crump, J.A., Kazwala, 
R.R., Maro, V.P., McGiven, J., Mkenda, N., Mmbaga, B.T., Rubach, M.P., 
Sakasaka, P., Shirima, G.M., Swai, E.S., Thomas, K.M., Whatmore, A.M., 
Haydon, D.T., Halliday, J.E.B., 2020. Prevalence and speciation of brucellosis in 
febrile patients from a pastoralist community of Tanzania. Scientific Reports. 
10, 7081 
 
 
2.1 Introduction 
Understanding risk factors for human brucellosis is invaluable in the 
development of successful brucellosis prevention and control interventions, and 
in effective policy-making (Dean et al., 2012a). Specifically, risk factor data can 
be used to feedback to the study community. This enables communication about 
high risk transmission activities, as well as methods to decrease transmission, 
therefore contributing towards reducing the impacts of human brucellosis 
(Corbel, 2006). 
 
In the identification of risk factors for human brucellosis, different definitions 
for human brucellosis status are frequently investigated. Often, reported risk 
factors for human brucellosis are defined by serology, this is because serology is 
an easier and safer diagnostic approach as compared to the gold standard 
method of bacterial isolation by culture (Díaz et al., 2011). However, when 
conducting brucellosis serology without quantifying antibody titres, it is not 
possible to distinguish the stage of infection (Al Dahouk et al., 2013), or indeed 
identify active infection from historic Brucella spp. exposure (Al Dahouk and 
Nöckler, 2011). This is because Brucella spp. antibodies can persist in the blood 
for years following recovery (Araj, 2010). Serology tests that identify a single 
high antibody titre or a four-fold increase in titre between acute and 
convalescent-phase sera are often classified as active brucellosis (Al Dahouk et 
al., 2013). Identifying risk factors for a population with acute brucellosis 
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infection will likely identify more temporally relevant risk activities than 
investigating risk factors for exposure to Brucella spp. If risk factors identified 
for acute brucellosis infection are used to guide disease prevention and control 
interventions, they may be more effective in impacting on Brucella spp. 
transmission than those risk factors determined by Brucella spp. exposure. 
 
Across high- to low-income countries, the risk factors for human brucellosis 
exposure broadly include, consumption of unpasteurised dairy products and 
direct contact with infected animals (Dean et al., 2012a; Rubach et al., 2013). 
However, risk factors for human brucellosis are setting-specific, and are 
determined by the activities of the human population under consideration and 
the host species present (Cash-Goldwasser et al., 2018). Focusing within East 
Africa (including Tanzania, Kenya, Uganda, Burundi and Rwanda), the risk 
factors for human brucellosis exposure can usually be classified within the 
following groups: ingestion of raw animal products (such as meat, blood and 
milk); close contact with livestock (such as assisting in animal parturition); 
slaughtering, cleaning and handling carcasses; occupation (which is often a 
proxy for some of the other frequently reported risk behaviours); and a reported 
family history of brucellosis (John et al., 2010; Migisha et al., 2018; Miller et al., 
2016; Nanyende, 2010; Nasinyama et al., 2014; Njeru et al., 2016b; Orsel et al., 
2015; Osoro et al., 2015; Qido, 2008; Rujeni and Mbanzamihigo, 2014; Swai and 
Schoonman, 2009; Tumwine et al., 2015). 
 
Pastoralist communities in particular are in frequent contact with livestock, and 
in endemic areas are at a high risk of human brucellosis infection (Mcdermott 
and Arimi, 2002; Rubach et al., 2013). In sub-Saharan Africa (SSA), 16% of the 
human population relies on pastoralism (Racloz et al., 2013). In Tanzania, 
approximately 40% of the population are exclusive pastoralists (PINGO’s Forum, 
2016). The highly mobile nature of pastoralist communities, coupled with low 
population densities make information gathering challenging, leading to scarcity 
of epidemiological data for brucellosis (Racloz et al., 2013), as well as for other 
infectious diseases. Human brucellosis often goes misdiagnosed and uncontrolled 
in many pastoralist communities (Plumb et al., 2013). 
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Examples of risk factor analyses for acute brucellosis infection in East Africa are 
rare. This is because there are few studies that have successfully isolated 
Brucella spp. from culture (Ducrotoy et al., 2017), used PCR confirmation 
(Doganay and Aygen, 2003), or quantification of serology titres. However, a 
study including a largely urban population seeking care at hospitals in Moshi, 
Tanzania, identified assisting in birthing of small ruminants and contact with 
cattle as risk factors for acute brucellosis infection, whereas consumption of 
pasteurised dairy products reduced the risk of acute brucellosis (Cash-
Goldwasser et al., 2018). In three largely agro-pastoralist communities of 
Uganda, ingestion of raw dairy products has also been reported as a risk factor 
for acute infection (Asiimwe et al., 2015). Identification of risk factors for acute 
brucellosis infection within pastoralist communities are limited. Two Kenyan 
studies of overlapping pastoralist communities found purchase and consumption 
of raw dairy products and contact with livestock species to be risk factors for 
acute brucellosis (Kiambi, 2012; Njeru et al., 2016a). This study is the first to 
perform a risk factor analysis to identify risk factors for acute brucellosis 
infection in a pastoralist community of Tanzania. 
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2.1.1 Study aims 
The aims of this study were:  
 
1. To identify risk factors for acute brucellosis infection in febrile patients 
from a pastoralist community presenting at a rural hospital in Tanzania 
 
2. To compare the risk factors identified for this study population to risk 
factors previously described for acute human brucellosis studies in 
Tanzania and East Africa 
 
  45 
 
 
2.2 Methods 
2.2.1 Study site and population 
This study was conducted at the Endulen Hospital in the Ngorongoro 
Conservation Area (NCA), Tanzania (see Figure 2.1). The NCA is an 8,292 km2 
multiple land use area designated for pastoralism, wildlife conservation and 
tourism (Government of Tanzania, 1996). The NCA has a human population of 
approximately 70,000 (NBS, 2013), largely comprised of semi-nomadic Maasai  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The Endulen Hospital (white X) location within the Ngorongoro 
Conservation Area (blue shading) within Arusha Region and adjacent to 
Simiyu Region (beige shading), and the location of Arusha and Simiyu Regions 
within a regional map of Tanzania (grey shading), polygon boundaries are 
shown for all villages within the NCA (blue shading). Shapefiles of 
administrative boundaries from the 2012 census were sourced from the 
Tanzania National Bureau of Statistics. Map reproduced from Bodenham et al., 
2020, Creative Commons Attribution license: 
http://creativecommons.org/licenses/by/4.0/ 
 
Simiyu
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pastoralists (Allen et al., 2013). The main livestock species kept by the local 
Maasai community are cattle, sheep and goats (Government of Tanzania, 1996).  
The Endulen Hospital is a rural 110-bed hospital (Orsel et al., 2015), and the  
only hospital facility within the NCA. It is situated approximately 1900 meters 
above sea level, and the local area typically has a long rainy season from March 
to May and a short rainy period between October to December (NBS and ORC 
Macro, 2005). 
 
2.2.2 Febrile hospital-based surveillance study 
The risk factor analysis presented in this research chapter utilised data collected 
from a febrile hospital-based surveillance study (hereafter referred to as the 
febrile hospital study). The febrile hospital study was conducted by a larger 
research collaborative group to determine the prevalence of acute brucellosis in 
febrile hospital patients presenting at the Endulen Hospital. The methods 
described in Sections 2.2.3 – 2.2.6 refer to the methods employed in the larger 
febrile hospital study. These sections are described so as to understand the 
eligibility and enrolment protocol, blood sample collection and processing and 
questionnaire data collection performed that informed the subsequent risk 
factor analyses. RFB contributed to the larger febrile hospital study and was 
involved in the conceptualisation, design and implementation of the febrile 
hospital study, and designed the participant questionnaire. This chapter focuses 
on the risk factor analysis, all elements of which were performed by RFB. The 
methods detailed in Sections 2.2.7 onwards were performed specifically for the 
purpose of this research chapter and describe the risk factor analyses conducted 
here. 
 
2.2.3 Febrile hospital study: Eligibility and enrolment 
All patients attending the outpatient department (OPD) at Endulen Hospital with 
a tympanic temperature of ≥ 38.0 °C at the time of OPD presentation, or with a 
reported history of fever in the 72 hours prior to OPD presentation and aged two 
years or above were eligible for inclusion in the febrile hospital study. Eligible 
febrile hospital patients were enrolled into the febrile hospital study following 
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completion of written informed consent (see Appendix 1 for Participant 
Information and Consent Forms). 
 
2.2.4 Febrile hospital study: Blood sample collection & 
processing 
Following febrile hospital study enrolment, a blood sample was drawn by a 
clinical study team member for culture and acute-phase Brucella spp. serology 
testing. The blood sampling and sample bottle inoculation procedure was as 
follows: the participant’s skin was cleaned around the selected blood draw site 
with isopropyl alcohol and povidone iodine. For febrile hospital participants 
weighing ≥25 kg, a 40 mL blood volume was collected at enrolment. Three 
culture bottles were inoculated with a target blood volume of 10 mL each: two 
BacT/ALERT (BioMérieux, Durham, NC, USA) aerobic culture bottles for 
automated culture; and a Castañeda (Ruiz Castañeda., 1961) bi-phasic media 
bottle. A plain vacutainer (BD, Franklin Lakes, NJ, USA) was filled with a target 
10 mL of blood for serological testing and malaria testing was performed using 
SD BIOLINE Malaria Ag P.f/Pan rapid diagnostic test (Standard 
Diagnostics/Abbott, Abbott Park, IL, USA) or CareStart Malaria HRP2 (Pf) 
(ACCESS BIO, INC. Somerset, NJ, USA). Febrile hospital participants weighing <25 
kg had a blood draw volume calculated based on weight. Sample bottle 
inoculation was the same as above, except that two paediatric BacT/ALERT 
bottles were inoculated for automated culture. Febrile hospital participants 
were approached four to six weeks after initial enrolment, for the collection of a 
target 10 mL blood volume which was inoculated into a plain vacutainer for 
convalescent-phase serology. 
 
Inoculated culture bottles were transported at between 4-10 ºC on the day of 
inoculation to the Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania. 
KCRI laboratory processing typically began the day after culture bottle inoculation 
and followed standardised protocols for identifying isolates (Crump et al., 2011b, 
2011a). 
 
Immediately following filling of the plain vacutainer, it was inverted 5 times and 
kept at ambient temperature for 45-60 minutes allowing clotting of the sample. 
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Following clotting, the vacutainer was spun at 1300-1500 g for 10 minutes in a 
centrifuge. Separated serum samples were pipetted into cryovials and stored at 
4 °C at the Endulen Hospital before transfer at between 4-10 °C, with inoculated 
culture bottles, to KCRI. At KCRI, sera were stored at -80 °C. At the conclusion 
of the febrile hospital study participant enrolment, all sera were shipped on dry 
ice to the Animal and Plant Health Agency (APHA), Weybridge, UK. The APHA 
conducted serological testing by the serum agglutination test (SAT). 
 
2.2.5 Definition: Acute brucellosis case 
An acute brucellosis case was based on the CDC 2010 brucellosis case definition 
(CDC, 2010) and is defined as follows: 
 
“A clinically compatible illness with:  
culture and identification of Brucella spp. (confirmed acute case) 
OR 
evidence of a four-fold or greater rise in Brucella antibody titre by SAT, 
between acute- and convalescent-phase sera obtained ≥2 weeks apart 
(confirmed acute case)  
OR 
a Brucella total antibody titre ≥160 by SAT in either acute- or 
convalescent-phase sera (probable acute case)” 
 
2.2.6 Febrile hospital study: Participant questionnaire 
Following blood sampling of each febrile hospital participant, a study team 
member administered a structured, closed-ended questionnaire. Questionnaire 
topics included: demographic data; current and recent illness symptoms; 
reported history of brucellosis; dietary practices over the past 12 months; 
animal-related activities over the past 12 months; and pregnancy history, for 
adult female participants. The study team member read through each question 
in the preferred language of the febrile hospital participant (Maa or Swahili), 
completing the questionnaire with each febrile hospital participant individually, 
or in the presence of a parent or guardian. Where children were unable to 
respond, a parent or guardian assisted in completing the questionnaire on their 
behalf. Questionnaire data were collected using a paper-based OpenText 
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Teleform (OpenText, Waterloo, Ontario, Canada) format. Questionnaire 
administration was tested by the study team during the first three months of the 
febrile hospital study and was revised where necessary. All questionnaire data 
collected throughout the study were included in the final questionnaire dataset 
for analysis. Questionnaire data were digitised using the OpenText Teleform 
System, which generated an Access database (Microsoft Corporation, Redmond, 
WA, USA). The full febrile hospital study participant questionnaire can be found 
in Appendix 2. 
 
2.2.7 Risk factor analysis: Questionnaire data cleaning 
Analysing large datasets in order to investigate risk in epidemiological studies is 
common (Dohoo et al., 1997). The participant questionnaire for this study 
comprised a large number of questions that were considered candidate variables 
for risk factor analyses. Any candidate variable with more than 10% missing data 
was discounted and removed from the dataset. Candidate variables that were 
suspected of being poorly completed were also removed, such as any variable 
where interpretation of the question by the study population was reported as 
repeatedly challenging by the questionnaire administrator. Those candidate 
variables with multiple choice for the time period of reference, such as 
activities conducted over the last 30 days and over the last 12 months, were 
reduced to activities over the last 12 months. For identical questions repeated 
for individual livestock species (cattle, sheep and goats), responses were 
aggregated into a combined ‘livestock’ candidate variable. The outcome 
variable for the risk factor analyses was acute brucellosis status (case or non-
case). 
 
There is no single answer as to how many candidate variables are too many to 
include in a regression, however any regression analysis will be subject to 
overfitting and the validity of the model estimates compromised if too many 
candidate variables are included. One heuristic approach is that there must be 
10 or more observations in the dataset per candidate variable included in the 
model (Dohoo et al., 2003a). Another suggestion is that to power a regression 
analysis, there should be a minimum of 50 observations, with a further 8 
observations for each candidate variable included in the analysis and that the 
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number of observations should be increased further if the effect size is small 
(Green, 1991). Here, in order to minimise the risks of overfitting and improve 
the robustness of the risk factor analysis, three different data reduction 
methods were tested on the candidate variable dataset: multiple 
correspondence analysis (MCA); literature-informed logistic regression; and lasso 
regression. The outcomes of each method were considered in the decision for 
the final risk factor variables identified. 
 
2.2.8 Risk factor analysis: Multiple correspondence 
analysis 
MCA is a form of exploratory data analysis that can be used as a dimension 
reduction technique for categorical variables (Dohoo et al., 2003a). MCA is 
similar to principle components analysis, as it aims to detect a reduced set of 
orthogonal dimensions that maximise the explained variability in a large dataset 
(D’Enza and Greenacre, 2012). This technique therefore allows investigation into 
correlation between candidate variables and how imposed dimensions on the 
data are related to an outcome variable (Dohoo et al., 2003a). Usually, 
interpretation of MCA dimensions are restricted to the first two or three 
dimensions generated (Abdi and Valentin, 2007). A reduced dimension dataset 
selected by MCA can then be used to inform regression model construction. 
 
Here, MCA was used to explore twenty-nine candidate variables, with acute 
brucellosis status (case or non-case) as the outcome variable. The only 
continuous variable, age in years, was discretised by creating age classes: 0-5 
years; 6-12 years; etc. MCA does not support incomplete data, therefore the 
missMDA R package (Husson and Josse, 2019) was used to impute missing data. 
The FactoMineR R package (Husson et al., 2019) was used for MCA 
implementation. All data manipulation and analyses were performed in R 
software version 3.6.1 (R Core Team, 2019). 
 
2.2.9 Risk factor analysis: Literature-informed logistic 
regression 
In a literature-informed logistic regression, scientific literature identifying risk 
factors for human brucellosis infection in East Africa informed the selection of 
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candidate variables from the larger dataset. Epidemiologic opinion-informed 
candidate variables regarding livestock-human interactions and possible 
transmission routes were also selected for logistic regression. Univariable 
Bernoulli-distributed generalised linear models (GLM) were used to individually 
investigate each of the selected candidate variables' association with the 
outcome variable: acute brucellosis status (case or non-case). For the continuous 
variable age in years, a quadratic relationship with the outcome variable was 
suspected and therefore fitting a second order polynomial was investigated. 
Crude odds ratios (OR) and 95% confidence intervals (CI) were estimated. 
 
Literature- or epidemiologic opinion-informed candidate risk factor variables 
were included in a multivariable Bernoulli-distributed GLM maximal model, with 
acute brucellosis status (case or non-case) as the outcome variable. For the age 
variable, inclusion of a quadratic polynomial was investigated again. Backward 
model selection was performed using likelihood ratio testing (LRT). Adjusted 
odds ratios (aOR) and 95% CI were calculated. The pseudo R-squared value is 
reported for maximal and final models. 
 
A p-value ≤0.05 was considered statistically significant across all logistic 
regression analyses. All data manipulation and GLM analyses were performed in 
R software version 3.6.1 (R Core Team, 2019). 
 
2.2.10 Risk factor analysis: Exploring candidate 
variable relationships 
Any candidate risk factor variables identified as significantly associated with 
acute brucellosis status in univariable analysis and dropped from the final 
multivariable model during model selection were investigated in order to 
identify any collinearity with final model risk factor variables. 
 
2.2.11 Risk factor analysis: Lasso regression 
Lasso regression is a data shrinkage technique that penalises the estimated 
regression coefficients, these coefficients are constrained so the sum of the 
absolute value of the estimated coefficients is less than the constant l 
(Tibshirani, 1996). The result of applying this constraint means that some 
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candidate variables will be shrunk to zero and can therefore can be removed 
from the model (Harrell Jr., 2015). Cross-validation is used to determine l. 
 
A lasso regression was fitted to the candidate variables from the literature- and 
epidemiologic opinion-informed logistic regression maximal model. This was 
performed in order to verify whether a similar set of final candidate variables 
were selected using this penalised regression analysis, as compared to logistic 
regression backward model selection using LRT. A value of l one standard error 
(SE) greater than the minimised l was chosen. The binomial deviance loss 
function was specified as recommended for logistic regression type models. 
Cross-validation and lasso regression were performed using the glmnet R 
package (Friedman et al., 2019) in R software version 3.6.1 (R Core Team, 
2019). 
 
2.2.12 Research clearance and ethics 
Implementation of the febrile hospital study was approved by the Tanzania 
Commission for Science and Technology, the Tanzania Wildlife Research Institute 
and the Ngorongoro Conservation Area Authority. The Kilimanjaro Christian 
Medical Centre Ethics Committee (698), the National Institute of Medical 
Research Tanzania (NIMR/HQ/R.8c/Vol.I/1140), the University of Otago Human 
Ethics Committee (H17/052), and the University of Glasgow College of Medical, 
Veterinary and Life Sciences Human Ethics Committee (200140149) gave ethical 
approval for this study. All research conducted was in accordance with the 
guidelines and regulations of the aforementioned organisations. 
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2.3 Results 
2.3.1 Risk factor analysis data set 
Between 15th August 2016 and 11th October 2017, 3,473 patients were screened 
at the Endulen Hospital. Of these patients, 435 (12.5%) were eligible for 
participation in the febrile hospital study. A total of 232 (53.3%) of 435 patients 
were enrolled and contributed data to analyses.  
 
Overall, 230 (99.1%) of 232 febrile hospital participants had a blood sample 
collected for culture and/or serological testing. Of 230 febrile hospital 
participants, 130 (56.5%) were female and the median febrile hospital 
participant age was 27 years (range: 2 - 78 years). A total of 228 (99.1%) of 230 
febrile hospital participants had at least one culture bottle inoculated. 
Bloodstream infections were detected in 14 (6.1%) of 228 febrile hospital 
participants. The different bloodstream infections identified are given in Table 
2.1. Eight (3.5%) of 228 febrile hospital participants were Brucella spp. culture 
positive. One (0.4%) of 230 febrile hospital participants had a four-fold increase 
in antibody titre between acute- and convalescent-phase sampling by SAT. 
Therefore, 9 (3.9%) of 230 febrile hospital participants could be defined as 
confirmed acute brucellosis cases. A further 5 (2.2%) of 230 febrile hospital 
participants had a single SAT titre ≥160 and could be defined as probable acute 
brucellosis. In total, 14 (6.1%) of 230 febrile hospital participants met the 
definition for an acute brucellosis case. Thus, the outcome variable for risk  
 
Table 2.1: The number and proportion of febrile hospital participants 
(n=228) with evidence of a bloodstream infection by blood culture identified 
during the febrile hospital study, reproduced from Bodenham et al., 2020, 
Creative Commons Attribution license: 
http://creativecommons.org/licenses/by/4.0/  
Microorganism Total number (%) of 
febrile hospital 
participants with 
microorganism 
bloodstream infection 
Brucella spp. 8 (3.5) 
Enterococcus spp. 1 (0.4) 
Escherichia coli 1 (0.4) 
Salmonella enterica 1 (0.4) 
Salmonella enterica serovar Typhi 1 (0.4) 
Staphylococcus aureus 1 (0.4) 
Streptococcus pneumoniae 1 (0.4) 
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factor analyses, acute brucellosis status, had 14 positive instances. Additionally, 
6 (2.6%) of 230 febrile hospital participants were malaria rapid test positive. The 
febrile hospital study screening, eligibility, enrolment and brucellosis data 
collection steps are shown in Figure 2.2. 
 
 
Figure 2.2: Flowchart of febrile hospital study screening, eligibility, 
enrolment and brucellosis data collection figures, reproduced from Bodenham 
et al., 2020, Creative Commons Attribution license: 
http://creativecommons.org/licenses/by/4.0/ 
 
All of the 230 febrile hospital participants had questionnaire data collected, 55 
(23.9%) of 230 febrile hospital participants had questionnaire data collected 
during the initial questionnaire testing period. The raw data set contained 346 
variables. Following the removal of variables with greater than 10% missing 
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values and any variables suspected to be poorly completed, as well as collapsing 
multiple choice variables, a total of 28 candidate variables remained. 
 
2.3.2 Multiple correspondence analysis 
The 28 candidate variables were included in an MCA. The outputs for the first 
three MCA dimensions were investigated. Dimension 1, 2 and 3 cumulatively 
explained 29.3% of the variance (see Table 2.2). Candidate variable factor levels 
(e.g. yes and no responses to risk factor questions) that contributed most to the 
construction of orthogonal dimensions 1, 2 and 3 are shown in Figure 2.3. 
Candidate variables identified in the first dimension explaining the most 
variance in the dataset were largely activities involving close contact with 
livestock, including: handled or had contact with any placental or birth products 
of livestock; assisted in the birthing of livestock; and herded any livestock. In 
the second dimension, the first candidate variables included demographic 
features such as marital status and age. The top ten contributing candidate 
variables to each of the first three MCA dimensions are described in Table 2.3. 
 
Table 2.2: Eigenvalues and proportion of variance explained by the first 5 
dimensions of multiple correspondence analysis 
Dimension Eigenvalue Variance (%) Cumulative  
variance (%) 
1 0.177 14.354 14.354 
2 0.101 8.158 22.512 
3 0.083 6.750 29.262 
4 0.070 5.669 34.931 
5 0.064 5.188 40.119 
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Figure 2.3: The proportion of contribution of the top ten candidate variable 
factors to the construction of three multiple correspondence analysis 
orthogonal dimensions, panels A, B and C show the proportion of contribution 
of the top ten candidate variable factors for dimensions 1, 2 and 3, 
respectively, red dashed line shows the average expected value if all candidate 
variable factor contributions were equal, Y and N are Yes and No factor levels, 
respectively, candidate variables represent activity performed over the past 
twelve months where applicable or otherwise stated, animal-related candidate 
variables represent responses for cattle, sheep and goat species   
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Table 2.3: Risk factor candidate variables contributing to the first three 
dimensions of multiple correspondence analysis (MCA), including factor 
levels, candidate variable description and period of reference, N/A is not 
applicable, candidate variable names in parentheses are the names as used in 
MCA analyses and outputs 
MCA  
candidate  
variable name Factor levels Description 
Period of 
reference 
Age 0-5 yrs 
6-12 yrs 
13-18 yrs 
19-34 yrs 
35-54 yrs 
55+ yrs 
Age class of participant 
at the time of enrolment 
N/A 
Sex Female 
Male 
Sex of participant N/A 
Marital status Single 
Not single 
Marital status of the 
participant 
N/A 
Education None 
Primary_education 
Secondary_education 
High_school_education 
Higher_education 
Formal education level 
of the participant  
N/A 
Occupation Livestock_Attendant 
Other 
The main occupation of 
the participant 
N/A 
Tribe Maasai 
Non-Maasai 
The identified tribe of 
the participant 
N/A 
Travelled 
(Travel_PastMonth) 
No 
Yes 
Has the participant 
travelled outside their 
home region? 
Past 
month 
Livestock abortions 
in herd or flock 
(Livestock_Abortion) 
No 
Yes 
Have any cattle, sheep 
or goats from the 
participant’s family herd 
or flock kept at the 
household aborted or 
delivered still-born 
offspring? 
Past 12 
months 
Assisted with the 
birth of livestock 
(Assisted_Birthing) 
 
No 
Yes 
Has the participant 
assisted with the birth 
of any cattle, sheep or 
goats? 
Past 12 
months 
Milked livestock 
(Milked_Livestock) 
No 
Yes 
Has the participant 
milked cattle, sheep or 
goats? 
Past 12 
months 
Herded livestock 
(Herded_Livestock) 
No 
Yes 
Has the participant 
herded cattle, sheep or 
goats? 
Past 12 
months 
Slaughtered or 
butchered livestock 
(Slaughtered/ 
Butchered) 
No 
Yes 
Has the participant 
slaughtered or 
butchered, or assisted in 
the slaughtering or 
butchering of cattle, 
sheep or goats? 
Past 12 
months 
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Handled livestock 
hide 
(Handled_Hides) 
No 
Yes 
Has the participant 
handled or prepared the 
hides of any cattle, 
sheep or goats? 
Past 12 
months 
Handled livestock 
birth products 
(Handled_Birth 
Products) 
No 
Yes 
Has the participant 
handled or had contact 
with any placental or 
both material of any 
cattle, sheep or goats? 
Past 12 
months 
Handled livestock 
aborted materials 
(Handled_Aborted 
BirthProducts) 
No 
Yes 
Has the participant 
handled or had contact 
with any aborted birth 
products from cattle, 
sheep or goats including: 
dead young or offspring; 
animal fluid; placenta; 
or blood? 
Past 12 
months 
Consumed raw 
meat, offal or blood 
(Consumed_Raw 
Meat/Blood) 
No 
Yes 
Has the participant 
consumed raw: meat; 
offal; or blood from 
cattle, sheep or goats? 
Past 12 
months 
Consumed aborted 
livestock materials 
(Consumed_Aborted
Products) 
No 
Yes 
Has the participant 
consumed meat, offal or 
placenta from aborted 
cattle, sheep or goats? 
Past 12 
months 
Consumed blood 
mixed with soup 
(Consumed_Soup& 
Blood) 
No 
Yes 
Has the participant 
consumed soup with 
cattle, sheep or goats’ 
blood? 
Past 12 
months 
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2.3.3 Literature-informed logistic regression 
A total of 18 literature- or epidemiologic opinion-informed candidate variables 
were selected from the larger 28 candidate variable dataset. Each of the 18 
selected candidate variables are described in Table 2.4. These 18 candidate 
variables were then individually assessed using univariable GLM analysis, in order 
to investigate each of the selected candidate variables' association with 
brucellosis case status. A quadratic relationship for the candidate variable age 
was fitted to the univariable analysis, however it did not significantly improve 
model fit and so a linear relationship was assumed. Eight of the selected 
candidate variables caused inflation of the estimated standard errors most likely 
due to lack of data in acute brucellosis cases and were dropped from the 
analyses. For each of the 10 remaining candidate variables, the proportion of 
febrile hospital patient responses for each factor level are given in Table 2.5. 
The univariable analyses indicated a significant association between acute 
brucellosis cases and declining age in years (OR = 0.89, 95% CI = 0.83 - 0.95, p 
<0.001), male sex (OR = 3.50, 95% CI = 1.13 – 13.08, p = 0.039) and having 
herded any livestock in the past 12 months (OR = 10.85, 95% CI = 2.86 – 70.95, p 
< 0.01). Univariable analysis OR, 95% CI and p values are given for the 10 
candidate variables in Table 2.5. 
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Table 2.4: Literature- or epidemiologic opinion-informed candidate risk 
factor variables selected for inclusion in logistic regression analyses, 
including factor levels, candidate variable description and period of 
reference, N/A is not applicable, * represents candidate variables that were 
included in the final logistic regression analyses 
Candidate  
variable Factor levels Description 
Period of 
reference 
Age* Years (continuous) Age of participant at the time of 
enrolment 
N/A 
Sex* Female 
Male 
Sex of participant N/A 
Education None 
Primary 
Secondary 
High school 
Higher 
Formal education level of the 
participant  
N/A 
Occupation Livestock attendant 
Other 
The main occupation of the 
participant 
N/A 
Livestock 
abortions in 
herd or flock* 
No 
Yes 
Have any cattle, sheep or goats 
from the participant’s family herd 
or flock kept at the household 
aborted or delivered still-born 
offspring? 
Past 12 
months 
Assisted with 
the birth of 
livestock* 
No 
Yes 
Has the participant assisted with 
the birth of any cattle, sheep or 
goats? 
Past 12 
months 
Milked 
livestock* 
No 
Yes 
Has the participant milked cattle, 
sheep or goats? 
Past 12 
months 
Herded 
livestock* 
No 
Yes 
Has the participant herded cattle, 
sheep or goats? 
Past 12 
months 
Handled 
livestock 
waste* 
No 
Yes 
Has the participant handled the 
manure of any cattle, sheep or 
goats including: during building 
construction; or cleaning animal 
pens? 
Past 12 
months 
Slaughtered 
or butchered 
livestock* 
No 
Yes 
Has the participant slaughtered or 
butchered, or assisted in the 
slaughtering or butchering of 
cattle, sheep or goats? 
Past 12 
months 
Handled 
livestock 
carcass 
No 
Yes 
Has the participant handled or 
had contact with the carcasses of 
any cattle, sheep or goats? 
Past 12 
months 
Handled 
livestock hide 
No 
Yes 
Has the participant handled or 
prepared the hides of any cattle, 
sheep or goats? 
Past 12 
months 
Handled 
livestock 
aborted 
materials 
No 
Yes 
Has the participant handled or 
had contact with any aborted 
birth products from cattle, sheep 
or goats including: dead young or 
offspring; animal fluid; placenta; 
or blood? 
Past 12 
months 
Consumed 
raw dairy 
products* 
No 
Yes 
Has the participant consumed raw 
dairy products including raw: 
milk, yoghurt, cheese, butter, 
Past 12 
months 
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cream or other products made 
with raw dairy? 
Consumed 
raw meat, 
offal or 
blood* 
No 
Yes 
Has the participant consumed 
raw: meat; offal; or blood from 
cattle, sheep or goats? 
Past 12 
months 
Consumed 
aborted 
livestock 
materials 
No 
Yes 
Has the participant consumed 
meat, offal or placenta from 
aborted cattle, sheep or goats? 
Past 12 
months 
Consumed 
blood mixed 
with soup 
No 
Yes 
Has the participant consumed 
soup with cattle, sheep or goats’ 
blood? 
Past 12 
months 
Consumed 
blood mixed 
with milk 
No 
Yes 
Has the participant consumed 
blood mixed with milk from 
cattle, sheep or goats? 
Past 12 
months 
 
 
Table 2.5: Univariable logistic regression results for ten literature- and 
epidemiologic opinion-informed candidate variables and the number and 
proportion of acute brucellosis cases at each candidate variable factor level, 
N is the total number of febrile hospital participants with data available, n is 
the number of acute brucellosis cases at each candidate variable factor level, % 
is the proportion of acute brucellosis cases, OR is crude odds ratios, CI is 
confidence intervals, p values reported to three decimal places, for Age in years 
median age and age range of acute brucellosis cases and total participants are 
reported 
  
Acute brucellosis 
cases 
Logistic regression 
Candidate variable  n/N (%) OR (95% CI) p value 
Age in years 
median (range)  11 (7, 20)/28 (2,78) 0.89 (0.83, 0.95) <0.001  
Sex  Female  4/130 (3.1)  Ref  
 Male  10/100 (10.0)  3.50 (1.13, 13.08) 0.039  
Livestock abortions in 
herd or flock 
No 
Yes 
4/127 (3.1) 
8/88 (9.1) 
Ref 
3.08 (0.94, 11.83) 
 
0.074 
Assisted with the 
birth of livestock  
No 
Yes  
11/170 (6.5) 
3/57 (5.3)   
Ref 
0.80 (0.18, 2.69) 
 
0.743 
Milked livestock  
No 
Yes 
6/142 (4.2) 
8/83 (9.6) 
Ref 
2.42 (0.81, 7.59) 
 
0.114 
Herded livestock  
No 
Yes 
2/134 (1.5) 
12/85 (14.1) 
Ref 
10.85 (2.86, 70.95) 
 
0.002 
Handled livestock 
waste  
No 
Yes 
7/109 (6.4) 
7/119 (5.9)  
Ref 
0.91 (0.30, 2.75) 0.865  
Slaughtered or 
butchered livestock  
No 
Yes 
5/43 (11.6) 
9/184 (4.9) 
Ref 
0.39 (0.13, 1.33) 
 
0.109 
Consumed raw dairy 
products  
No 
Yes 
7/167 (4.2)  
7/62 (11.3) 
Ref 
2.91 (0.96, 8.86) 0.055 
Consumed raw meat, 
offal or blood 
No 
Yes 
10/169 (5.9) 
4/60 (6.7) 
Ref 
1.14 (0.30, 3.55) 0.835 
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Multivariable analyses were not informed by univariable analysis outcomes. All 
10 candidate variables were included in the maximal multivariable GLM so that 
backwards model selection could be performed. The model estimates for the 10 
candidate variables included in the maximal model are given in Table 2.6. 
Stepwise model selection indicated that the most parsimonious model included: 
age of participant (LRT !2= 18.17, df = 1, p < 0.001), with probability of acute 
brucellosis infection declining with age in years (aOR = 0.88, 95% CI = 0.81 - 
0.94, p < 0.01); and participating in herding any livestock in the last 12 months 
(LRT !2 = 11.71, df = 1, p < 0.001), with participating in herding increasing the 
probability of acute brucellosis infection (aOR = 10.16, 95% CI = 2.49 – 69.75, p < 
0.01) (see Table 2.5). This final model had a pseudo R-squared value of 0.32 (see 
Table 2.6). 
 
 
   
Table 2.6: Multivariable logistic regression results for maximal and final models investigating association between ten literature- 
and epidemiologic opinion-informed candidate variables and febrile hospital participant acute brucellosis case status, aOR is 
adjusted odds ratios, CI is confidence intervals, LRT is likelihood ratio test, !2 is Chi-squared statistic, df is degrees of freedom, AIC is 
Akaike Information Criterion 
  Maximal model Final model 
Candidate variable  aOR (95% CI) 
aOR  
p value 
LRT 
 !2 LRT  p value aOR (95% CI) aOR  p value LRT  !2 LRT  p value 
Age in years   0.89 (0.76 – 0.97) 0.047 7.46 0.006 0.88 (0.81, 0.94)  0.002  18.17 <0.001 
Sex  Female  Ref 
20.73 (1.86 – 715.42) 
   
 
   
 Male  0.036 6.47 0.011    
Livestock abortions in herd or flock 
No 
Yes 
Ref 
3.33 (0.58 – 26.69) 0.204 1.77 0.184     
Assisted with the birth of livestock  
No 
Yes  
Ref 
0.01 (0.00 – 0.18) 0.007 11.71 <0.001  
 
  
Milked livestock  
No 
Yes 
Ref 
83.45 (5.17 – 4567.67) 0.008 11.58 <0.001  
 
  
Herded livestock  
No 
Yes 
Ref 
36.92 (2.49 – 1871.79) 0.026 7.52 0.006 
Ref 
10.16 (2.49, 69.75) 
 
0.004 11.71 <0.001 
Handled livestock waste  
No 
Yes 
Ref 
0.05 (0.00 – 0.50) 0.030 6.93 0.008  
 
  
Slaughtered or butchered livestock  
No 
Yes 
Ref 
0.48 (0.03 – 7.07) 0.588 0.29 0.587     
Consumed raw dairy products  
No 
Yes 
Ref 
1.05 (0.10 – 8.71) 0.966 0.00 0.966  
 
  
Consumed raw meat, offal or blood 
No 
Yes 
Ref 
0.25 (0.02 – 2.49) 0.264 1.35 0.245     
  
Null deviance = 90.66, df = 198 
Residual deviance = 39.79, df = 188 
AIC = 61.79 
Pseudo R-squared = 0.62 
Null deviance = 104.09, df = 218 
Residual deviance = 71.82, df = 216 
AIC = 77.82 
Pseudo R-squared = 0.32 
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2.3.4 Exploring the relationship between sex, age and 
herded livestock candidate variables 
The candidate variables sex, age (years) and herded livestock were significantly 
associated with brucellosis case status in univariable analyses and the 
multivariable maximal model. Sex was not selected for inclusion in the final 
model. Relationships between sex and herded livestock, and sex and age (years) 
were evaluated for evidence of collinearity. A contingency table showing the 
raw descriptive data for febrile hospital participant sex and herded livestock 
candidate variables is given in Table 2.7. 
 
Table 2.7: Febrile hospital participants relationship between sex and herded 
livestock risk factor candidate variables, herded livestock is having herded 
cattle, sheep and/or goats in the past 12 months, N is the total number of 
febrile hospital participants with data available, n is the number of febrile 
hospital participants at each candidate variable factor level, CI is confidence 
intervals 
Sex 
Herded livestock 
No Yes 
n/N  % (95% CI) n/N  % (95% CI) 
Female 96/134 71.6 (63.21 – 79.09) 25/85 29.4 (20.02 – 40.29) 
Male 38/134 28.4 (20.91 – 36.79) 60/85 70.6 (59.71 – 79.98) 
 
 
2.3.5 Lasso regression 
All of the ten candidate variables that were included in the maximal 
multivariable logistic regression analysis were also fit to a lasso regression 
model. The model estimate for l one SE greater than minimised l was 0.041. 
Eight of the ten candidate variables shrank to zero. The two covariables selected 
by lasso regression were age and herded livestock, see Table 2.8 for candidate 
variable coefficient estimates. 
 
Table 2.8: Lasso regression coefficient estimates (Coef.) for non-zero 
candidate risk factor variables 
 
Candidate  
variable 
 Lasso regression 
 
Coef. 
Age in years  -0.04 
Herded livestock  No 
Yes 
Ref 
0.98 
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2.4 Discussion 
This study is the first risk factor analysis of acute brucellosis infection for a 
pastoralist community in Tanzania, and one of few studies reported for East 
Africa. Febrile hospital participant questionnaire data were considered as 
candidate variables for risk factor analyses. The candidate variable dataset was 
large, so in order to avoid overfitting of the data and increase the robustness of 
a risk factor analysis, three different data reduction techniques were applied to 
the data: MCA; literature-informed logistic regression; and lasso regression. The 
final risk factors identified for acute brucellosis infection in febrile hospital 
participants were: having herded livestock; and decreasing age in years. 
 
An MCA was applied to the candidate variable dataset The MCA grouped 
candidate variables according to the proportion of variance explained by the 
construction of each orthogonal dimension. Broadly, the first dimension included 
candidate variables involving livestock contacts and the second dimension 
included candidate variables describing demographic characteristics. However, 
dataset simplification resulting from dimension reduction was not sufficient to 
mitigate the reduced interpretability caused by grouping of the candidate 
variables. Therefore, the outputs of the MCA analysis were not considered as an 
effective candidate variable reduction technique for this dataset and did not 
further inform risk factor analyses in this study. 
 
In the literature- and epidemiologic opinion-informed multivariable logistic 
regression, two risk factors for acute brucellosis in febrile hospital participants 
were identified in the final model. These risk factors were: having herded 
cattle, sheep and or goats in the past 12 months; and decreasing age of the 
participant. Sex was a significant candidate variable in univariable analysis, 
however was not included in the final multivariable model. Inspection of the 
relationship between sex and having herding livestock indicated collinearity 
between these candidate variables, with males more likely to herd livestock. 
Additionally, collinearity was identified between sex and age candidate 
variables, with males more likely to be of younger age. 
 
The logistic regression maximal model included 10 candidate variables. It was 
therefore possible that the backwards model selection used to determine the 
  66 
final model risk factor variables was influenced by overfitting of the data. Lasso 
regression data reduction was performed to further investigate the same 10 
candidate variables. Lasso regression selected the same two candidate variables 
as the logistic regression model. This suggests that the two identified risk factors 
for acute brucellosis do have a true effect on acute brucellosis status and are 
not an artefact of overfitting. 
 
The pseudo R-squared value for the final logistic regression model indicated that 
0.32 of variation was explained by the model. Therefore, the final model does 
not capture all of the variation in risk of acute brucellosis in this population. It is 
likely that there are additional risk factors for acute brucellosis in this setting 
that have not yet been identified. Increasing the sample size may lead to the 
detection of additional risk factors for acute brucellosis. Achieving a larger 
acute brucellosis case sample size in this population however, would be a 
significant logistical challenge. 
 
The risk factors identified in this study, being a young person and involved in 
herding, do not align explicitly with other risk factor studies conducted in 
Tanzania or East Africa. In the only other study of risk factors for acute 
brucellosis in Tanzania, Cash-Goldwasser et al. conducted a study of febrile 
patients from a largely urban-based community in Kilimanjaro Region. 
Brucellosis prevalence by BMAT was reported as 8.9% (n = 562) and risk factors 
for acute brucellosis included: assisting in small ruminant births; contact with 
cattle; and consumption of boiled dairy products which was protective against 
acute brucellosis (Cash-Goldwasser et al., 2018). In the study reported in this 
thesis, a brucellosis prevalence of 6.1% (n = 230) was detected using a 
combination of culture and SAT. The differences in study design between the 
two studies, including: diagnostics used; and study location, including size of 
study hospital, may in part account for differences in brucellosis prevalence and 
risk factors identified. The difference in risk factors identified could also be 
explained by differences in Brucella spp. exposure risk between the largely rural 
versus largely urban study populations. There may be important differences in 
Brucella spp. transmission pathways in different settings. Here, the study area 
was rural, and the community were almost exclusively pastoralists. Behavioural 
practices, such as livelihood activities, and their linked Brucella spp. 
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transmission risks for this study population are very different to the livelihood 
activities of a study population from an urban area. Additionally, the median age 
of infection for acute brucellosis was 11 years and for Cash-Goldwasser et al. it 
was 31 years. In nomadic communities such as that of the Maasai of the NCA, it 
has been suggested that members of the community are exposed to Brucella 
spp. from a young age, and as a result adults do not manifest acute disease but 
may be suffering from chronic infection (Corbel, 2006). Therefore, perhaps the 
difference in identified risk factors between these two studies could be 
explained by a more common, constant Brucella spp. exposure risk in endemic 
rural settings as compared to urban settings. The prevalence detected in these 
febrile patient studies was slightly higher in the study reported by Cash-
Goldwasser et al. and the urban referral hospital, as compared to the rural 
hospital in the study reported in this thesis. A higher human brucellosis burden 
in rural, pastoral settings as compared to other livestock-keeping settings has 
been reported previously in Tanzania (Shirima et al., 2010). The difference in 
prevalence estimates reported for the Cash-Goldwasser et al. study and the 
study reported here could have been influenced by differing hospital catchment 
populations, as well as the health seeking behaviour of the febrile population. 
 
Another explanation for the difference in identified acute brucellosis risk factors 
may be that not all acute brucellosis cases present to a healthcare provider, and 
that those that do reach a healthcare facility in rural versus urban study areas 
are very different. In rural areas there are many barriers to accessing healthcare 
facilities, some include: distance to healthcare facility; lack of funds for 
treatment; and the inability to lose the time required to visit a healthcare 
facility (Maudlin et al., 2009). Thus, it may be that more severely symptomatic 
individuals are prioritised for visiting a healthcare provider, meaning that an 
even smaller proportion of acutely infected individuals make it to a healthcare 
facility in rural settings than urban settings. Barriers to healthcare therefore can 
impact on the risk factors detected in different study locations and populations. 
 
A study of a largely pastoralist community of Kenya investigating brucellosis in 
febrile patients similarly found contact with multiple animal species to be a 
significant risk factor for acute brucellosis infection, as well as reporting herding 
as an occupation (Njeru et al., 2016a). However, reporting herding as an 
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occupation is arguably not the same classification as a participant reporting they 
have been involved in herding over the past 12 months. In the present study, the 
age range of acute brucellosis cases was 7 to 20 years old and likely describes a 
different demographic of individuals to those who might report their occupation 
as herding. Indeed the brucellosis positive patients in the Kenya-based study 
ranged from 23 to 46 years old (Njeru et al., 2016a). 
 
When comparing the risk factors identified in this study to those reported in 
other studies, it is important to consider the stage of brucellosis infection that 
has been measured. For example, in a cross-sectional study of a pastoralist 
community in Kenya, increasing age by decade was significantly associated with 
evidence of Brucella spp. exposure (Osoro et al., 2015). A Ugandan study also 
found that female patients were significantly more likely than males to be 
exposed to Brucella spp. and that female patients were significantly older than 
male patients exposed to Brucella spp. (Makita et al., 2011b). These findings are 
the converse of the present study. The diagnostic tests used in Osoro et al. and 
Makita et al. detected any antibody response to Brucella spp. exposure, which 
will have included (and not differentiated between) active brucellosis cases and 
historic exposure to Brucella spp. In endemic areas, it is likely that adult 
members of the community will have persistent Brucella spp. antibodies due to 
repeat exposures and test serologically positive (Al Dahouk and Nöckler, 2011). 
Therefore, Brucella spp. exposure may increase with age. In this study, the case 
definition was specific to acute infections, and therefore would have resulted in 
underestimation of more advanced stages of brucellosis infection or historic 
exposure. 
 
Surprisingly, consumption of raw dairy products was not identified as a risk 
factor in the present study. Previously, in East Africa raw milk consumption has 
been frequently identified as a risk factor for acute brucellosis (Asiimwe et al., 
2015; Kiambi, 2012; Njeru et al., 2016a), or consumption of boiled dairy 
products has been reported as protective against infection (Cash-Goldwasser et 
al., 2018). However, it is possible that responses to the raw milk consumption 
practices question were subject to a type of questionnaire bias referred to as 
‘faking good’, whereby the participant alters their response to a response they 
perceive to be preferred by the investigator (Choi and Pak, 2005). Brucellosis is 
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considered to be endemic in pastoralist communities (McDermott et al., 2013) 
and when visiting a healthcare facility patients may be commonly tested for 
brucellosis. There have also been a number of brucellosis sensitisation activities 
conducted in this study community and febrile hospital participants were aware 
that they were participating in a study on human brucellosis. Therefore, it is 
possible that only 50.0% of acute brucellosis cases reported raw dairy product 
consumption because the questionnaire was subject to faking good bias. Raw 
dairy consumption may be a confounder variable and with a larger sample size, 
or further investigation into young herding individuals in the community, it could 
prove to be a risk behaviour. Alternatively, it is also possible that in this 
community, where only 6.1% of the total study population reported consuming 
raw dairy products, there is a behavioural shift towards milk boiling. 
 
Following consideration of the literature on risk factors for acute brucellosis 
infection within East Africa, it would appear that broad risk factor categories are 
similar across various settings, such as general contact with livestock species. 
However, details of the precise livestock-related activities or the demographic 
at highest risk appear to vary by study. Focusing on this study community, it is 
common that younger individuals, particularly boys, are given responsibility for 
herding cattle, sheep and goats (Mangesho et al., 2017). There are many 
activities conducted whilst herding that could increase the probability of 
transmission of Brucella spp. including: contact with livestock deaths; 
butchering livestock and ingesting raw organs or undercooked meat and blood; 
assisting livestock births; contact with new-born livestock; and consuming raw 
milk directly from livestock (personal communication with community 
members). The probability of transmission of Brucella spp. whilst herding is 
further increased due to the unavailability of basic hygiene measures, such as 
soap and water for handwashing. 
 
Finally, in thinking about the larger febrile hospital study results (as opposed to 
the aspects that directly contributed to this research chapter only), seven 
distinct bloodstream infections were identified in 6.1% of febrile hospital 
participants sampled for culture. Brucella spp. infections were the most 
frequently detected bloodstream infection, identified in 3.5% of those febrile 
participants sampled (Bodenham et al., 2020). Other human bloodstream 
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infection studies within Africa report Brucella spp. as a rare cause of infection 
as compared to other bloodstream infections, such as Salmonella enterica or 
Streptococcus pneumoniae (Marchello et al., 2020; Reddy et al., 2010). Malaria, 
as diagnosed by rapid diagnostic testing, was also a relatively infrequent cause 
of febrile illness. Malaria was identified in only 2.6% of febrile participants, 
whereas a total of 6.1% of febrile participants were identified as brucellosis 
cases (Bodenham et al., 2020). Diagnostic testing for leptospirosis (Leptospira 
spp.) has also detected a comparable number of Leptospira spp. exposures to 
brucellosis cases for the febrile hospital study participants (Maze MJ & Halliday 
JEB, unpublished data). These febrile hospital study results highlight the 
importance of human brucellosis in this rural pastoralist community as compared 
to other causes of febrile illness. 
 
A limitation of this study was that questionnaire data collection can be 
susceptible to a variety of biases. For example, data collection may have been 
subject to recall bias, whereby respondents’ accuracy in recalling past events 
varies (Choi and Pak, 2005). Another example is that of response fatigue. The 
questionnaire administration took approximately 40 minutes, due to response 
fatigue during that time respondents may have given inaccurate or repetitive 
responses (Choi and Pak, 2005). Restricting the length of the questionnaire is an 
obvious way to reduce response fatigue. Additionally, randomisation of question 
ordering may reduce systematic bias for questions that were repeatedly 
answered poorly due to response fatigue, potentially because they were 
positioned towards the end of the questionnaire or grouped together and 
repetitive. An alternative approach to reducing questionnaire bias is through the 
implementation of other data collection techniques in the study population, 
such as focus group discussions or key-informant interviews in an attempt to 
verify questionnaire data collection. It is also important to consider that in 
suspected high brucellosis-risk communities, effectiveness of traditional risk 
factor analyses may be limited due to a large proportion of the community being 
involved in the broad risk factors for brucellosis transmission such as direct 
contact with animals. It is also important to highlight that the findings of this 
study must be interpreted in line with the study design used, particularly with 
respect to the denominator population. The risk factors for acute brucellosis 
cases identified in this study are those applicable to febrile hospital 
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participants. As the non-brucellosis case febrile hospital participants may have 
been involved in risk factors that overlapped brucellosis and other febrile 
illnesses, this may have influenced the ability of the study to identify risk factors 
for acute brucellosis. This could have been reduced by choosing a random 
community control group, although this approach would have been much more 
resource-intensive. Another consequence of study design and the sampled 
population was selection bias introduced at the different steps of study 
screening and enrolment, for example only 53.8% of eligible patients were 
enrolled into the study. This selection bias may have been for a number of 
reasons including that eligible patients may have refused participation because 
they were focused on receiving care for their current illness, or because the 
family decision maker was not present. Due to the high proportion of eligible 
febrile patients not enrolled in the study, it is possible that the prevalence of 
acute brucellosis in febrile patients was biased. One way to reduce selection 
bias could be to combine hospital surveillance with active community-based 
surveillance. 
 
Further research might explore the risk factors for acute brucellosis identified in 
this study by investigating the herding-specific activities that are increasing 
Brucella spp. transmission for young herders. Sensitisation to the risks of 
brucellosis transmission in this high-risk demographic group would also be a 
logical next step. These risk factor data coupled with further investigation would 
be invaluable in informing brucellosis prevention and control interventions in the 
NCA. 
 
2.5 Conclusion 
The need for effective, achievable brucellosis control is great in endemic 
pastoralist communities (Racloz et al., 2013). Understanding setting-specific risk 
factors for brucellosis infection is a vital tool in the formation of an efficient, 
evidence-based disease prevention and control strategy. The investigation of risk 
factors associated with acute disease is particularly important, as this allows 
identification of temporally relevant risk practices related to active infection. 
This is one of the first studies in East Africa to identify risk factors associated 
with acute brucellosis infection. Risk factors included herding livestock and 
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decreasing age in years. It is recommended that these data are used to inform 
further research that investigates the herding-specific risk activities that put 
young herders at high risk of infection. The consideration of these risk factors in 
the development of brucellosis prevention and control interventions has the 
potential to make a substantial impact on human brucellosis burden in this 
pastoralist community, as well as in similar communities in Tanzania and wider 
SSA. 
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Chapter 3 Human brucellosis active surveillance: 
Screening household members of febrile hospital patients  
 
3.1 Introduction 
Zoonotic disease burden is disproportionately high among impoverished 
pastoralist communities (WHO et al., 2006). These communities are believed to 
be particularly vulnerable to the impacts of endemic zoonoses due to reasons 
that include living in close contact with livestock, reduced availability of 
healthcare facilities in rural areas, and inability to afford both treatment and 
the time lost by visiting a healthcare provider (Maudlin et al., 2009). 
Consequently, the burden of zoonotic diseases in these endemic areas is often 
underestimated (Maudlin et al., 2009). 
 
Human disease surveillance data can play an important role in understanding the 
true burden of endemic diseases, especially in impoverished communities 
(Halliday et al., 2012). Disease surveillance is also fundamental in informing 
effective disease control measures, and has been referred to as “the foundation 
for the control of infectious diseases” (Berkelman et al., 1994). The World 
Health Organization (WHO) defines disease surveillance as “the ongoing 
systematic collection, analysis and interpretation of health data needed for 
planning, implementation and evaluation of public health practice” (WHO, 
2006). There are two main mechanisms of disease surveillance: passive and 
active. Passive surveillance is the routine collection of disease data by 
healthcare facilities and laboratories that is reported to the appropriate health 
authority (WHO, 2020). In contrast, active surveillance involves active searching 
for cases of infectious disease in the community, such as regular phone calls to 
clinicians and visits to healthcare centres and laboratories (Kramer et al., 2010). 
 
Passive disease surveillance in the form of routine clinical reporting is 
advantageous in its potential to generate longitudinal data, in its role in early 
detection of disease outbreaks, and relative low cost (Hadorn et al., 2008; 
Robinson, 2003). However, this form of surveillance suffers from a lack of 
control over the quality and often the detail of data collected (Hattendorf et 
al., 2017). Passive surveillance in the form of hospital-based surveillance may 
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underestimate the burden of disease. There are multiple reasons for this, 
including: social, economic and geographical barriers to accessing healthcare; 
clinical and laboratory diagnostic misdiagnosis of patients; and high levels of 
under-reporting (Dean et al., 2012b; WHO et al., 2006). In general, under-
reporting is thought to be due to various factors that can be largely categorised 
as unwillingness (e.g. due to: lack of compensation; or negative consequences of 
reporting, such as slaughter or trade bans) or the inability (e.g. due to: lack of 
diagnostic testing; or lack of awareness by patient, clinician or livestock-keeper; 
lack of communication between stakeholders) to report on zoonotic disease 
(Halliday et al., 2012). Regarding brucellosis surveillance, a study in Greece 
investigating passive reporting of hospital records to the public health 
department found that 38.0% of notifiable infectious diseases were not reported, 
including 26.0% of brucellosis cases not reported (Jelastopulu et al., 2010). A 
study in Moshi, Tanzania analysed 528 hospital clinical diagnoses of febrile 
patients (Crump et al., 2013). No clinical diagnosis of brucellosis was recorded, 
however study diagnostic testing showed that 3.5% of febrile patients had acute 
brucellosis (Crump et al., 2013). These findings indicate that passive surveillance 
reliant on clinical diagnosis alone can result in under-reporting of brucellosis. 
Conversely, hospital-based passive surveillance data can also lead to 
overestimation of disease burden. For example, the routine use of brucellosis 
point-of-care diagnostic tests with low specificity, combined with the absence of 
confirmatory testing, can result in overdiagnosis of brucellosis (de Glanville et 
al., 2017). Implementation of suboptimal diagnostic testing procedures may 
often be performed in resource-limited settings and will ultimately misrepresent 
the burden of disease. Another issue regarding the ability of passive surveillance 
to improve our understanding of the burden of brucellosis is disease prevalence. 
In endemic areas, such as in the agro-pastoral and pastoral areas of Tanzania, 
cross-sectional surveys estimate human brucellosis seroprevalence to range from 
0.0% to 8.3% (Assenga et al., 2015; Shirima et al., 2010; Shirima and Kunda, 
2016). If the true seroprevalence in these endemic areas lies within this range, 
then low brucellosis prevalence coupled with passive surveillance limitations 
such as under-reporting, make understanding the burden of brucellosis and 
informing disease prevention and control via passive surveillance a challenge. 
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Data generated through active surveillance can be more accurate compared with 
passive surveillance (Mphande, 2016), temporally, spatially and 
demographically. Active surveillance data combined with passive surveillance 
can provide more representative data and an effective brucellosis surveillance 
strategy should combine passive data acquisition with active surveillance 
wherever possible (Robinson, 2003). However, active surveillance is generally 
expensive to implement, especially in the form of randomised field surveys. 
Randomised field surveys may also fail to effectively represent diseases that are 
spatially grouped (Hattendorf et al., 2017). This form of active surveillance may 
be especially problematic for brucellosis, which is considered to be spatially 
grouped in risk populations (WHO et al., 2006). 
 
Adapted active surveillance strategies have been applied to various infectious 
diseases in order to gain a better understanding of disease burden in hard to 
reach populations, that potentially have a grouped distribution. One example is 
contact tracing, this technique is used in the identification of potential rabies 
virus exposures. A single report of an animal bite victim at a healthcare facility 
is investigated and an interview with the victim or family is conducted in order 
to identify the source of exposure and any additional bite victims (also referred 
to as contacts) (Hampson et al., 2008). This process is then repeated for each 
identified contact (Hampson et al., 2008). A similar technique, referred to as 
active case finding, has been implemented among tuberculosis (Mycobacterium 
tuberculosis) cases in many countries globally and is reported to improve case 
detection rates (Golub et al., 2005). An example of the implementation of active 
case finding for tuberculosis is through screening of household members of 
tuberculosis patients (Zachariah et al., 2003). 
 
The household members of hospital patients with brucellosis are likely to share 
many risk factors for the disease such as meat and dairy consumption practices, 
therefore these individuals are at high risk of exposure (Tabak et al., 2008). 
Consequently, active case finding in the form of brucellosis screening household 
members of brucellosis patients in endemic settings has been advocated 
(Moreno, 2014). Active case finding, as compared to randomised field survey 
techniques, may prove a more effective form of active surveillance for the 
detection of Brucella spp. exposures in settings where there are close contacts 
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with livestock species and/or consumption of raw animal products. In Eastern 
Europe, the Middle East, and Latin America, screening of household members of 
brucellosis patients for exposure to Brucella spp. has been implemented. These 
studies report that the screening of household members of brucellosis patients 
leads to increased detection of Brucella spp. exposures, including detection of 
acute brucellosis cases (Almuneef et al., 2004; Alsubaie et al., 2005; Ismayilova 
et al., 2013; Mendoza-Nunez et al., 2008; Sanodze et al., 2015; Sofian et al., 
2013; Tabak et al., 2008). 
 
Similar examples of household member screening for brucellosis in SSA are 
lacking, with brucellosis surveillance of any form seldom implemented in 
pastoral areas (Njeru et al., 2016b). Yet, studies investigating risk factors for 
human brucellosis in East Africa have identified a positive association between 
family history of brucellosis and exposure to Brucella spp. in febrile hospital 
patients (Asiimwe et al., 2015; John et al., 2010; Migisha et al., 2018), and 
suggest the importance of household member brucellosis screening as a tool in 
the control of brucellosis (Asiimwe et al., 2015; Migisha et al., 2018). In 
Tanzania, a study at a referral hospital in Moshi, estimated that only 4% of 
people with febrile illness attended hospital, study participants instead reported 
a preference for self-management of fever (Panzner et al., 2016). Active 
surveillance in Tanzania may therefore be especially effective in detecting 
Brucella spp. exposures, including acute brucellosis cases, and in generating a 
more accurate estimate for the burden of brucellosis. 
 
There are no evident examples in the scientific literature for Africa of studies 
implementing brucellosis active surveillance through the screening of household 
members of brucellosis patients. In this study, the ability of an active case 
finding approach to detect brucellosis in household members of febrile hospital 
patients will be evaluated. 
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3.1.1 Study aims 
The overall aim of this study was to investigate whether screening of household 
members of febrile hospital patients with acute brucellosis could detect 
additional acute brucellosis cases or Brucella spp. exposures, and to evaluate 
evidence of grouping in the distribution of Brucella spp. exposure status of 
household members. 
 
The five study aims were: 
 
1. To determine if new acute brucellosis cases could be identified amongst the 
household members of febrile hospital participants with acute brucellosis 
 
2. To estimate the prevalence of Brucella spp. exposure amongst the household 
members of febrile hospital participants  
 
3. To evaluate evidence of association between the Brucella spp. exposure 
status of household members and febrile hospital participants 
 
4. To compare the age and sex distributions of febrile hospital study 
participants (as described in Chapter 2) and household member study 
participants 
 
5. To compare the age and sex distributions of RBT-defined Brucella spp. 
exposed febrile hospital study participants (as described in Chapter 2) and 
household member study participants 
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3.2 Methods 
3.2.1 Study area 
This prospective study was conducted in the Ngorongoro Conservation Area, 
Tanzania. See Chapter 2 Section 2.2.1 for description of the study site and 
population. 
 
3.2.2 Febrile hospital study 
The febrile hospital study at the Endulen Hospital enrolled eligible and 
consenting patients presenting to the outpatient department (OPD) between 15th 
August 2016 and 11th October 2017 (see Chapter 2 Section 2.2.3 for further 
details of the febrile hospital study eligibility and enrolment protocol). All 
febrile hospital participants enrolled into the febrile hospital study between 5th 
April and 11th October 2017 were eligible for household member sampling. 
During this period, the febrile hospital participants were informed at the time of 
their enrolment that they may be approached for additional data collection and 
household follow-up visits in order to identify acute brucellosis cases or evidence 
of Brucella spp. exposures in their household. 
 
3.2.3 Definitions: Acute brucellosis case and Brucella 
spp. exposure 
• An acute brucellosis case is defined as: 
“A clinically compatible illness with: culture and identification of 
Brucella spp. (confirmed acute case); or evidence of a four-fold or 
greater rise in Brucella antibody titre by serum agglutination test 
(SAT), between acute- and convalescent-phase sera obtained ≥2 
weeks apart (confirmed acute case); or a Brucella total antibody 
titre ≥160 by SAT (probable acute case)” (CDC, 2010) 
 
• Brucella spp. exposure is defined as: 
An individual classified as an acute brucellosis case 
AND/OR 
seropositive by the Rose Bengal plate test (RBT) 
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3.2.4 Febrile hospital participant sampling and RBT 
testing 
All febrile hospital participants had a blood sample drawn for culture and acute-
phase serology at the time of hospital presentation and four to six weeks 
following hospital presentation were approached for a second blood sample for 
convalescent-phase serology (see Chapter 2 Section 2.2.4 for full details of the 
febrile hospital study blood sample collection and processing protocol). 
 
Febrile hospital participant serum was tested by the Rose Bengal plate test 
(RBT) at the Endulen Hospital within a week following febrile hospital 
participant enrolment. RBT testing was performed following standard protocols 
(Corbel, 2006; Díaz et al., 2011) as follows: serum, RBT antigen, positive and 
negative controls (Animal and Plant Health Agency (APHA), Weybridge, UK) were 
brought to ambient temperature. Serum was inverted several times and RBT 
antigen and controls were shaken to ensure homogenisation of the suspension. A 
volume of 25 µL serum was pipetted onto a glossy white ceramic tile, and an 
equal volume of antigen pipetted next to the serum sample. Serum was mixed 
thoroughly with the antigen using a clean toothpick, producing an approximately 
2 cm oval-shaped suspension per serum sample. For each tile, 25 µL positive and 
negative control were included, and an equal volume of antigen pipetted next to 
each control. Controls and antigen were also mixed using a clean toothpick. The 
tile was then rotated and tilted by hand for 4 minutes. After four minutes, the 
tile was read in a well-lit environment. Any visible clumping of the antigen was 
identified as a positive result (see Fig. 3.1). 
 
Figure 3.1: Examples of negative and positive agglutination using the Rose 
Bengal plate test (RBT), reproduced from Diaz et al., 2011, Creative Commons 
Attribution license: https://creativecommons.org/licenses/by/4.0/ 
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3.2.5 Definitions: Brucellosis positive and brucellosis 
negative febrile hospital participants 
Brucellosis Positive Hospital participants (hereafter referred to as BPH) were 
defined as: 
• BPH: 
Febrile hospital participants explicitly diagnosed as:  
 
an acute brucellosis case 
OR 
were classified as Brucella spp. exposures 
 
Brucellosis Negative Hospital participants (hereafter referred to as BNH) were 
defined as: 
• BNH: 
Febrile hospital participants that did not meet the criteria for: 
 
an acute brucellosis case 
AND 
were not classified as Brucella spp. exposures 
 
3.2.6 Household classification 
A list of febrile hospital participants was generated 1 to 4 days following hospital 
enrolment to determine the order of approach of febrile hospital participants for 
household follow-up visits. At the time of household follow-up, febrile hospital 
participant RBT was the only blood test available to guide identification of BPHs, 
as culture and SAT results were only available months after initial data 
collection. The approach list was semi-randomised in that prioritisation was 
given to BPHs. The approach list was updated every 1-4 days to include newly 
enrolled febrile hospital participants. At the conclusion of the study, SAT and 
culture results were used to retrospectively inform classification of BPHs and 
BNHs and their households. See Figure 3.2 for further description of household 
classification beginning with a febrile patient’s first presentation at the Endulen 
Hospital OPD. 
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3.2.7 Definitions: BPH and BNH households 
The Brucellosis Positive Hospital participant Household (hereafter referred to as 
BPHH) was defined as: 
• BPHH: 
All individuals in a compound (a group of houses and animal pens) 
where members of multiple houses may share ownership of the 
same livestock as the BPH 
 
The Brucellosis Negative Hospital participant Household (hereafter referred to as 
BNHH) was defined as: 
• BNHH: 
All individuals in a compound (a group of houses and animal pens) 
where members of multiple houses may share ownership of the 
same livestock as the BNH 
 
3.2.8 Household selection 
Study team members were blinded to febrile hospital participant RBT results and 
the semi-randomised approach list generation process. A study team member 
was provided with the approach list and the first febrile hospital participant (or 
parent/guardian) was approached by phone call so as to obtain verbal consent to 
visit their household. If a febrile hospital participant declined the household visit 
or did not answer the phone following three attempts, the study team member 
recorded the outcome of the approach and moved onto the next febrile hospital 
participant on the approach list. When the study team member reached the end 
of the approach list, time-permitting, the study team member would attempt to 
contact unreachable febrile hospital participants once more. Household visits 
were arranged between 1 to 10 days following febrile hospital participant 
enrolment. 
 
3.2.9 Selection of household members 
All household members aged 2 years and above, and who had been resident in 
the household for at least 2 months, were eligible for participation in the study. 
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On arrival at a household, the head of the household was identified and provided 
 
Figure 3.2: Flow diagram showing identification of BPHs and BNHs, BPHHs 
and BNHHs and household members for the household member study: OPD is 
outpatient department; RBT is the Rose Bengal plate test; SAT is the serum 
agglutination test; BPH and BNH are brucellosis positive and negative febrile 
hospital participants, respectively; BPHH and BNHH are BPH and BNH 
households, respectively 
 
 
with information on the study. Following verbal consent from the head of the 
household, study participant information was then communicated to all present 
household members by a study team member. Household members that met the 
aforementioned eligibility criteria, were read the study participant information 
Household member
study
Febrile hospital 
study
Febrile patient presents at 
Endulen Hospital OPD
Febrile patient enrolled into 
febrile surveillance study 
Febrile hospital participant 
blood sample testing
Febrile patient declines 
participation in febrile 
surveillance study 
BPHH
BPH household
BNHH
BNH household
BPH declines  
participation in household 
member study
BNH declines  
participation in household 
member study
BPHH household 
member 
enrolment
BNHH household 
member 
enrolment
BNH
Culture and SAT and RBT
negative febrile hospital 
participant
BPH
Culture and/or SAT and/or RBT
positive febrile hospital 
participant
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sheet (see Appendix 3 for the Participant Information Sheet). Those individuals 
agreeing to study participation provided written consent and were enrolled into 
the study. Household members less than 18 years of age were classified as 
children and could participate in the study if consent was provided by a parent 
or guardian (see Appendix 3 for Consent Sheets). Due to sampling time 
constraints, household participant enrolment was limited to the first six eligible 
household members that consented to study enrolment. 
 
3.2.10 Household participant sampling 
Each household participant was weighed, had their tympanic temperature 
recorded and was asked about any history of fever in the previous 72 hours by a 
study team member. A structured, closed-ended questionnaire was administered 
for each participant. Questionnaire topics included: demographic data; current 
and recent illness symptoms; and reported history of brucellosis. The 
questionnaire was the same as that used for febrile hospital participants in 
Chapter 2 (see Appendix 2). 
 
For household participants with a tympanic temperature ≥38 ºC at the time of 
sampling, or a history of fever in the past 72 hours, blood was drawn for culture 
and serology by a clinical study team member. For household participants 
weighing ≥25 kg, a 40 mL blood volume was collected. Three culture bottles 
were inoculated with a target blood volume of 10 mL each: two BacT/ALERT 
(BioMérieux, Durham, NC, USA) aerobic culture bottles for automated culture; 
and a Castañeda (Ruiz Castañeda., 1961) bi-phasic media bottle. A plain 
vacutainer (BD, Franklin Lakes, NJ, USA) was inoculated with a target 10 mL of 
blood for serological testing. Household participants weighing <25 kg had a blood 
draw volume calculated based on weight. Sample bottle inoculation was the 
same as above, except that two paediatric BacT/ALERT bottles were inoculated 
for automated culture. 
 
For household participants with a tympanic temperature of <38ºC at the time of 
sampling, and not reporting a history of fever in the past 72 hours, a 10 mL 
blood sample was drawn for serology and inoculated into a plain vacutainer. 
These non-febrile household participants were not sampled for blood culture 
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because without evidence of current or recent fever, it was unlikely that the 
participant had a bloodstream infection and would therefore have a low 
probability of testing culture positive. 
 
All blood sampling and sample bottle inoculation for culture and serology 
followed the same protocols as the febrile hospital study (see Chapter 2 Section 
2.2.4). Blood culture bottles were inoculated at the household and immediately 
put on ice until return of the study team to the Endulen Hospital. Plain 
vacutainer tubes for serology were inoculated and were stood to clot at the 
household. Vacutainer tubes were then put on ice and transported with the 
study team to the Endulen Hospital. 
 
3.2.11 Sample processing and laboratory diagnostics 
On return to the Endulen Hospital, inoculated culture bottles were packed at 2-
8°C for transport and transferred to the Kilimanjaro Clinical Research Institute 
(KCRI), Moshi, Tanzania. Inoculated blood culture bottles arrived at KCRI within 
approximately 48 hours of sample collection. Both BacT/ALERT and Castañeda 
blood culture bottles were processed at KCRI, following the same standardised 
protocols as the febrile hospital study. 
 
Serum was separated at the Endulen Hospital, pipetted into cryovials, put on ice 
and transported with the inoculated culture bottles to KCRI. Sera were stored at 
KCRI at -80ºC. Sera were tested by RBT, at the Endulen Hospital or at KCRI, using 
the same testing protocol as described in Section 3.2.4. When the field data 
collection was complete, all sera were shipped to the APHA, Weybridge, UK for 
serology testing by SAT. 
 
3.2.12 Power analysis 
A power analysis was performed in order to estimate the sample size required to 
detect a difference in prevalence between household participants of brucellosis 
case and non-case febrile hospital participants. A community brucellosis baseline 
seroprevalence of 3.4% was assumed based on the results from two cross-
sectional surveys using RBT in pastoral areas of northern Tanzania (Halliday JEB, 
unpublished data). This baseline estimate was used as the estimate for 
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seroprevalence in BNHH household members. Due to a lack of similar household 
member screening studies in Africa, seroprevalence estimates from comparable 
studies in Eastern Europe, the Middle East and Latin America were used to 
estimate expected brucellosis seroprevalence in household members of 
brucellosis patients, which would represent the expected seroprevalence in 
BPHH household members. Examples of such studies outside Africa have 
estimated seroprevalence between 7% and 20% in brucellosis patients (Alsubaie 
et al., 2005; Ismayilova et al., 2013; Mendoza-Nunez et al., 2008; Sanodze et 
al., 2015; Sharifi-Mood et al., 2007; Sofian et al., 2013; Tabak et al., 2008). 
Based on these empirical data a sample size was selected (n = 40 BPHH 
household members, n = 200 BNHH household members) that would enable 
detection of a prevalence difference of at least 14%, with alpha = 0.05, power = 
80%. Power analysis was performed using G*Power software version 3.1 (Faul et 
al., 2009). 
 
3.2.13 Statistical analyses 
A Bernoulli distributed generalised linear mixed-effect model (GLMM) was fitted 
to evaluate the relationship between the Brucella spp. exposure status of 
household members and febrile hospital study participants. The response 
variable was household participant Brucella spp. exposure status (positive or 
negative), as measured by culture and/or SAT and/or RBT. The explanatory 
variable was household status of the household participant (BPHH or BNHH, 
defined by the Brucella spp. exposure status of the febrile hospital participant). 
An individual household identifier variable was fitted as a random effect so that 
autocorrelation in the data caused by multiple household participants screened 
from the same household could be accounted for. This model was used to 
evaluate evidence of any grouping of household participant Brucella spp. 
exposures dependent on the brucellosis status of the febrile hospital participant 
from that household. 
 
A Bernoulli distributed generalised linear model (GLM) was used to investigate 
and compare the age and sex distributions of household participants from both 
hospital and household study populations. The model response variable was the 
study population (febrile hospital study participants versus household member 
  86 
study participants), and the explanatory variables were participant sex and age 
in years. 
 
Finally, a second Bernoulli distributed GLM was used to investigate any 
correlation between the age and sex distributions of Brucella spp. exposed 
household participants, as compared to Brucella spp. exposed febrile hospital 
participants. For this evaluation, the response variable was Brucella spp. 
exposure as defined by RBT in the two study populations (febrile hospital study 
participants versus household member study participants). The explanatory 
variables were participant sex and age in years. 
 
A p value ≤0.05 was considered statistically significant across analyses. All data 
analysis and visualisation was performed in R software version 3.6.1 (R Core 
Team, 2019) using the lme4 R package (Bates et al., 2019) and ggplot2 R 
package (Wickham et al., 2019). 
 
3.2.14 Research clearance and ethics 
Implementation of the household member study was approved by the Tanzania 
Commission for Science and Technology, the Tanzania Wildlife Research Institute 
and the Ngorongoro Conservation Area Authority. The Kilimanjaro Christian 
Medical Centre Ethics Committee (698), the National Institute of Medical 
Research Tanzania (NIMR/HQ/R.8c/Vol.I/1140), and the University of Glasgow 
College of Medical, Veterinary and Life Sciences Human Ethics Committee 
(200140149) gave ethical approval for this study. All research conducted was in 
accordance with the guidelines and regulations of the aforementioned 
organisations. 
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3.3 Results 
3.3.1 Febrile hospital study participants 
The household member study was conducted from the 5th April to 11th October 
2017. During this time, 114 febrile hospital participants were enrolled into the 
febrile hospital study. A total of 113 (99.1%) of 114 febrile participants had 
blood culture and serum samples collected. 
 
Five (4.4%) of 113 febrile hospital participants were culture positive and 
classified as confirmed acute brucellosis. One (0.9%) of 113 febrile hospital 
participants showed a four-fold increase in SAT titre and was also classified as 
confirmed acute brucellosis. Three (2.7%) of 113 febrile hospital participants had 
a SAT titre ≥160 and were classified as probable acute brucellosis. A total of 109 
(96.5%) of 113 febrile hospital participants had serum available for RBT. Thirteen 
(11.9%) of 109 febrile hospital participants tested RBT positive. Overall, 14 
(12.4%) of 113 febrile hospital participants were positive by culture and/or SAT 
and/or RBT and were classified as a BPH. The remaining 99 (87.6%) febrile 
hospital participants that were culture, SAT and RBT negative were classified as 
a BNH. 
 
A total of 103 (91.2%) of the 113 febrile hospital participants were approached 
for household member sampling. Forty-five (43.7%) of 103 febrile hospital 
participants consented to household follow-up. Five (11.1%) out of 45 households 
sampled were classified as BPHH, four of which had acute brucellosis case BPHs 
and one was BPH by an RBT-identified Brucella spp. exposure, see Table 3.1. 
The remaining 40 households were households of BNHs (febrile hospital 
participant that was culture, SAT and RBT negative), these households were 
therefore classified as BNHH, see Figure 3.3 for the household identification 
process. 
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Table 3.1: Brucellosis status as defined by diagnostic test outcome for 
brucellosis positive febrile hospital participants (BPH), where RBT is Rose 
Bengal plate test, SAT is serum agglutination test 
BPH  RBT  positive  
SAT positive  
(≥160 titre)  
Blood 
culture 
positive  
Brucellosis status  
A Y Y Y Acute brucellosis (confirmed) 
B N N Y Acute brucellosis (confirmed) 
C Y Y N Acute brucellosis (probable) 
D Y Y N  Acute brucellosis (probable) 
E Y N N Brucella spp. exposure 
 
 
 
Figure 3.3: Flow diagram of household member study household 
identification process: BPH and BNH are brucellosis positive and negative 
febrile hospital participants, respectively; BPHH and BNHH are BPH and BNH 
households, respectively 
 
 
3.3.2 Household participant characteristics 
Between the 5th April 2017 and the 11th October 2017, 180 household 
participants were enrolled from 45 households. Twenty-two (12.2%) of 180 
household participants came from BPHHs and 158 from BNHHs. The achieved 
sample size was less than that indicated in the power analysis (BPHH n = 40 and 
BNHH n = 200), due to constraints on sample collection which is elaborated on in 
113 febrile hospital 
participants’ blood samples 
tested
5 (35.7%) BPHH 
sampled
40 (40.4%) BNHH 
sampled
8 BPH were approached 
and declined participation 
in household member study
1 BPH was not approached
99 (87.6%) BNH
(RBT and SAT and culture 
negative)
14 (12.4%) BPH
(RBT and/or SAT and/or 
culture positive)
50 BPH were approached 
and declined participation 
in household member study
9 BNH were not 
approached
  89 
the discussion section. A total of 121 (67.2%) of 180 household participants were 
female and the median household participant age was 20 years (range: 3 - 80 
years). Of those enrolled, 77 (43.0%) of 179 with age data available were 
children. Ten (5.6%) of 180 household participants had a tympanic temperature 
≥38.0°C indicating febrile illness on the day of sampling, one was a BPH 
household participant and nine were BNH household participants. Household 
participants without a current fever but reporting a history of fever in the last 
72 hours included 56 (32.9%) of 170 household participants with data available, 
five were from BPHHs and 51 were from BNHHs. The majority of household 
participants 145 (80.6%) of 180 lived within Endulen village, which is the village 
where Endulen Hospital is situated. The distribution of household participant 
characteristics across BPHHs and BNHHs is shown in Table 3.2. 
 
Table 3.2: Household participant characteristics for brucellosis positive and 
brucellosis negative febrile hospital participant households (BPHH and BNHH), 
where all household participant characteristics indicate total number of 
participants that data are available for (N), the number of participants within 
each factor level (n) and the proportion for each factor level (%), with the 
exception of Age in years where the median and range age is reported for BPH 
and BNH household participants 
Participant characteristics  
 BPHH household 
participant 
n/N (%)  
BNHH household 
participant 
n/N (%)  
Age in years, median (range)   24.5 (7, 80) 19 (3, 80)  
Sex  Female 15/22 (68.2)  106/158 (67.1)  
 Male 7/22 (31.8)  52/158 (32.9)  
Location  Endulen village  22/22 (100)  123/158 (77.8)  
 Other  0/22 (0.0)  35/158 (22.2)  
Current fever  No  21/22 (95.5)  149/158 (94.3)  
 Yes  1/22 (4.5)  9/158 (5.7)  
History of fever  No  16/21 (76.2)  98/149 (65.8)  
 Yes  5/21 (23.8)  51/149 (34.2)  
 
 
3.3.3 Aim 1: Determining if new acute brucellosis cases 
could be identified amongst the household members of 
febrile hospital participants with acute brucellosis 
A total of 66 (36.7%) of 180 household participants had a current temperature of 
≥38.0°C at the time of household visit or reported a history of fever (within the 
past 72 hours) and were therefore eligible for blood culture. Sixty-five (98.5%) of 
66 household participants had one or more blood culture bottle filled. A total of 
  90 
141 blood culture bottles were inoculated, 107 BacT/ALERT and 34 Castañeda. 
No Brucella spp. or any other bloodstream infections were identified by culture. 
 
All household participants had a serum sample tested by SAT. Two (1.1%) of 180 
household participants had a SAT titre ≥160 and were classified as probable 
acute brucellosis cases. These acute brucellosis cases came from two different 
BPHHs. The first acute brucellosis case was a 7 year-old male and reported a 
history of fever in the last 72 hours. The second acute brucellosis case was a 7 
year-old female and did not show evidence of current fever or report a recent 
history of febrile illness. 
 
3.3.4 Aim 2: Estimating the prevalence of Brucella spp. 
exposure amongst the household members of febrile 
hospital study participants 
Of 180 household participants, 176 (97.8%) had a serum sample available for 
RBT. Nineteen (10.8%) of 176 household participants from 13 different 
households were RBT positive and classified as Brucella spp. exposures. Sixteen 
(84.2%) of 19 Brucella spp. exposures came from ten different BNHHs. The 
remaining three Brucella spp. exposures came from three different BPHHs (see 
Table 3.3). Estimated seroprevalence by RBT and 95% confidence intervals for 
BPHH and BNHH household participants, as well as RBT seroprevalence estimates 
and 95% confidence intervals for four comparison human brucellosis studies in 
Tanzania are shown in Figure 3.4. 
 
Combining both SAT and RBT results, 21 of 180 household participants tested 
seropositive, indicating a seroprevalence of 11.7% across household participants. 
Separating the results into BPH and BNH household participants, seroprevalence 
was 22.7% and 10.1%, respectively by SAT and RBT (see Table 3.3). Regarding 
household-level SAT and RBT serostatus, 3 (60.0%) of 5 BPHHs had one or more 
seropositive household participant, and 10 (25.0%) of 40 BNHHs had one or more 
seropositive household participant (see Table 3.3). A summary of household 
participant enrolment and brucellosis test results is given in Figure 3.5. 
   
 
 
Table 3.3: Seroprevalence at the individual household participant-level and household-level as indicated by the Rose Bengal plate 
test (RBT) and the serum agglutination test (SAT): N is the total number of household participants that serology test data are 
available for; n is the number of seropositive household participants; CI is confidence intervals; and BPHH and BNHH are the brucellosis 
positive and brucellosis negative febrile hospital participant households, respectively; confidence intervals are reported to 2 decimal 
places 
Serological test 
BPHH household participant 
seroprevalence  
BNHH household participant 
seroprevalence  
BPHH with ≥1 seropositive 
household participant 
BNHH with ≥1 seropositive 
household participant 
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) 
SAT  2/22  9.1 (1.12 – 29.16)  0/158  0.0 (0.00 – 2.31)  2/5  40.0 (5.27 – 85.34)  0/40  0.0 (0.00 – 8.81) 
RBT    4/22  18.2 (5.19 – 40.28)  16/154  10.4 (6.06 – 16.32)  3/5  60.0 (14.66 – 94.73)  10/40  25.0 (12.69 – 41.20) 
SAT & RBT 5/22 22.7 (7.82 – 40.65)  16/158  10.1 (5.90 – 15.92)  3/5  60.0 (14.66 – 94.73)  10/40 25.0 (12.69 – 41.20) 
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Figure 3.4: Mean seroprevalence estimates and 95% confidence intervals for 
human brucellosis studies conducted in agro-pastoral and/or pastoral areas of 
Tanzania: points represent mean seroprevalence estimates per study and bars 
represent 95% confidence intervals; RBT is the Rose Bengal plate test; SAT is the 
serum agglutination test; all cross-sectional studies refer to sampling of 
livestock-keeping households, cross-sectional study Katavi is Assenga et al., 
2015; cross-sectional study Arusha/Kilimanjaro and Arusha/Manyara are 
Halliday JEB, unpublished data; febrile hospital study Ngorongoro is Bodenham 
et al., 2020; BNHH household participants are household participants in the 
current study from brucellosis negative hospital participant households, for RBT 
tested BNHH household participants n = 154, for RBT & SAT tested BNHH 
household participants n = 158; BPHH household participants are household 
participants in the current study from brucellosis positive hospital participant 
households, for RBT tested and RBT & SAT tested BPHH household participants n 
= 22  
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Figure 3.5: Flow diagram of household member study participant enrolment 
and brucellosis test results: BPH and BNH are brucellosis positive and negative 
febrile hospital participants, respectively; BPHH and BNHH are BPH and BNH 
households, respectively 
 
 
 
  
113 febrile hospital 
participants’ blood samples 
tested
5 (35.7%) BPHH 
sampled
40 (40.4%) BNHH 
sampled
8 BPH were approached 
and declined participation 
in household member study
1 BPH was not approached
99 (87.6%) BNH
(RBT and SAT and culture 
negative)
14 (12.4%) BPH
(RBT and/or SAT and/or 
culture positive)
50 BPH were approached 
and declined participation 
in household member study
9 BNH were not 
approached
22 household 
participants 
enrolled
158 household 
participants 
enrolled
3 (13.6%) of 
22 household 
participants 
Brucella spp. 
exposed
2 (9.1%) of 22 
household 
participants 
with acute 
brucellosis
17 (77.3%) of 
22 household 
participants 
brucellosis 
test negative
16 (10.4%) of 
158 household 
participants 
Brucella spp. 
exposed
0 (0.0%) of 158 
household 
participants 
with acute 
brucellosis
142 (89.9%) of 
158 household 
participants 
brucellosis test 
negative
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3.3.5 Aim 3: Evaluating evidence of association 
between Brucella spp. exposure status of household 
participants and febrile hospital participants 
A GLMM analysis to evaluate any association between Brucella spp. exposure 
status of household participants and febrile hospital participants was performed. 
Household status (BPHH or BNHH) was included in the model as the explanatory 
variable, a unique household identifier was included as a random effect and 
household participant Brucella spp. exposure status was the response variable. 
There was no significant association between the Brucella spp. exposure status 
of household participants and febrile hospital participants. GLMM estimates are 
found in Table 3.4. 
 
Table 3.4: Generalised linear mixed-effect model evaluating association 
between Brucella spp. exposure status of household participants and febrile 
hospital participants, OR is odds ratio, CI is confidence intervals, p value 
reported to three decimal places, sd is standard deviation 
 
Variable 
 
 
OR (95% CI) 
 
p value 
Intercept  
4.45 (0.01 – 31.61) <0.001 
Household status BNHH Ref  
 BPHH 0.04 (0.53 – 68.82) 0.170 
Random effect: Household ID (Variance = 2.51, sd = 1.59, no. of groups = 45) 
 
 
3.3.6 Aim 4: Comparing the age and sex distributions of 
febrile hospital study and household member study 
participants  
A total of 228 (98.2%) of 232 febrile hospital participants enrolled during the 
febrile hospital study had age and sex data available. Of household participants, 
179 (99.4%) of 180 had age and sex data available. Age and sex distributions for 
the two study populations are shown in Figure 3.6. Febrile hospital participants 
had a median age of 27 years (range: 2-78 years). Household participants had a 
median age of 20 years (range: 3-80 years). A total of 129 (56.6%) of 228 febrile 
hospital participants were female and 120 (67.0%) of 179 household participants 
were female. 
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Multivariable GLM analysis to compare the febrile hospital study versus 
household member study (reference population) participant sex and age (years) 
distributions was performed. Analyses show that study population was 
significantly associated with: sex (LRT !2 = 5.00, df = 1, p = 0.025, n = 407), with 
participants in the febrile hospital study having higher odds of being male as 
compared to participants in the household member study (aOR = 1.59, 95% CI = 
1.06 – 2.41, p = 0.026); and age (LRT !2 = 4.64, df = 1, p = 0.031, n = 407), with 
participants in the febrile hospital study having higher odds of increasing age in 
years as compared to participants in the household member study (aOR = 1.01, 
95% CI = 1.00 – 1.02, p = 0.034), see Table 3.5 for further details. 
 
 
 
Figure 3.6: Age and sex distribution of febrile hospital study participants (left 
panel) and age and sex distribution of household member study participants 
(right panel) 
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Table 3.5: Multivariable generalised linear model evaluating the relationship 
between febrile hospital participant versus household member participant 
(reference population) study populations and the covariables sex and age in 
years, aOR is adjusted odds ratio, CI is confidence interval, LRT is likelihood 
ratio test, "2 is chi-squared test statistic, p values are reported to three 
decimal places 
Variable  
aOR  
(95% CI) 
aOR 
p value 
LRT "2 LRT p value 
Intercept  
0.77 (0.52 – 1.1) 0.196   
Sex Female Ref    
 Male 1.59 (1.06 – 2.41) 0.026 5.00 0.025 
Age (years)  
1.01 (1.00 – 1.02) 0.034 4.64 0.031 
 
 
3.3.7 Aim 5: Comparing the age and sex distributions of 
RBT-defined Brucella spp. exposed febrile hospital 
study and household member study participants  
RBT was performed on 224 (96.6%) of 232 febrile hospital participants with 
serum available and 176 (97.8%) of 180 household participants with serum 
available. Twenty (8.9%) of 224 febrile hospital participants were RBT positive. 
Twenty (11.4%) of 176 household participants were RBT positive. Age and sex 
distributions for RBT-defined Brucella spp. exposed febrile hospital participants 
and household participants are shown in Figure 3.7. Of 20 RBT positive febrile 
hospital participants, the median age was 13.5 years (range: 7-62 years). Of 
twenty RBT positive household participants, the median age was 23 years 
(range: 7-80 years). Seven (35.0%) of 20 RBT positive febrile hospital participants 
were female. Fourteen (70.0%) of 20 RBT positive household participants were 
female. 
 
A GLM analysis comparing RBT-defined Brucella spp. exposed febrile hospital 
study versus household member study participant (reference population) sex and 
age (years) distributions was performed. The most parsimonious final model 
included the variable sex (LRT !2 = 5.019, df = 1, p = 0.025, n = 40), with 
Brucella spp. exposed participants in the febrile hospital study having higher 
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odds of being male as compared to Brucella spp. exposed participants in the 
household member study (OR = 4.33, 95% CI = 1.20 – 17.43, p = 0.030), see Table 
3.6.  
 
 
 
Figure 3.7: Age and sex distribution of febrile hospital study RBT-defined 
Brucella spp. exposed participants (left panel) and age and sex distribution of 
household member study RBT-defined Brucella spp. exposed participants 
(right panel), RBT is the Rose Bengal plate test 
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Table 3.6: Maximal and final generalised linear models evaluating relationship between RBT-defined Brucella spp. exposed 
participants in the febrile hospital study versus household member study (reference population) and the covariables sex and age 
(years), aOR is adjusted odds ratio, CI is confidence interval, LRT is likelihood ratio test, !2 is chi-squared test statistic, p values are 
reported to three decimal places 
Variable  
Maximal model Final model 
aOR  
(95% CI) 
aOR 
p value 
LRT !2 LRT p value OR  (95% CI) OR p value LRT !2 LRT p value 
Intercept  
0.82 (0.22 – 3.05) 0.771   0.50 (0.19 – 1.20) 0.134   
Sex Female Ref    Ref    
 Male 4.05 (1.09 – 16.59) 0.042 4.36 0.037 4.33 (1.20 – 17.43) 0.030 5.02 0.025 
Age (years)  
0.98 (0.94 – 1.02) 0.304 1.09 0.295     
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3.4 Discussion 
This is the first study in Tanzania, and possibly in SSA, to investigate brucellosis 
active surveillance in the form of active case finding in household members of 
febrile hospital patients. Two household participants were identified as acute 
brucellosis cases in two separate BPHHs, no acute brucellosis case was identified 
in BNHHs. Seroprevalence in household participants from BPHHs and BNHHs was 
estimated at 22.7% (95% CI: 7.82 – 40.65) and 10.1% (95% CI: 5.90 – 15.92), 
respectively. Three of 5 BPHHs and 10 of 40 BNHHs had one or more seropositive 
household participant. In the GLMM analysis, there was no significant association 
between the Brucella spp. exposure status of household participants and febrile 
hospital participants. A GLM comparing the age and sex distributions of the 
febrile hospital study participants and the household member study participants 
indicated a significant association with age and sex. Being male and of 
increasing age in years was significantly associated with febrile hospital 
participants. A further GLM comparing the age and sex distributions of Brucella 
spp. exposed (as measured by RBT) febrile hospital participants and household 
participants showed an association with sex. Being male was significantly 
associated with Brucella spp. exposed febrile hospital participants. 
 
This household member study detected two acute brucellosis cases in the 
household participants of two separate BPHHs. The identification of acute 
brucellosis cases in household members that have not visited hospital suggests 
that hospital-based surveillance alone will underestimate acute brucellosis 
burden. Although this is a small sample size, this finding is consistent with the 
hypothesis that there are shared risk factors for Brucella spp. infections at the 
household-level (Tabak et al., 2008). In Chapter 2, low age was identified as a 
risk factor for acute brucellosis in febrile hospital participants, with acutely 
infected individuals having a median age of 11 years (range: 7-20 years). Here, 
both acute brucellosis household participants were 7 years-old and therefore fit 
into the pre-identified age range for acute brucellosis cases in the febrile 
hospital population. Having herded any livestock over the past 12 months was 
also a risk factor for acute brucellosis in febrile hospital participants in Chapter 
2. Here, one of the two household participants identified as a probable acute 
brucellosis case reported having herded livestock. 
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The seroprevalence of Brucella spp. exposure in household participants from 
BPHHs was 22.7% and was higher than seroprevalence in household participants 
from BNHHs estimated as 10.1%. However, the confidence intervals for these 
estimates do substantially overlap. Other studies in Eastern Europe and the 
Middle East have estimated seroprevalence between 7% to 20% for household 
members of brucellosis patients (Almuneef et al., 2004; Alsubaie et al., 2005; 
Ismayilova et al., 2013; Sanodze et al., 2015; Sharifi-Mood et al., 2007; Sofian et 
al., 2013; Tabak et al., 2008). The aforementioned studies do differ in study 
design and in geographical setting. They are therefore not directly comparable 
to the present study, but they do however give an indication of an approximate 
seroprevalence range in the absence of an evident comparable study in SSA.  
 
There are examples of cross-sectional studies that have used RBT to investigate 
seroprevalence of Brucella spp. exposure in agro-pastoralist and pastoralist 
households in Tanzania. These human seroprevalence estimates ranged from 
1.5% to 5.1% (Assenga et al., 2015) (Halliday JEB, unpublished data). In the 
linked febrile hospital study, seroprevalence of brucellosis in febrile hospital 
participants as defined by RBT was 8.9%. In the current study, considering RBT-
defined seroprevalence estimates only so as to compare to previous studies in 
similar settings in Tanzania, BPHH and BNHH seroprevalence was 18.2% (95% CI: 
5.19 – 40.28) and 10.4% (95% CI: 6.06 – 16.32), respectively. The higher 
seroprevalence estimates (albeit with wide confidence intervals) in this study 
are not surprising considering the difference in the sampled population as 
compared to the other study examples. For example, the studies differed in: 
surveillance location (household, hospital); health status of participant (febrile, 
non-febrile); geographic location; and livestock-keeping practices (pastoral, 
agro-pastoral). 
 
The GLMM was fitted to investigate any association between the Brucella spp. 
exposure status of household participants and febrile hospital participants. The 
study sample size achieved was ultimately not sufficient to power this analysis 
investigating evidence of grouping in Brucella spp. exposures and no significant 
association was identified. However, a trend towards an increased number of 
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Brucella spp. exposed household participants in BPHHs was observed, although 
this was not significant. 
 
The sex and age distributions of the febrile hospital study and household 
member study populations were compared using a multivariable GLM. There was 
significant association found for both sex and age distributions in the two study 
populations. Being male and of increasing age in years was significantly 
associated with febrile hospital participants. The sex and age distributions of 
RBT-defined Brucella spp. exposed febrile hospital and household participants 
were also compared by multivariable GLM. The final model identified that being 
male was significantly associated with Brucella spp. exposed febrile hospital 
study participants as compared to household study participants. It should be 
highlighted that the two study populations being compared here were: febrile 
hospital patients; and household members of febrile hospital participants. The 
selection steps for these two populations were different and therefore the 
results from these analyses should be interpreted with caution. Comprehensive 
studies investigating gender differences in disease burden such as for 
tuberculosis and HIV in LMICs have found that males are relatively disadvantaged 
in accessing healthcare (Auld et al., 2015; Horton et al., 2016). It is possible that 
being female and of decreasing age in years, and equally being female and 
Brucella spp. exposed, was associated with enrolment in the household member 
study because younger females were relatively more likely to be present during 
household member sampling. Of all study participants enrolled in the household 
member study, 67.2% were female. Males may have been more likely to be 
absent from the household due to livestock-keeping or employment 
responsibilities. For the febrile hospital study, 56.6% of all participants were 
female. However, 75.0% of RBT-defined Brucella spp. exposures were male, 
indicating a relatively higher Brucella spp. seroprevalence in male febrile 
hospital study participants. Similarly, regarding the brucellosis case data for the 
febrile hospital study, 71.4% of brucellosis cases (defined but culture or SAT) 
were male (Bodenham et al., 2020). Overall, these findings suggest that both 
males and females are at risk of Brucella spp. exposure, and there are varying 
factors influencing male and female enrolment in both healthcare facility and 
community-based surveillance approaches. These findings reinforce that analysis 
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of hospital-based data alone will likely not be representative of the true disease 
burden in the community. 
 
A limitation of this study was that the household member sample size estimated 
by the power analysis was not achieved. Therefore, a lack of sufficient power 
may be the reason why there was no significant association between household 
participant and febrile hospital participant Brucella spp. exposure status. 
Meaning that grouping of exposures to Brucella spp. at the household-level was 
not found. There were different study challenges that negatively impacted on 
the number of samples collected. Firstly, the household study sample size pool 
was limited by the total number of febrile hospital participants enrolled (n = 
113), during the household study timeframe. It is important to acknowledge that 
this study was also subject to selection bias as the household participation 
decline rate was 56.3%. Reasons for study participation decline included the 
highly mobile nature of the study community, and the invasive sampling 
requested. Those households that did participate may have had a head of 
household that was more highly educated and more aware of brucellosis. 
Participating households may have been at a lower risk of exposure to Brucella 
spp. due to this disease awareness, interest in family health, and reduced 
household mobility, as compared to the non-participating, more mobile 
households. Additionally, household members sampling was not randomised; the 
first six household members that consented to participate were sampled. This 
approach may have resulted in more influential household members self-
selecting which individuals would be sampled and potentially prioritising those 
individuals with a history or suspected brucellosis, meaning that a true 
representation of household member health was less likely to be achieved. 
Therefore, selection biases may have resulted in underestimation of the 
prevalence of brucellosis in the household members of febrile hospital 
participants due to a high household decline rate, or overestimated prevalence 
due to non-randomised household member sampling and the potential for 
preferential selection of sick household members. 
 
As a national active surveillance tool, screening of household members of febrile 
hospital patients may be too resource-intensive to justify its routine 
implementation in Tanzania. However, further study may benefit from 
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increasing the duration of a household-based surveillance research, alongside 
the continuation of hospital-based surveillance. This would improve power to 
detect any grouping of Brucella spp. exposures in the households of febrile 
hospital participants, if truly present. The availability of these Brucella spp. 
exposure data from community members that do not reach a healthcare facility 
are important in informing effective, targeted implementation of brucellosis 
prevention and control interventions. 
 
3.5 Conclusion 
Active surveillance in the form of screening household members of brucellosis 
patients has been suggested for areas endemic to brucellosis (Moreno, 2014; 
Tabak et al., 2008), and in combination with routine passive surveillance can 
help in understanding the true burden of brucellosis (Mantur and Amarnath, 
2008). Examples of this form of active case finding surveillance are hard to find 
in SSA, however studies have indicated their necessity in this region (Asiimwe et 
al., 2015; Migisha et al., 2018). In the current study, acute brucellosis cases 
were detected in household participants of BPHHs. Despite the number of 
additional acute brucellosis cases detected being small, this method of targeted 
active surveillance indicates that the use of hospital-based surveillance alone 
will underestimate the true brucellosis burden. The seroprevalence estimate was 
highest for household participants of BPHHs as compared to BNHHs. However, no 
significant association was identified between Brucella spp. exposures in 
household participants and febrile hospital participants. This is likely due to the 
challenges of data collection of this type and consequent limited power for this 
analysis. Active surveillance by screening household members requires further 
study but may prove too resource-intensive for routine implementation. 
However, it could provide valuable data on disease burden for the population 
that do not reach a healthcare facility, as well as assist in targeting prevention 
and control measures towards high-risk populations in Tanzania and other 
comparable areas in SSA. 
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Chapter 4 Evaluating the performance of serological tests 
in detecting animal brucellosis in Tanzania 
 
4.1 Introduction 
Brucellosis is endemic in many of the pastoral areas of sub-Saharan Africa (SSA) 
(Mcdermott and Arimi, 2002), where people commonly live in close contact with 
livestock species (Pappas et al., 2006). Animal reservoirs are the source of 
human infections (Godfroid et al., 2005). Therefore, the control and prevention 
of brucellosis in animal host species is a key approach in the control and 
prevention of human brucellosis (Corbel, 1997; Doganay and Aygen, 2003). The 
ability to successfully identify animal host species is important in reducing the 
burden of human brucellosis (Bronsvoort et al., 2009). The application of 
effective diagnostic tools for the identification of brucellosis in livestock is 
particularly important in high-risk pastoralist communities. Effective diagnostic 
tools can assist in understanding the epidemiology of brucellosis in these areas, 
and these data can be used to guide animal control activities.  
 
Diagnostic test performance is evaluated by assessment of a test’s sensitivity 
and specificity, which pertain to the capacity of a test in indicating the true 
disease status (Speybroeck et al., 2013). The gold standard diagnostic test for 
brucellosis is isolation of Brucella spp. by culture, which enables confirmation of 
a positive infection status (Ducrotoy et al., 2018). Although culture specificity is 
high, sensitivity can be low as Brucella spp. are fastidious and may be easily out-
competed by contaminating bacteria (Matope et al., 2011). Equally, the type of 
sample collected for culture and the selective media used can also affect 
diagnostic sensitivity (Ducrotoy and Bardosh, 2017; Miguel et al., 2011). The high 
cost of diagnosis by culture, as well as the need for high-security laboratory 
facilities and bacteriological expertise, make this diagnostic approach largely 
inaccessible in low- and middle-income countries (LMICs) (Ducrotoy and Bardosh, 
2017). Serological tests are easier to implement than bacteriological culture and 
do not require high-security laboratory infrastructure (Díaz et al., 2011), making 
serology a more feasible routine brucellosis diagnostic approach in LMICs. 
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Serological tests use blood serum to identify an antibody response to Brucella 
spp. exposure (Ducrotoy and Bardosh, 2017). There are a large number of 
serological tests available that can be broken down into the following groups: 
agglutination tests; primary binding assays; precipitation tests; and complement 
fixation tests (Nielsen, 2002). There is no single serological test that performs 
with high sensitivity and specificity in all epidemiological situations, nor for all 
animal species. Therefore, it is recommended that sera be tested by both a 
recognised screening test and an established confirmatory test to optimise 
sensitivity and specificity of diagnostic testing (OIE, 2018). For cattle and small 
ruminants, the Rose Bengal plate test (RBT), is a joint World Health Organization 
(WHO), Food and Agriculture Organization of the United Nations (FAO) and World 
Organisation for Animal Health (OIE) suitable screening test for animal 
brucellosis (OIE, 2018). The RBT is an agglutination test that is reported as 
having a high sensitivity when testing animal samples in field and laboratory 
settings (Robinson, 2003). Enzyme-linked immunosorbent assay (ELISA) methods 
are also suitable screening tests in the detection of animal brucellosis (OIE, 
2018). The competitive enzyme-linked immunosorbent assay (cELISA) is a 
primary binding assay that is usually more specific than the RBT and indirect 
ELISA (iELISA) (Makita et al., 2011a; OIE, 2018). However, cELISA sensitivity may 
be lower than that of RBT or iELISA (OIE, 2018). 
 
The evaluation of diagnostic tests in the epidemiological setting in which they 
are implemented is important in understanding setting-specific test 
performance, especially in the absence of a gold standard approach. The Hui 
and Walter latent class model can be used to generate estimates of disease 
prevalence, as well as the sensitivity and specificity of a number of diagnostic 
tests where no gold standard is available (Hui and Walter, 1980). Test evaluation 
by latent class analysis requires a minimum of two diagnostic tests in a minimum 
of two subpopulations (Branscum et al., 2005). There are three model 
assumptions that should be met: (a) that prevalence is different between each 
subpopulation; (b) that the diagnostic tests perform the same across 
subpopulations; and (c) that the diagnostic tests are conditionally independent 
regarding disease status (Hui and Walter, 1980). Bayesian adaptation of the no 
gold standard latent class model allows the inclusion of prior knowledge of 
disease prevalence, as well as sensitivity and specificity of each diagnostic test 
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being evaluated based on available estimates from previous studies (Branscum et 
al., 2005). Alternatively, uniform prior distributions may be used if prior 
information is not available (Branscum et al., 2005). Probabilities of each 
diagnostic test outcome conditional on an unknown disease status are estimated 
using the sensitivity and specificity of each diagnostic test and the prevalence of 
the disease in each subpopulation (Mazeri et al., 2016). Bayesian latent class 
models can also be expanded to include estimation of test performance under 
different diagnostic testing approaches, such as in-series and in-parallel testing. 
These different approaches allow the evaluation of using multiple tests in 
disease detection. Using an in-series approach with two diagnostic tests, a 
sample should test positive by both tests to be classified as disease positive. This 
diagnostic approach has the advantage of increasing the overall specificity of the 
selected tests but decreases sensitivity (Dohoo et al., 2003b). With an in-parallel 
approach, all samples are tested by both diagnostic tests and a positive result in 
either test is classified as a disease positive. This approach improves overall 
sensitivity but causes a reduction in specificity (Dohoo et al., 2003b). 
 
There are recent examples across Africa for the evaluation of RBT or cELISA 
performance in diagnosing brucellosis in cattle (Bronsvoort et al., 2009; Chisi et 
al., 2017; Etman et al., 2014; Getachew et al., 2016; Hosein et al., 2017; 
Matope et al., 2011; Muma et al., 2007; Sanogo et al., 2013). A handful have 
assessed both RBT and cELISA (Chisi et al., 2017; Etman et al., 2014; Matope et 
al., 2011; Muma et al., 2007). A study in Zimbabwe reported relatively high 
cELISA sensitivity and high RBT specificity for cattle samples, advocating the use 
of these two tests in combination (Matope et al., 2011). Similar studies in Africa 
for sheep and goats are not evident, although there are examples for Asia, 
Europe and the Americas (García-Bocanegra et al., 2014; Nielsen et al., 2005; 
Rahman et al., 2013; Ramírez-Pfeiffer et al., 2008). 
 
In Tanzania, 40% of the population practices exclusive pastoralism (PINGO’s 
Forum, 2016), and can be considered at high-risk for brucellosis infection. There 
is currently no national standardised and validated testing procedure for animal 
brucellosis in Tanzania (Government of Tanzania, 2018a). Therefore, the 
evaluation of diagnostic test performance and the identification of an evidence-
based diagnostic testing approach for animal brucellosis in this context 
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specifically are vital. The implementation of a standardised and validated 
testing procedure for animal brucellosis can assist in generating a more robust 
true burden estimate for brucellosis in Tanzania and the wider SSA. These data 
can also be used to inform and evaluate evidence-based surveillance and control 
activities in Tanzania. 
 
Here, the performance of the RBT and cELISA diagnostic tests, including in-series 
and in-parallel diagnostic testing approaches, were evaluated for cattle, sheep 
and goats sampled in northern Tanzania using variants of a no gold standard 
Bayesian adaptation of the Hui-Walter latent class model. 
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4.1.1 Study aims 
The aims of this study were: 
 
1 – To estimate the sensitivity and specificity of RBT and cELISA tests for cattle, 
sheep and goats of northern Tanzania  
 
2 – To estimate the prevalence of brucellosis in cattle, sheep and goats of 
northern Tanzania for two subpopulations: exclusive pastoralist and non-
exclusive pastoralist 
 
3 – To compare these estimates to existing literature estimates for cattle, sheep 
and goats 
 
4 - To evaluate RBT and cELISA combined test performance when using in-series 
and in-parallel testing approaches 
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4.2 Methods 
The methods detailed in Sections 4.2.1 – 4.2.5 were not conducted as part of 
this research chapter, but these methodological sections are described so as to 
understand the source of the data used to inform the latent class analyses 
performed here. Methods that were performed and contributed specifically to 
the research outcomes for this chapter include Sections 4.2.6 onwards. 
 
4.2.1 Study area 
Animal data collection was conducted in three regions of northern Tanzania: 
Arusha, Manyara and Kilimanjaro. Across these neighbouring regions there are a 
mix of livestock-keeping systems including exclusive pastoral, agro-pastoral and 
commercial. The Tanzanian 2016 to 2017 livestock census estimated a cattle 
population of approximately 1.2 million for Arusha, 2.2 million for Manyara and 
794,000 for Kilimanjaro (Government of Tanzania, 2017). For sheep, the 
approximate population for Arusha was 659,000, Manyara was 444,000 and 
Kilimanjaro was 182,000 (Government of Tanzania, 2017). From the same 
census, the goat population was estimated at approximately 2.6 million for 
Arusha, 1.8 million for Manyara and 664,000 for Kilimanjaro (Government of 
Tanzania, 2017). 
 
4.2.2 Study design 
The data used to support the latent class analyses came from two cross-sectional 
studies. The first study was conducted in Arusha and Kilimanjaro Regions 
between September 2013 to March 2015, and the second in Arusha and Manyara 
Regions from January to December 2016. 
 
Arusha/Kilimanjaro study: A survey of livestock-owning households was 
conducted across seven districts in Arusha and Kilimanjaro Regions: Hai; 
Longido; Monduli; Moshi Municipal; Moshi Rural; Mwanga; and Rombo. A list of 
the wards within each district was obtained from census records. Wards were 
first identified as rural or urban based on national census data (NBS, 2013). 
Urban wards within Hai, Moshi Municipal, Moshi Rural, Mwanga and Rombo 
districts were classified as peri-urban production areas. Rural wards within Hai, 
Moshi Municipal, Moshi Rural, Mwanga and Rombo districts that did not contain a 
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substantial population of pastoralist livestock-keepers were classified as agro-
pastoral production areas. Rural wards within Longido and Monduli districts of 
the Arusha Region that included a substantial population of pastoralist livestock-
keepers were classified as pastoral production areas. 
 
A multistage sampling approach was adopted to select wards, villages, sub-
villages and livestock-owning households for inclusion in the study. Six wards 
were selected at random from each production area to give a total of 18 
randomly selected study wards. One village or sub-village (depending on the 
smallest unit applicable) from each ward was randomly selected for inclusion, 
see Figure 1 for the distribution of villages/sub-villages sampled. Households 
were randomly selected from a list of livestock-keeping households generated 
through consultation with local community leaders in each village. A minimum of 
five households were selected in each village/sub-village. At each household, up 
to 15 cattle, sheep and goats were randomly selected. In households with more 
than 15 of each livestock species, adult females were prioritised. Individual-
level animal data were collected including: species; age; sex; breed; and 
vaccination status. 
 
Arusha/Manyara study: A survey of livestock keepers was conducted in ten 
districts in Arusha and Manyara Regions: Longido; Monduli; Arusha; Karatu; Meru; 
Ngorongoro; Babati Rural; Babati Urban; Mbulu; and Simanjiro. Villages lists 
were obtained from national census data (NBS, 2013). Villages in wards specified 
in the census data as urban were excluded from the selection procedure. 
Villages were classified as: pastoral, where livestock rearing was considered to 
be the primary livelihood activity; and mixed, where a combination of crop 
production and livestock keeping were important. Classification of villages was 
performed in consultation with district government officials. Village selection 
was stratified by production classification, with 11 pastoral villages and 9 mixed 
villages selected, see Figure 1 for the distribution of villages sampled. 
 
A multistage sampling approach was used for the selection of households. Each 
selected village consisted of two to four sub-villages. Two to three sub-villages 
were randomly selected for sampling in each village. In each selected sub-
village, a central point sampling approach was applied, where livestock keepers  
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Figure 4.1: Arusha, Kilimanjaro, and Manyara Regions (green shading) in 
Tanzania, the solid black line represents the border with Kenya, yellow circles 
show the villages/sub-villages sampled for the Arusha/Kilimanjaro study, blue 
triangles show the villages/sub-villages sampled for the Arusha/Manyara study. 
In the top right insert, white polygons show Arusha, Kilimanjaro and Manyara 
Region locations within an outline map of Tanzania (grey shading). Shapefiles of 
administrative boundaries from the 2012 census were sourced from the 
Tanzania National Bureau of Statistics. 
 
and their animals were invited to a predetermined point within the sub-village. 
At this central point, a list of the attending households was recorded, and a 
maximum of ten households selected using a random number generator. From  
the selected households, a maximum of 10 cattle, 10 sheep and 10 goats were 
sampled. A target of at least 5 juvenile animals, including 2 juvenile males and 5  
Kilimanjaro
Arusha
Manyara
0 25 50 km
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adult animals, including 2 adult males were selected at random per species, per 
household. Individual-level animal data were collected including: species; age; 
sex; breed; and vaccination status. The full study methodology is described 
elsewhere (Herzog et al., 2019). 
 
4.2.3 Sample collection 
Both studies collected up to 10 mL of venous blood into a plain vacutainer (BD, 
Franklin Lakes, NJ, USA) from all selected livestock. Blood samples were allowed 
to clot and centrifuged at 1300 g for 10 minutes. Serum was aliquoted into 
sterile samples tubes in the field and stored at 4 °C in a mobile refrigerator for 
up to 72 hours before being heat treated at 56 °C for two hours and stored at -
80 °C.  
 
All sera were tested by both RBT and cELISA. Based on the absence of reports of 
any vaccination efforts for Brucella in the study regions and no reports of 
Brucella vaccination in the sampled households, detected seropositivity was 
assumed to reflect natural exposure to Brucella spp. 
 
4.2.4 Rose Bengal plate test 
All sera were tested by the Rose Bengal plate test (RBT) at the field site or in 
the Kilimanjaro Clinical Research Institute (KCRI) laboratory, Tanzania. The 
same RBT standard protocol was used as described in Chapter 3, Section 3.2.4., 
except that the serum to antigen ratio used for each livestock species varied. 
For cattle samples, the ratio remained the same as in humans, using 25 µL serum 
to 25 µL antigen. For sheep and goats, the recommended modified serum to 
antigen ratio, 75 µL serum to 25 µL antigen, was used (OIE, 2018). 
 
4.2.5 Competitive enzyme-linked immunosorbent assay 
Sera testing by competitive enzyme-linked immunosorbent assay (cELISA) for the 
2013 to 2015 study was performed at the Animal and Plant Health Agency 
(APHA), UK. Diagnostic testing by cELISA for the 2016 study was conducted at 
KCRI. Cattle, sheep and goat sera testing for both studies was performed using 
the COMPELISA kit (APHA SCIENTIFIC, Weybridge, UK). cELISA was implemented 
following the COMPELISA kit instructions as follows: diluting buffer was brought 
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to ambient temperature and conjugate concentrate was then diluted to working 
strength. Using a 96-well plate, 20 µL of each serum sample was pipetted into an 
individual well. Positive and negative control sera were pipetted at 20 µL 
volumes into 5 wells each. Four empty wells acted as conjugate controls. 
Immediately, 100 µL of conjugate solution was pipetted into all wells. The plate 
was then vigorously shaken for two minutes. Next, the plate was covered and 
incubated at 21ºC ± 6ºC for 30 minutes on a rotary shaker at 160 revs/min. 
Following incubation, the plate was inverted, and the solution tapped from the 
wells. Drinking water was used to wash the plate 5 times and the plate inverted 
again and dried using absorbent towel until no more liquid could be removed. 
Prior to use, OPD solution was prepared by dissolving one tablet of urea 
hydrogen peroxide in 12 mL of distilled water, one OPD tablet was then added to 
the solution and mixed thoroughly. A 100 µL volume of OPD solution was 
pipetted into each well. The plate was then incubated at 21ºC ± 6ºC for between 
10 and 20 minutes. Finally, 100 µL of stopping solution was pipetted into each 
well and the plate read on a microplate reader at 450 nm. Positive sera were 
those lacking colour development. The 4 conjugate control wells were used to 
calculate 60% of the mean optical density (OD), which was used as the 
positive/negative cut-off value. Sera with an OD value equal to or less than the 
cut-off value were classified as positive. 
 
4.2.6 Subpopulation classifications 
The animal diagnostic test data from both studies were combined and classified 
as coming from one of two subpopulations: pastoralist, or non-pastoralist. 
Exclusive pastoralist was defined as: all animals sampled in villages/sub-villages 
previously identified as predominantly livestock keeping production areas. Non-
exclusive pastoralist was defined as: all animals sampled in villages/sub-villages 
previously identified as a combination of crop and livestock keeping production 
areas. 
 
4.2.7 Statistical analyses: Bayesian Hui-Walter model 
A previously described Bayesian version of the no gold standard Hui-Walter 
model (Bronsvoort et al., 2009; Mazeri et al., 2016; Toft et al., 2005) was used 
to evaluate performance of the RBT and cELISA diagnostic tests and estimate 
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true disease prevalence for cattle, sheep and goats of northern Tanzania. Using 
this Bayesian latent class model, RBT and cELISA test outcome probabilities 
conditional on an unknown livestock disease status were specified using the 
sensitivity (Se) and specificity (Sp) of the two diagnostic tests and the 
prevalence (p) of disease in two subpopulations (Branscum et al., 2005; Mazeri 
et al., 2016). For this analysis, the RBT and cELISA test results were specified as 
either positive or negative, and diagnostic test data were classified as one of 
two subpopulations: exclusive pastoralist; or non-exclusive pastoralist. The 
model assumes that for the ith subpopulation, the counts (Oi) with each 
combination of test results (+/+; +/-; -/+; -/-) follows a multinomial distribution 
(Bronsvoort et al., 2009; Mazeri et al., 2016; Toft et al., 2005): 
 !"|	Se', Sp', p*	~	Multinomial(67", n*)				for	i = 1,2, … , S				and	j = 1,2, … , T 
 
Where Pri is a vector of probabilities of observing the 4 combinations of 
diagnostic test results for the ith subpopulation, ni is the total number of 
observations of the ith subpopulation, S is the number of different 
subpopulations and T is the number of diagnostic tests. 
 
Individual test estimates for sensitivity and specificity were then used to 
estimate an overall sensitivity and specificity for in-series and in-parallel 
diagnostic testing approaches. The in-series diagnostic testing approach only 
identified animals as positive if the animal tested positive by both RBT and 
cELISA. The in-parallel approach identified an animal as positive if test positive 
by either RBT or cELISA. The equations for sensitivity and specificity estimates 
using in-series and in-parallel diagnostic testing approaches are as follows: 
 Series	Se = SeC ∗ SeE Series	Sp = 1 − (1 −	SpC) ∗ (1 −	SpE) Parallel	Se = 1 − (1 − SeC) ∗ (1 − SeE) Parallel	Sp = 	 SpC ∗ SpE 
 
4.2.8 Statistical analyses: Model assumptions 
Model assumption (a) was a difference in disease prevalence between the 
subpopulations being tested. The data for cattle, sheep and goats were split into 
  115 
two subpopulations: exclusive pastoralist and non-exclusive pastoralist. It can be 
assumed that brucellosis prevalence is different between exclusive pastoralist 
communities and other livestock-keeping communities (Racloz et al., 2013), 
which has been reported in Tanzania (Shirima et al., 2010; Swai and Schoonman, 
2010). Therefore, model assumption (a) was assumed to be met. 
 
Model assumption (b) was that a diagnostic test performs comparably across 
subpopulations. This assumption was considered to be met because the majority 
of cattle, sheep and goat samples used in this analysis were of the same 
indigenous breed, the RBT and cELISA testing followed the same standard 
operating procedures, and test antigens and control sera were sourced from the 
same manufacturer. 
 
The final model assumption (c) was that of conditional independence regarding 
disease status between RBT and cELISA tests. As RBT and cELISA are both 
serological tests that detect an antibody response to Brucella spp. exposure, it 
was likely that this model assumption could not be met. Therefore, the model 
was extended to include conditional dependence between diagnostic tests using 
a covariance parameterisation (Branscum et al., 2005; Bronsvoort et al., 2019; 
Mazeri et al., 2016): 
 Pr(TC+, TE +) = I(SeC ∗ SeE) + covDpM ∗ p* + (I(1 − SpC) ∗ (1 − SpE)M + covDn) ∗ (1 − p*) Pr(TC+, TE −) = NI(SeC) ∗ (1 − SeE)M − covDpO ∗ p* + (I(1 − SpC) ∗ SpEM − covDn) ∗ (1 − p*) Pr(TC−, TE +) = I(1 − SeC) ∗ SeEM − covDp) ∗ p* + (ISpC ∗ (1 − SpE)M − covDn) ∗ (1 − p*) Pr(TC−, TE −) = I(1 − SeC) ∗ (1 − SeE) + covDpM ∗ p* + ((SpC ∗ SpE) + covDn) ∗ (1 − p*) 
 
Where Pr is the probability of observing the specific combination of diagnostic 
test outcomes (+/+; +/-; -/+; -/-), T+ is diagnostic test positive and T- is 
diagnostic test negative, 1 represents the RBT, 2 represents the cELISA. The 
covDp and covDn are the covariance between the diagnostic tests when an 
animal is disease positive or disease negative, respectively, and pi represents 
infection prevalence in the ith subpopulations. 
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The inclusion of conditional dependence in a two-test, two-population model 
increases the number of parameters being estimated to eight, with only six 
degrees of freedom available. In order to allow model parameter estimation in 
this case, it was necessary that at least some of the model parameters had 
informative (non-uniform) priors (Branscum et al., 2005). 
 
4.2.9 Statistical analyses: Prior distributions 
For the cattle model, a set of test sensitivity and specificity prior distributions 
were informed by literature on RBT and cELISA test performance mean estimates 
in Africa (see Tables 4.1 and 4.2). For sheep and goats, a set of RBT and cELISA 
test parameter prior distributions were informed by the available literature 
reporting mean estimates for diagnostic test performance outside of Africa (see 
Tables 4.3 and 4.4). 
 
The beta distribution shape parameters (α, β) for test sensitivity and specificity 
priors used to analyse data from cattle were calculated by extracting the mean 
estimates from Tables 4.1 and 4.2. The ‘fitdist’ function found in the fitdistrplus 
R package (Delignette-Muller et al., 2019) was used to estimate the beta 
distribution shape parameters from these data. The same approach was applied 
to generate priors for the analysis of both sheep and goat data using the mean 
estimates of RBT and cELISA specificity and sensitivity found in Table 4.3 and 
4.4. Beta distribution parameters to the nearest integer for cattle and small 
ruminants are given in Table 4.5. 
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Table 4.1: Sensitivity (Se) and specificity (Sp) mean estimates using the Rose 
Bengal plate test (RBT) for cattle in Africa, LCA is latent class analysis 
Reference Test property estimation 
technique 
Location Se Sp 
(Muma et al., 
2007) 
LCA uniform priors Zambia 0.930 0.820 
(Matope et al., 
2011) 
LCA uniform priors Zimbabwe 0.947 0.990 
(Sanogo et al., 
2013) 
LCA informed priors: 
(Nielsen, 2002) 
Ivory Coast 0.547 0.978 
(Etman et al., 
2014) 
Culture & vaccinated Egypt 0.961 0.993 
(Getachew et al., 
2016) 
LCA informed priors: 
(Gall and Nielsen, 2004; 
Mainar-Jaime et al., 2005) 
Ethiopia 0.896 0.845 
(Chisi et al., 
2017) 
Culture South Africa 0.958 1 
(Hosein et al., 
2017) 
Culture Egypt 0.943 0.857 
 
 
Table 4.2: Sensitivity (Se) and specificity (Sp) mean estimates using the 
competitive enzyme-linked immunosorbent assay (cELISA) for cattle in 
Africa, LCA is latent class analysis 
Reference Test property estimation 
technique 
Location Se Sp 
(Muma et al., 
2007) 
LCA uniform priors Zambia 0.970 0.600 
(Bronsvoort et 
al., 2009) 
LCA informed priors: 
(Fosgate et al., 2003; Gall 
et al., 1998; McGiven et 
al., 2003; Nielsen et al., 
1996, 1995; Stack et al., 
1999) 
Cameroon 0.978 0.987 
(Matope et al., 
2011) 
LCA uniform priors Zimbabwe 0.990 0.954 
(Etman et al., 
2014) 
Culture Egypt 0.971 1 
(Chisi et al., 
2017) 
Culture South Africa 0.939 0.950 
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Table 4.3: Sensitivity (Se) and specificity (Sp) mean estimates using the Rose 
Bengal plate test (RBT) for small ruminants, S is sheep, G is goats and SG is 
sheep and goats, LCA is latent class analysis 
Reference Test property 
estimation technique 
Location Species Se Sp 
(Marín et al., 
1999) 
Culture Unknown S 1 1 
(Nielsen et 
al., 2004) 
Experimentally infected Canada & 
Unknown 
S 
 
0.997 0.880 
(Minas et al., 
2005) 
Culture Greece S 0.904 0.996 
(EFSA, 2006) Culture Multiple SG 0.925 0.999 
(Minas et al., 
2008) 
Culture Greece SG 0.758 0.997 
(Ramírez-
Pfeiffer et 
al., 2008) 
Culture Mexico & 
Canada 
G 0.997 0.327 
(Rahman et 
al., 2013) 
LCA informed priors: 
(Abuharfeil and Abo-
Shehada, 1998; Blasco et 
al., 1994; EFSA, 2006; 
Minas et al., 2008, 2005; 
Nielsen et al., 2004; 
Ramírez-Pfeiffer et al., 
2008) 
Bangladesh S 
G 
0.828 
0.802 
0.983 
0.996 
(García-
Bocanegra et 
al., 2014) 
LCA informed priors:  
(EFSA, 2006) 
Spain S 0.750 0.974 
(Gupta et al., 
2014) 
Culture India G 0.700 0.900 
 
 
Table 4.4: Sensitivity (Se) and specificity (Sp) mean estimates of the 
competitive enzyme-linked immunosorbent assay (cELISA) for small 
ruminants, S is sheep, G is goats and SG is sheep and goats 
Reference Test property 
estimation technique 
Location Species Se Sp 
(Marín et al., 
1999) 
Culture Unknown S 0.960 1 
(Burriel et al., 
2004) 
Vaccinated Greece SG 0.885 0.985 
(Nielsen et al., 
2004) 
Experimentally 
infected 
Canada & 
Unknown 
S 
 
0.750 0.998 
(Minas et al., 
2005) 
Culture Greece S 0.964 0.994 
(Nielsen et al., 
2005) 
Culture Mexico & 
Canada 
G 0.936 0.994 
(Minas et al., 
2008) 
Culture Greece SG 0.779 0.972 
(García-
Bocanegra et 
al., 2014) 
Culture Spain S 1 1 
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Table 4.5: Prior distribution diagnostic test parameter estimates for 
sensitivity and specificity of the Rose Bengal plate test (RBT) and the 
competitive enzyme-linked immunosorbent assay (cELISA) used for cattle, 
sheep and goat models, Se is sensitivity and Sp is specificity 
Test parameters 
Beta distribution 
(R, S) 
Cattle  Small ruminants  
RBT Se (8, 1) (4, 1) 
Sp (7, 1) (2, 1) 
cELISA Se (102, 3) (7, 1) 
Sp (4, 1) (104, 1) 
 
 
Brucellosis prevalence priors for exclusive pastoralist and non-exclusive 
pastoralist subpopulations were informed by other published studies in Tanzania, 
that estimated brucellosis seroprevalence using RBT and or cELISA tests in 
similar livestock-keeping systems with a comparable study design (see Table 4.6 
for cattle and Table 4.7 for sheep and goats). A vague prevalence prior of 0 to 
0.49 was set for all livestock models, which encompassed the range of 
seroprevalence estimates in the literature and allowed exploration of the wider 
parameter space.  
  120 
Table 4.6: Brucellosis seroprevalence estimates for cattle in Tanzania 
generated using the Rose Bengal plate test (RBT) and/or the competitive 
enzyme-linked immunosorbent assay (cELISA) 
Prevalence 
(%) 
Study design Livestock- 
keeping 
system 
Tests Location Reference 
3.0 Matched case-
control 
Pastoral/ 
Agro-pastoral 
RBT & 
cELISA 
Arusha & 
Manyara 
(John et al., 
2010) 
4.1 Cross-sectional Smallholder RBT Tanga (Swai and 
Schoonman, 
2010) 
4.9 Cross-sectional Pastoral/ 
Agro-pastoral 
cELISA Arusha & 
Manyara 
(Shirima et 
al., 2010) 
5.6 Cross-sectional Agro-pastoral RBT & 
cELISA 
Kigoma (Chitupila et 
al., 2015) 
5.6 Cross-sectional Agro-pastoral RBT & 
cELISA 
Mara (Shirima and 
Kunda, 2016) 
6.8 Cross-sectional Agro-pastoral RBT & 
cELISA 
Katavi (Assenga et 
al., 2015) 
7.3 Cross-sectional Pastoral RBT Tanga (Swai and 
Schoonman, 
2010) 
9.3 Cross-sectional Agro-pastoral/ 
Commercial 
RBT & 
cELISA 
Mbeya (Sagamiko et 
al., 2018) 
10.0 Cross-sectional Pastoral RBT 
 
Arusha (Mellau et 
al., 2009) 
18.4 Cross-sectional Smallholder cELISA Morogoro (Lyimo, 
2013) 
21.5 Cross-sectional Commercial RBT Mbeya 
 
(Mathew et 
al., 2015) 
 
 
Table 4.7: Brucellosis seroprevalence estimates for sheep and goats in 
Tanzania using the Rose Bengal plate test (RBT) and/or the competitive 
enzyme-linked immunosorbent assay (cELISA), S is sheep, G is goats and SG is 
sheep and goats 
Prevalence 
(%) 
Species Study 
design 
Livestock-
keeping 
system 
Tests Location Reference 
0 
0 
S 
G 
Cross-
sectional 
Commercial RBT Mbeya 
 
(Mathew et 
al., 2015) 
0 SG Cross-
sectional 
Agro-pastoral RBT & 
cELISA 
Mara (Shirima 
and Kunda, 
2016) 
1.6 G Cross-
sectional 
Agro-pastoral RBT & 
cELISA 
Katavi (Assenga et 
al., 2015) 
3.4 
4.6 
S 
G 
Matched 
case-
control 
Pastoral/ 
Agro-pastoral 
RBT & 
cELISA 
Arusha & 
Manyara 
(John et 
al., 2010) 
6.5 SG Cross-
sectional 
Pastoral/ 
Agro-pastoral 
cELISA Arusha & 
Manyara 
(Shirima et 
al., 2010) 
7.7 
11.5 
S 
G 
Cross-
sectional 
Pastoral RBT 
 
Arusha (Mellau et 
al., 2009) 
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4.2.10 Statistical analyses: Model implementation 
Three species models including: a bovine model (using cattle data with cattle 
prior distributions); an ovine model (using sheep data with small ruminant prior 
distributions); and a caprine model (using goat data with small ruminant prior 
distributions) were implemented separately. All livestock models were 
implemented with JAGS (Plummer, 2003) in R software version 3.6.1 (R Core 
Team, 2019), using the rjags R package (Plummer et al., 2019b). Three Markov 
Chain Monte Carlo (MCMC) chains with different initial starting values were used. 
The first 50,000 iterations were considered burn-in and discarded. Another 
250,000 iterations were run per chain. Of these, every 100th iteration per chain, 
totalling 7,500 iterations, was used to inform the posterior distribution. Model 
posterior distributions included the mean estimate and associated 0.025 and 
0.975 Bayesian credibility intervals (BCI). 
 
4.2.11 Statistical analyses: Model sensitivity analyses 
Sensitivity analyses were performed to explore the effects of relaxing the 
literature-informed prior distributions on posterior inference. Each livestock 
species model was implemented with a series of three test parameter prior sets 
including: the ‘strict’ literature-informed priors described above; uniformly 
distributed priors; and a ‘relaxed’ prior set distribution between the strict and 
uniform priors. The beta distributions for each prior set in cattle, sheep and 
goat models are given in Table 4.8, 4.9 and 4.10. Frequency plots of prior and 
posterior distributions were visually inspected to select a prior set that looked to 
avoid inversion of the parameter space or overwhelming the data by driving the 
model posterior estimates. 
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Table 4.8: Beta distributions (dbeta) used to define priors for sensitivity (Se) 
and specificity (Sp) of Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) parameters for the bovine model, 
ranging from uniform prior distributions to literature-informed strict prior 
distributions 
Parameter 
dbeta(R,S) 
Uniform 
priors 
Relaxed 
priors 
Strict 
priors 
Se RBT 1,1 7,1 8,1 
Sp RBT 1,1 1,1 7,1 
Se cELISA 1,1 30,2 102,3 
Sp cELISA 1,1 1,1 4,1 
 
 
Table 4.9: Beta distributions (dbeta) used to define priors for sensitivity (Se) 
and specificity (Sp) of Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) parameters for the ovine model, 
ranging from uniform prior distributions to literature-informed strict prior 
distributions 
Parameter 
dbeta(R,S) 
Uniform 
priors 
Relaxed 
priors 
Strict 
priors 
Se RBT 1,1 4,1 4,1 
Sp RBT 1,1 1,1 2,1 
Se cELISA 1,1 7,1 7,1 
Sp cELISA 1,1 1,1 104,1 
 
 
Table 4.10: Beta distributions (dbeta) used to define priors for sensitivity 
(Se) and specificity (Sp) of Rose Bengal plate test (RBT) and competitive 
enzyme-linked immunosorbent assay (cELISA) parameters for the caprine 
model, ranging from uniform prior distributions to literature-informed strict 
prior distributions 
Parameter 
dbeta(R,S) 
Uniform 
priors 
Relaxed 
priors 
Strict 
priors 
Se RBT 1,1 4,1 4,1 
Sp RBT 1,1 1,1 2,1 
Se cELISA 1,1 7,1 7,1 
Sp cELISA 1,1 1,1 104,1 
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4.2.12 Statistical analyses: Model diagnostics 
All models were implemented with and without the covariance 
parameterisation, so that the effect of assuming conditional dependence (with 
covariance) between RBT and cELISA could be evaluated. Model selection was 
performed by comparing posterior estimates and deviance information criterion 
(DIC) scores, which is a Bayesian measure of model fit (Spiegelhalter et al., 
2002). 
 
MCMC chain convergence was assessed using the Gelman-Rubin potential scale 
reduction factor and by visual inspection of Gelman-Rubin, density and trace 
plots for each parameter of the model to confirm satisfactory convergence. 
Model diagnostics and visualisation were performed using the coda R package 
(Plummer et al., 2019a). 
 
4.2.13 Statistical analyses: Positive and negative 
predictive values  
The positive predictive value (PPV) and negative predictive value (NPV) were 
calculated for four diagnostic testing approaches in the pastoralist subpopulation 
for each final model. The diagnostic test approaches included: RBT; cELISA; in-
series; and in-parallel. PPV and NPV measure the probability that when a test is 
positive that the animal actually has the disease and that when a test is negative 
that the animal really does not have the disease, respectively (Dohoo et al., 
2003b). PPV and NPV are based on Bayes’ theorem (Price and Bayes, 1763), and 
are estimated using the posterior estimates for the true subpopulation 
prevalence (p), sensitivity (Se) and specificity (Sp) (Linn, 2004): 
 
PPV =  
Se * p(Se * p) + (1 - Sp) * (1 - p) 
 
NPV =  
Sp * (1 - p)ISp * (1 - p)M + (1 - Se) * p 
 
The final model RBT, cELISA, in-series and in-parallel sensitivity and specificity 
estimates and PPVs and NPVs were compared. The diagnostic testing approach 
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with a high combined sensitivity and specificity as well as high NPV was 
considered the most effective approach. 
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4.3 Results 
4.3.1 Livestock data 
Data available for the bovine model included 3479 cattle samples both RBT and 
cELISA tested, of which 2064 were from the exclusive pastoralist livestock-
keeping subpopulation and 1415 from the non-exclusive pastoralist livestock-
keeping subpopulation. Ovine data included a total of 2516 samples, 1739 from 
the exclusive pastoralist subpopulation and 777 from the non-exclusive 
pastoralist subpopulation. A total of 3193 samples were available for the caprine 
model, 1892 samples were from the exclusive pastoralist subpopulation and 1301 
from the non-exclusive pastoralist subpopulation. The total number of RBT and 
cELISA test positives for each livestock species in exclusive and non-exclusive 
pastoralist subpopulations are given in Table 4.11. 
 
Table 4.11: Rose Bengal plate test (RBT) and competitive enzyme-linked 
immunosorbent assay (cELISA) positive test results for cattle, sheep and goats 
in exclusive pastoralist and non-exclusive pastoralist subpopulations from 
two cross-sectional studies in northern Tanzania, N is total number of samples 
tested, n is total number of test positive samples 
Livestock 
species 
Exclusive pastoralist 
subpopulation 
Non-exclusive pastoralist 
subpopulation 
RBT 
n/N 
cELISA 
n/N 
RBT 
n/N 
cELISA 
n/N 
Cattle 89/2064 120/2064 12/1415 21/1415 
Sheep 36/1739 59/1739 15/777 5/777 
Goat 81/1892 96/1892 25/1301 19/1301 
 
 
4.3.2 Bovine final model: Specifications 
Sensitivity, specificity and prevalence estimates for each diagnostic test 
generated by running the bovine model with and without a covariance 
parameterisation and using three prior sets are compared in Figure 4.2. The 
posterior mean estimates and 95% BCI for in-series and in-parallel diagnostic 
testing approaches generated by running the bovine model with and without a 
covariance parameterisation and using three prior sets are given in Figure 4.3. 
Frequency plots were also visually inspected for the bovine model using the 
three prior sets (see Appendix 4 for frequency plots). All model runs showed 
satisfactory convergence (see Appendix 4 for diagnostic plots). Relaxed priors 
were selected for the final model. The DIC value for a model with and without 
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the covariance parameterisation did not indicate a major difference (≥2 points) 
between the two models, so the simpler model was selected (see Table 4.12). 
Therefore, the bovine model assuming conditional independence (without 
covariance) and the relaxed prior set was selected as the final model for the 
analysis of cattle data. 
 
 
 
Figure 4.2: Sensitivity, specificity and prevalence mean estimates and ranges 
for each combination of bovine model with uniform, relaxed and strict 
literature-informed prior sets, and conditional dependence (with covariance) 
or conditional independence (without covariance), w/o denotes without, Se is 
sensitivity, Sp is specificity, RBT is Rose Bengal plate test, cELISA is competitive 
enzyme-linked immunosorbent assay, P is prevalence, non-exclusive is the non-
exclusive pastoralist subpopulation and exclusive is the exclusive pastoralist 
subpopulation 
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Figure 4.3: In-series and in-parallel sensitivity and specificity mean posterior 
estimates and 95% Bayesian credibility intervals (BCI) for each combination of 
bovine model with uniform, relaxed and strict literature-informed prior sets, 
and conditional dependence (with covariance) or conditional independence 
(without covariance), w/o denotes without, Se_parallel is in-parallel 
sensitivity, Se_series is in-series sensitivity, Sp_parallel is in-parallel 
specificity, Sp_series is in-series specificity 
 
 
Table 4.12: Deviance information criterion (DIC) scores for each combination 
of bovine model with uniform, relaxed and strict literature-informed prior 
sets, and conditional dependence (with covariance) or conditional 
independence (without covariance) 
Model  
assumption 
DIC 
Uniform 
priors 
Relaxed 
priors 
Strict  
priors 
With covariance 39.37 46.62 52.44 
Without covariance 39.27 47.10 52.76 
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4.3.3 Bovine final model: Estimates and diagnostics 
The final bovine model mean posterior and 95% BCI estimates for sensitivity and 
specificity of the RBT, cELISA, in-series and in-parallel model parameters as well 
as prevalence in exclusive and non-exclusive pastoralist subpopulations are given 
in Table 4.13. The mean posterior sensitivity for the RBT and cELISA tests were 
estimated as 0.819 (95% BCI: 0.715-0.939) and 0.835 (95% BCI: 0.678-0.971), 
respectively. The mean posterior estimates for specificity of the RBT and cELISA 
were 0.986 (95% BCI: 0.979-0.994) and 0.998 (95% BCI: 0.993-1), respectively. 
The estimated prevalence of bovine brucellosis in the exclusive pastoralist 
subpopulation was 0.052 (95% BCI: 0.037-0.069) and in the non-exclusive 
pastoralist subpopulation was 0.009 (95% BCI: 0.004-0.016). The final bovine 
model had a Gelman-Rubin reduction factor of <1.1 and showed satisfactory 
convergence for all model parameters (see Figure 4.4, 4.5 and 4.6). The PPV and 
NPV exclusive pastoralist subpopulation estimates for the final bovine model are 
given in Table 4.14. The best diagnostic testing approach for the final bovine 
model was in-parallel. Sensitivity and specificity in-parallel were estimated at 
0.970 (95% BCI: 0.930-0.996) and 0.984 (95% BCI: 0.976-0.992), respectively (see 
Table 4.13). For the model code for the final bovine model see Appendix 5. 
 
Table 4.13: Mean posterior parameter estimates and 95% Bayesian Credibility 
Intervals (BCI) for the final bovine model using the relaxed prior set* and 
assuming conditional independence, Se is sensitivity, Sp is specificity, RBT is 
Rose Bengal plate test and cELISA is competitive enzyme-linked immunosorbent 
assay 
Parameter Mean 2.5% BCI 97.5% BCI  
Se: RBT 0.819 0.715 0.939 
Sp: RBT 0.986 0.979 0.994 
Se: cELISA 0.835 0.678 0.971 
Sp: cELISA 0.998 0.993 1 
Se: in-series 0.683 0.533 0.840 
Sp: in-series 1 1 1 
Se: in-parallel 0.970 0.930 0.996 
Sp: in-parallel 0.984 0.976 0.992 
Prevalence: exclusive 
pastoralist subpopulation 0.052 0.037 0.069 
Prevalence: non-exclusive 
pastoralist subpopulation 0.009 0.004 0.016 
*relaxed prior set: 
Se RBT ~ dbeta(7,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(30,2) 
Sp cELISA ~ dbeta(1,1)  
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Table 4.14: Positive and negative predictive values for RBT, cELISA, in-series 
and in-parallel diagnostic approaches in an exclusive pastoralist 
subpopulation for the final bovine model, RBT is Rose Bengal plate test and 
cELISA is competitive enzyme-linked immunosorbent assay, in-series is testing 
all RBT positive samples by cELISA, in-parallel is testing all samples by RBT and 
cELISA 
Diagnostic approach 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
RBT 0.762 0.990 
cELISA 0.958 0.991 
In-series 1 0.983 
In-parallel 0.769 0.998 
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Figure 4.4: Density plots for each parameter of the final bovine model, Se[1] 
is sensitivity of the Rose Bengal plate test (RBT), Se[2] is sensitivity of the 
competitive enzyme-linked immunosorbent assay (cELISA), Sp[1] is specificity of 
RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity of RBT and cELISA run 
in-series, Sp_series is specificity of RBT and cELISA run in-series, Se_parallel is 
sensitivity of RBT and cELISA run in-parallel, Sp_parallel is specificity of RBT 
and cELISA run in-parallel, p[1] is prevalence in a non-exclusive pastoralist 
subpopulation and p[2] is prevalence in an exclusive pastoralist subpopulation 
  
  131 
 
 
Figure 4.5: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the final bovine model, Se[1] is sensitivity of the Rose Bengal 
plate test (RBT), Se[2] is sensitivity of the competitive enzyme-linked 
immunosorbent assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of 
cELISA, Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is 
specificity of RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and 
cELISA run in-parallel, Sp_parallel is specificity of RBT and cELISA run in-
parallel, p[1] is prevalence in a non-exclusive pastoralist subpopulation and p[2] 
is prevalence in an exclusive pastoralist subpopulation 
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Figure 4.6: Trace plots showing MCMC chain convergence for each parameter 
of the final bovine model, Se[1] is sensitivity of the Rose Bengal plate test 
(RBT), Se[2] is sensitivity of the competitive enzyme-linked immunosorbent 
assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, 
Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is specificity of 
RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and cELISA run in-
parallel, Sp_parallel is specificity of RBT and cELISA run in-parallel, p[1] is 
prevalence in a non-exclusive pastoralist subpopulation and p[2] is prevalence in 
an exclusive pastoralist subpopulation  
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4.3.4 Ovine final model: Specifications 
Sensitivity, specificity and prevalence estimates for each diagnostic test 
generated by running the ovine model with and without a covariance 
parameterisation and using three prior sets are compared in Figure 4.7. The 
posterior mean estimates and 95% BCI for in-series and in-parallel diagnostic 
testing approaches generated by running the ovine model with and without a 
covariance parameterisation and using three prior sets are given in Figure 4.8.  
 
 
Figure 4.7: Sensitivity, specificity and prevalence mean estimates and ranges 
for each combination of ovine model with uniform, relaxed and strict 
literature-informed prior sets, and conditional dependence (with covariance) 
or conditional independence (without covariance), w/o denotes without, Se is 
sensitivity, Sp is specificity, RBT is Rose Bengal plate test, cELISA is competitive 
enzyme-linked immunosorbent assay, P is prevalence, non-exclusive is the non-
exclusive pastoralist subpopulation and exclusive is the exclusive pastoralist 
subpopulation 
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Figure 4.8: In-series and in-parallel sensitivity and specificity mean posterior 
estimates and 95% Bayesian credibility intervals (BCI) for each combination of 
ovine model with uniform, relaxed and strict literature-informed prior sets, 
and conditional dependence (with covariance) or conditional independence 
(without covariance), w/o denotes without, Se_parallel is in-parallel 
sensitivity, Se_series is in-series sensitivity, Sp_parallel is in-parallel 
specificity, Sp_series is in-series specificity 
 
Frequency plots were also visually inspected for the ovine model using the three 
prior sets (see Appendix 6 for frequency plots). All model runs showed 
satisfactory convergence (see Appendix 6 for diagnostic plots). Relaxed priors 
were selected for the final model. The ovine model with covariance gave a 
lower DIC value (<2 points) than the model without covariance, so the more 
complex model was selected (see Table 4.15). Therefore, the ovine model 
assuming conditional dependence (with covariance) and the relaxed prior set 
was selected as the final ovine model for the analysis of sheep data. 
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Table 4.15: Deviance information criterion (DIC) scores for each combination 
of ovine model with uniform, relaxed and strict literature-informed prior 
sets, and conditional dependence (with covariance) or conditional 
independence (without covariance) 
Model  
assumption 
DIC 
Uniform 
priors 
Relaxed 
priors 
Strict  
priors 
With covariance 38.31 40.63 40.76 
Without covariance 40.16 42.95 43.19 
 
 
4.3.5 Ovine final model: Estimates and diagnostics 
The ovine final model mean posterior and 95% BCI estimates for sensitivity and 
specificity of the RBT, cELISA, in-series and in-parallel model parameters as well 
as prevalence in exclusive and non-exclusive pastoralist subpopulations are 
shown in Table 4.16. The mean posterior sensitivity for the RBT and cELISA tests 
were estimated as 0.902 (95% BCI: 0.679-0.997) and 0.472 (95% BCI: 0.301-
0.821), respectively. The mean posterior estimates for specificity of the RBT and 
cELISA were 0.995 (95% BCI: 0.983-1) and 0.988 (95% BCI: 0.982-0.993), 
respectively. The estimated prevalence of ovine brucellosis in the exclusive 
pastoralist subpopulation was 0.032 (95% BCI: 0.014-0.046) and in the non-
exclusive pastoralist subpopulation was 0.006 (95% BCI: 0.000-0.015). The ovine 
final model had a Gelman-Rubin reduction factor of <1.1 and showed 
satisfactory convergence for all model parameters (see Appendix 7 for ovine 
final model diagnostic plots). The PPV and NPV exclusive pastoralist 
subpopulation estimates for the final ovine model are given in Table 4.17. The 
best diagnostic testing approach for the final ovine model was in-parallel. 
Sensitivity and specificity in-parallel were estimated at 0.949 (95% BCI: 0.823-
0.999) and 0.983 (95% BCI: 0.969-0.992), respectively (see Table 4.16). The 
model code for the final ovine model is available in Appendix 8. 
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Table 4.16: Mean posterior parameter estimates and 95% Bayesian Credibility 
Intervals (BCI) for the final ovine model using the relaxed prior set* and 
assuming conditional dependence, Se is sensitivity, Sp is specificity, RBT is 
Rose Bengal plate test and cELISA is competitive enzyme-linked immunosorbent 
assay, covDn is covariance when animal is disease negative, covDp is covariance 
when animal is disease positive 
*relaxed prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(1,1) 
 
 
Table 4.17: Positive and negative predictive values for RBT, cELISA, in-series 
and in-parallel diagnostic approaches in an exclusive pastoralist 
subpopulation for the final ovine model, RBT is Rose Bengal plate test and 
cELISA is competitive enzyme-linked immunosorbent assay, in-series is testing 
all RBT positive samples by cELISA, in-parallel is testing all samples by RBT and 
cELISA 
Diagnostic approach 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
RBT 0.856 0.997 
cELISA 0.565 0.983 
In-series 1 0.981 
In-parallel 0.649 0.998 
 
  
Parameter Mean 2.5% BCI 97.5% BCI  
Se: RBT 0.902 0.679 0.997 
Sp: RBT 0.995 0.983 1 
Se: cELISA 0.472 0.301 0.821 
Sp: cELISA 0.988 0.982 0.993 
Se: in-series 0.425 0.245 0.705 
Sp: in-series 1 1 1 
Se: in-parallel 0.949 0.823 0.999 
Sp: in-parallel 0.983 0.969 0.992 
Prevalence: exclusive 
pastoralist subpopulation 0.032 0.014 0.046 
Prevalence: non-exclusive 
pastoralist subpopulation 0.006 0.000 0.015 
covDn 0.002 0.000 0.006 
covDp -0.001 -0.065 0.066 
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4.3.6 Caprine final model: Specifications 
Sensitivity, specificity and prevalence estimates for each diagnostic test 
generated by running the caprine model with and without a covariance 
parameterisation and using three prior sets are compared in Figure 4.9.  
The posterior mean estimates and 95% BCI for in-series and in-parallel diagnostic 
testing approaches generated by running the caprine model with and without a 
covariance parameterisation and using three prior sets are given in Figure 4.10.  
 
 
Figure 4.9: Sensitivity, specificity and prevalence mean estimates and ranges 
for each combination of caprine model with uniform, relaxed and strict 
literature-informed prior sets, and conditional dependence (with covariance) 
or conditional independence (without covariance), w/o denotes without, Se is 
sensitivity, Sp is specificity, RBT is Rose Bengal plate test, cELISA is competitive 
enzyme-linked immunosorbent assay, P is prevalence, non-exclusive is the non-
exclusive pastoralist subpopulation and exclusive is the exclusive pastoralist 
subpopulation 
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Figure 4.10: In-series and in-parallel sensitivity and specificity mean 
posterior estimates and 95% Bayesian credibility intervals (BCI) for each 
combination of caprine model with uniform, relaxed and strict literature-
informed prior sets, and conditional dependence (with covariance) or 
conditional independence (without covariance), w/o denotes without, 
Se_parallel is in-parallel sensitivity, Se_series is in-series sensitivity, 
Sp_parallel is in-parallel specificity, Sp_series is in-series specificity 
 
 
Frequency plots were also visually inspected for the caprine model using the 
three prior sets (see Appendix 9 for frequency plots). All model runs showed 
satisfactory convergence (see Appendix 9 for diagnostic plots). Relaxed priors 
were selected for the final model. The caprine model with covariance gave a 
lower DIC value (<2 points) than the model not including the covariance 
parameterisation, so the more complex model was selected (see Table 4.18). 
Therefore, the caprine model assuming conditional dependence (with 
covariance) and the relaxed prior set was selected as the final caprine model for 
the analysis of goat data. 
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Table 4.18: Deviance information criterion (DIC) scores for each combination 
of caprine model with uniform, relaxed and strict literature-informed prior 
sets, and conditional dependence (with covariance) or conditional 
independence (without covariance) 
Model  
assumption 
DIC 
Uniform priors Relaxed priors Strict priors 
With covariance 40.93 41.70 42.29 
Without covariance 44.39 45.10 44.91 
 
 
4.3.7 Caprine final model: Estimates and diagnostics 
The caprine final model mean posterior and 95% BCI estimates for sensitivity and 
specificity of the RBT, cELISA, in-series and in-parallel model parameters as well 
as prevalence in exclusive and non-exclusive pastoralist subpopulations are 
shown in Table 4.19. The mean posterior sensitivity for the RBT and cELISA tests 
were estimated as 0.820 (95% BCI: 0.612-0.984) and 0.595 (95% BCI: 0.432-
0.736), respectively. The mean posterior estimates for specificity of the RBT and 
cELISA were 0.991 (95% BCI: 0.981-1) and 0.986 (95% BCI: 0.976-0.997), 
respectively. The estimated prevalence of caprine brucellosis in the exclusive 
pastoralist subpopulation was 0.053 (95% BCI: 0.035-0.075) and in the non-
exclusive pastoralist subpopulation was 0.009 (95% BCI: 0.000-0.023). The 
caprine final model had a Gelman-Rubin reduction factor of <1.1 and showed 
satisfactory convergence for all model parameters (see Appendix 10 for caprine 
final model diagnostic plots). The PPV and NPV exclusive pastoralist 
subpopulation estimates for the final caprine model are given in Table 4.20. The 
best diagnostic testing approach for the final caprine model was in-parallel. 
Sensitivity and specificity in-parallel were estimated at 0.926 (95% BCI: 0.807-
0.994) and 0.977 (95% BCI: 0.959-0.995), respectively (see Table 4.19). The 
model code for the final caprine model is available in Appendix 11. 
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Table 4.19: Mean posterior parameter estimates and 95% Bayesian Credibility 
Intervals (BCI) for the final caprine model using the relaxed prior set* and 
assuming conditional dependence, Se is sensitivity, Sp is specificity, RBT is 
Rose Bengal plate test and cELISA is competitive enzyme-linked immunosorbent 
assay, covDn is covariance when animal is disease negative, covDp is covariance 
when animal is disease positive 
Parameter Mean 2.5% BCI 97.5% BCI  
Se: RBT 0.820 0.612 0.984 
Sp: RBT 0.991 0.981 1 
Se: cELISA 0.595 0.432 0.736 
Sp: cELISA 0.986 0.976 0.997 
Se: series 0.489 0.294 0.648 
Sp: series 1 1 1 
Se: parallel 0.926 0.807 0.994 
Sp: parallel 0.977 0.959 0.995 
Prevalence: exclusive 
pastoralist subpopulation 0.053 0.035 0.075 
Prevalence: non-exclusive 
pastoralist subpopulation 0.009 0.000 0.023 
covDn 0.007 0.000 0.015 
covDp -0.009 -0.075 0.077 
*relaxed prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(1,1) 
 
 
Table 4.20: Positive and negative predictive values for RBT, cELISA, in-series 
and in-parallel diagnostic approaches in an exclusive pastoralist 
subpopulation for the final ovine model, RBT is Rose Bengal plate test and 
cELISA is competitive enzyme-linked immunosorbent assay, in-series is testing 
all RBT positive samples by cELISA, in-parallel is testing all samples by RBT and 
cELISA 
Diagnostic approach 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
RBT 0.836 0.990 
cELISA 0.704 0.978 
In-series 1 0.972 
In-parallel 0.693 0.996 
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4.3.8 Final model estimates for all livestock models 
Sensitivity, specificity and prevalence estimates for each diagnostic test for the 
final bovine model with conditional independence and relaxed prior set and 
ovine and caprine models with conditional dependence and relaxed prior sets 
are shown in Figure 4.11. The posterior mean estimates and 95% BCI for in-series 
and in-parallel diagnostic testing approaches for the final bovine, ovine and 
caprine models are shown in Figure 4.12. 
 
 
Figure 4.11: Sensitivity, specificity and prevalence posterior mean estimates 
and ranges for the final bovine model with relaxed priors and conditional 
independence (without covariance) and the final ovine and final caprine 
models with relaxed prior sets and conditional dependence (with 
covariance), Se is sensitivity, Sp is specificity, RBT is Rose Bengal plate test, 
cELISA is competitive enzyme-linked immunosorbent assay, P is prevalence, non-
exclusive is the non-exclusive pastoralist subpopulation and exclusive is the 
exclusive pastoralist subpopulation 
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Figure 4.12: In-series and in-parallel sensitivity and specificity posterior 
mean estimates and 95% Bayesian credibility intervals (BCI) for the final 
bovine model with relaxed priors and conditional independence (without 
covariance) and the final ovine and final caprine models with relaxed prior 
sets and conditional dependence (with covariance), Se_parallel is in-parallel 
sensitivity, Se_series is in-series sensitivity, Sp_parallel is in-parallel 
specificity, Sp_series is in-series specificity 
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4.4 Discussion 
There is no standardised diagnostic testing approach for animal brucellosis in 
Tanzania (Government of Tanzania, 2018a). Evaluations of the performance of 
diagnostic tests are crucial in gaining a true understanding of the epidemiology 
of brucellosis and to inform effective disease surveillance and control strategies. 
Here, the performance of two serological tests for brucellosis: RBT and cELISA, 
were evaluated for naturally exposed cattle, sheep and goats in northern 
Tanzania using Bayesian latent class analyses. Sensitivity was variable across 
livestock models; RBT sensitivity was comparable to cELISA in the bovine model 
and greater than cELISA in ovine and caprine models. RBT and cELISA specificity 
was comparable across livestock models. Conducting RBT and cELISA testing in 
parallel optimised diagnostic test performance in all livestock models. 
 
The final bovine model included relaxed priors guided by the available literature 
on RBT and cELISA test performances for cattle in Africa. The same was true for 
ovine and caprine models, except priors were guided by literature from studies 
outside Africa. The RBT and cELISA sensitivity priors were informative for all 
livestock species final models, as posterior estimates had wide credibility 
intervals without informative priors. This was likely because of the low number 
of sample positives for each livestock species. RBT and cELISA specificity had 
uniformly distributed priors specified in all livestock species final models, as the 
posterior estimates remained consistently high without informative priors. This 
was expected to be in part due to the large sample size available for each 
species. 
 
For the bovine model, the inclusion of covariance resulted in a marginally 
different DIC to the model without covariance. This indicated a minimal 
correlation between RBT and cELISA tests for cattle, so the simpler conditional 
independence model was preferred. For both the ovine and caprine models, DIC 
values indicated correlation between RBT and cELISA. Therefore, the ovine and 
caprine models assuming conditional dependence were preferred over the 
simpler models. The issue of assuming conditional independence or dependence 
is not straightforward, as diagnostic tests that identify similar responses to 
disease are likely all dependent to some extent (Branscum et al., 2005). In the 
case of RBT and cELISA it seems likely that there is dependence as both are 
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serological tests detecting antibodies to Brucella smooth lipopolysaccharides. 
However, serological tests such as these differ in the isotypes detected and 
isotype-specific properties also differ during the course of infection, altering 
detectability (Ducrotoy et al., 2018). Therefore, due to varying isotype ratios 
and properties, dependence between these tests may not be constant 
throughout Brucella spp. infection (Ducrotoy et al., 2018). 
 
For the final bovine model, the mean posterior RBT sensitivity estimate was in 
accordance with other studies in Africa (Chisi et al., 2017; Etman et al., 2014; 
Getachew et al., 2016; Hosein et al., 2017; Matope et al., 2011; Muma et al., 
2007; Sanogo et al., 2013). However, the cELISA estimate for this study was 
lower than estimates reported for previous studies (Bronsvoort et al., 2009; Chisi 
et al., 2017; Etman et al., 2014; Matope et al., 2011; Muma et al., 2007). As 
mentioned earlier, posterior estimates for sensitivity may have been low due to 
a small number of positive animals in the dataset, which is a consequence of the 
generally low-level prevalence nature of Brucella spp. in naturally infected 
livestock. The final bovine model mean posterior estimates for RBT and cELISA 
specificity place this study towards the high end of the reported specificity 
range for cattle in Africa (Bronsvoort et al., 2009; Chisi et al., 2017; Etman et 
al., 2014; Getachew et al., 2016; Hosein et al., 2017; Matope et al., 2011; Muma 
et al., 2007; Sanogo et al., 2013). 
 
For the final ovine and caprine models the RBT sensitivity mean posterior 
estimates were positioned towards the top of the estimate range identified for 
other small ruminant test performance studies outside of Africa (García-
Bocanegra et al., 2014; Gupta et al., 2014; Marín et al., 1999; Minas et al., 
2008, 2005; Nielsen et al., 2004; Patel et al., 2017; Rahman et al., 2013; 
Ramírez-Pfeiffer et al., 2008).The cELISA sensitivity posterior estimates for the 
ovine and caprine models in this study were lower than the identified literature 
estimate range (Burriel et al., 2004; García-Bocanegra et al., 2014; Marín et al., 
1999; Minas et al., 2008, 2005; Nielsen et al., 2005, 2004), as was found for 
cattle also. For the ovine and caprine models in this study, both RBT and cELISA 
specificity mean posterior estimates are positioned towards the top of the 
identified estimate range from previous studies (Burriel et al., 2004; García-
Bocanegra et al., 2014; Gupta et al., 2014; Marín et al., 1999; Minas et al., 
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2008, 2005; Nielsen et al., 2005, 2004; Patel et al., 2017; Rahman et al., 2013; 
Ramírez-Pfeiffer et al., 2008). Interestingly, it is generally considered that the 
cELISA is a more specific test than the RBT (Makita et al., 2011a; OIE, 2018). 
However, in this study RBT outperformed the cELISA in both the ovine and 
caprine models. 
 
Across the livestock models in this study, sensitivity was the most variable test 
performance measure, particularly for cELISA (0.472 – 0.835). These results 
suggest that running the cELISA test alone would create a high proportion of 
false negatives, especially in sheep samples. RBT sensitivity was less variable 
and greater across livestock models (0.819 – 0.902) as compared to cELISA. In 
contrast to cELISA, RBT sensitivity was marginally higher in sheep samples than 
cattle and goats. Specificity for both RBT and cELISA was consistently high across 
livestock models. These results are important in informing an evidence-based 
diagnostic testing approach for livestock brucellosis in Tanzania. As an initial 
screening or single test in routine surveillance, cELISA is not recommended in 
this setting. The results of this study indicate that RBT performs more 
consistently and with higher sensitivity as a single testing approach across 
cattle, sheep and goat samples as compared to cELISA. 
 
In this study, the bovine model estimated brucellosis seroprevalence at 5.2% 
(95% BCI: 3.7% - 6.9%) and 1.0% (95% BCI: 0.4% - 1.6%) for the exclusive 
pastoralist and non-exclusive pastoralist subpopulations, respectively. Ovine 
model seroprevalence posterior estimates were 3.2% (95% BCI: 1.4% - 4.6%) and 
1.0% (0.0% - 1.5%) for exclusive and non-exclusive pastoralist subpopulations, 
respectively. Caprine model seroprevalence posterior estimates were 5.3% (95% 
BCI: 3.5% - 7.5%) and 1.0% (95% BCI: 0.0% - 2.3%) for exclusive and non-exclusive 
pastoralist subpopulations. These prevalence estimates are within the reported 
estimate species ranges for other studies in Tanzania (Assenga et al., 2015; 
Chitupila et al., 2015; John et al., 2010; Lyimo, 2013; Mathew et al., 2015; 
Mellau et al., 2009; Sagamiko et al., 2018; Shirima et al., 2010; Swai and 
Schoonman, 2010). The ovine model had the lowest prevalence estimates of 
three livestock species. Caprine and bovine models had similar prevalence 
estimates. It has been reported in SSA that the prevalence of ovine or caprine 
brucellosis is generally lower than bovine brucellosis (Mcdermott and Arimi, 
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2002). Posterior prevalence estimates in this study do not indicate a substantial 
difference between these livestock species. Across all livestock species models, 
brucellosis prevalence was estimated to be highest in the exclusive pastoralist 
subpopulation. This is in agreement with previous studies where prevalence has 
been estimated to be higher in exclusive pastoral areas as compared to non-
exclusive pastoral areas, such as agro-pastoralist or smallholder populations 
(Mcdermott and Arimi, 2002; Shirima et al., 2010; Swai and Schoonman, 2010). A 
higher prevalence in exclusive pastoral settings, as compared to other settings, 
is reported to be attributable to larger herds or flocks, mixing of livestock 
species and higher contact rates between animals (Mcdermott and Arimi, 2002; 
Racloz et al., 2013). Additionally, exclusive pastoralist communities are more 
likely to be involved in transhumance. These national and cross-border livestock 
movements, as well as trade, are important factors facilitating livestock disease 
transmission, including brucellosis (Dean et al., 2013b, 2013a).Therefore, 
prioritising brucellosis prevention and control activities in exclusive pastoralist 
communities in Tanzania may achieve the most effective reduction in brucellosis 
prevalence. 
 
There is no single recommended serological test for the diagnosis of brucellosis 
and therefore the use of a screening test in combination with a confirmatory or 
complementary test is advisable (OIE, 2018). In this study, in-series and in-
parallel, as well as single diagnostic testing approaches for RBT and cELISA were 
assessed. Sensitivity and specificity estimates and PPVs and NPVs under each of 
the diagnostic approaches were compared. An increased probability of an animal 
that is truly brucellosis negative testing negative (high NPV) is important in 
classifying that an individual or herd/flock is truly disease-free. During routine 
national surveillance that would be used to guide prioritisation of national 
brucellosis prevention and control interventions in high-risk areas, a high NPV at 
the individual or herd/flock level is arguably more important than an improved 
probability of truly disease positive animals testing positive. This is because the 
ability to classify disease-free status would allow more precise prioritisation of 
areas that require immediate brucellosis prevention and control intervention 
resources. In contrast, a high PPV may be most important when surveillance is 
conducted for the purpose of providing information on individual animal disease 
status, for example in giving feedback to livestock-keepers. A high PPV may be 
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more important in moving towards brucellosis eradication and the ability to 
successfully classify individual animals as truly disease positive. Eradication 
cannot be considered until progress has first been made in the prevention and 
control of brucellosis. Here, the diagnostic testing approach with a high 
combined sensitivity and specificity, as well as high NPV was selected as the 
most effective diagnostic approach for use in routine brucellosis surveillance and 
informing national prevention and control interventions. In-series specificity 
posterior mean estimates were high for all livestock species models. However, as 
expected with this diagnostic approach sensitivity was reduced, and 
substantially so, as compared to the in-parallel approach. Running the two tests 
in-parallel gave an improved mean posterior estimate for sensitivity and the in-
parallel specificity was only marginally reduced for each livestock species model 
as compared to in-series testing. In-parallel diagnostic test performance was 
comparable across all livestock species, with the highest sensitivity in the bovine 
model 0.970 (95% BCI: 0.930 – 0.996) and the lowest in the caprine model 0.926 
(95% BCI: 0.807 – 0.994). In-parallel specificity was consistently high with all 
livestock models indicating 0.977 (95% BCI: 0.959 – 0.995) or greater. Although 
the PPV was lowest for an in-parallel testing approach, NPV was higher for in-
parallel as compared to in-series testing for all livestock models. A testing 
protocol applying RBT and cELISA in-parallel for bovine, ovine and caprine 
brucellosis in Tanzania would be an ideal approach for use in routine national 
surveillance in order to classify individual animals or herds/flocks as truly 
disease-free, and guide prioritisation of prevention and control interventions. 
 
There is no nationally adopted diagnostic testing strategy for brucellosis in 
Tanzania (Government of Tanzania, 2018a), suggested diagnostic tests include 
initial screening by RBT and confirmation by ELISA, or PCR or culture 
(Government of Tanzania, 2018b). The RBT is a recognised screening test for 
livestock brucellosis, and the iELISA is the OIE recommended ELISA for 
confirmatory testing (OIE, 2018). Here, the cELISA was investigated as a 
confirmatory test, as it was considered a more practical test to implement in 
Tanzania. The cELISA can be used for multiple host species, whereas variants of 
the iELISA are host species-specific, as well as immunoglobulin-specific. The 
iELISA is also a more expensive test per sample (APHA, 2020). However, it has 
been recognised that the application of cELISA testing in LMICs may also be 
  148 
challenging, as it requires equipment that may not be routinely accessible 
(Matope et al., 2011). The cELISA is available in a limited number of laboratories 
in Tanzania but is not routinely used. Currently, animal samples would need to 
be received by centralised laboratories for testing, which would delay test 
turnaround times. Nevertheless, this study indicates that the cELISA can be an 
invaluable confirmatory test to the RBT. 
 
In Tanzania, the national guidelines for surveillance of the prioritised zoonotic 
diseases indicates the need for animal brucellosis active surveillance in the form 
of mass screening (Government of Tanzania, 2018b). If mass animal brucellosis 
screening in Tanzania were to be conducted, applying the results of this study 
would be problematic as parallel testing every individual animal by both 
diagnostic tests would require significant resources, including increasing 
regional-level laboratory capacity for cELISA diagnostics. The diagnosis of 
brucellosis at the herd- or flock-level is expected to be more useful in terms of 
surveillance for disease prevention and control, as opposed to diagnosis at the 
individual animal level (Corbel, 2006; OIE, 2018). Herd/flock testing would 
involve testing a proportion of animals in every herd/flock; this would reduce 
resource requirements yet still enable national-scale data collection. In order to 
reduce resource requirements further, a pragmatic approach could be to run 
RBT and cELISA in-parallel on a single pooled sample from a herd/flock. This 
pooled sample would be taken from a proportion of individuals and would 
require a single RBT and cELISA test per herd/flock. Pooled sample testing to 
determine the herd/flock disease status can be more cost-effective than 
individual animal testing when disease prevalence is expected to be less than 
10% (Cowling et al., 1999). Additionally, focusing resources and prioritising 
surveillance in exclusive pastoralist populations, where seroprevalence has been 
shown to be higher than other livestock-keeping populations, may help to 
understand the true burden of brucellosis and the effects of prevention and 
control activities. RBT testing could be conducted by trained local government 
veterinary representatives in the field with standardised reagents. Diagnostic 
testing capacity could be strengthened to provide trained personnel and 
standardised cELISA equipment at the regional government veterinary 
laboratories. This approach would allow for animal brucellosis screening by RBT 
in the field and complementary in-parallel testing by cELISA in selected 
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laboratories. Which has been indicated in this study as the diagnostic testing 
approach with the greatest test performance as compared to using either test 
alone, or in-series diagnostic test approaches. 
 
A limitation of the model implemented here was that it included two serological 
tests in two subpopulations, which was not ideal for the inclusion of a 
conditional dependence parameterisation (Toft et al., 2005). Further study may 
benefit from collecting different samples from the same animal such as sera and 
milk and to test these by both serological and molecular approaches, such as 
PCR. It may be possible to then implement a latent class model with RBT and 
PCR or cELISA and PCR, where the assumption of conditional independence may 
be better satisfied. Additionally, model assumption (b) that diagnostic test 
performance is the same across subpopulations could be investigated further. It 
is possible that as brucellosis prevalence is variable in different subpopulations, 
that pathogens causing serological cross-reactions may also be variable. This 
could therefore affect test performance in the different livestock subpopulations 
sampled. 
 
4.5 Conclusion 
This is the first study to evaluate the test performance of RBT and cELISA for 
detecting bovine brucellosis in Tanzania and is likely the first for ovine and 
caprine brucellosis in Africa by Bayesian latent class analysis. Sensitivity of test 
performance varied for RBT (0.819 – 0.902), and even more so for the cELISA 
(0.472 - 0.835), in all livestock models. RBT sensitivity was comparable to cELISA 
in the bovine model and greater than cELISA sensitivity in the ovine and caprine 
models. RBT and cELISA specificity was consistently high for all livestock models 
(0.986 - 0.995) (0.986 - 0.998), respectively. The prevalence of brucellosis was 
higher for the exclusive pastoralist subpopulation than the non-exclusive 
pastoralist subpopulation for bovine, ovine and caprine models, reinforcing that 
the burden of brucellosis is greater in exclusive pastoralist communities. In the 
detection of bovine, ovine and caprine brucellosis, conducting RBT and cELISA 
parallel testing optimised diagnostic test performance, as compared to using 
either test alone or a series approach. These test performance and prevalence 
findings can assist in the development of a national disease surveillance strategy 
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that can generate robust true burden estimates for brucellosis in Tanzania and 
wider SSA. The implementation of an effective and standardised approach to the 
detection of animal brucellosis is a crucial step towards the control and 
prevention of brucellosis in both animals and humans. 
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Chapter 5 Discussion 
Brucellosis is a “difficult disease” for many reasons, including the non-
distinguishing and inconsistent clinical symptoms in both humans and animals, 
the variable performance of brucellosis diagnostic tools, and the presence of 
multiple pathogen species infecting multiple animal host species (Ducrotoy et 
al., 2017). More robust epidemiological data are required in order to better 
understand the true burden of brucellosis and to inform the development of 
effective disease prevention and control interventions (Dean et al., 2012b). This 
is especially true for sub-Saharan Africa (SSA), where the global burden of 
brucellosis is estimated to be greatest (Racloz et al., 2013). Pastoralist 
communities in particular are suspected to carry a high brucellosis burden, with 
people suffering from regular Brucella spp. exposures (Mcdermott and Arimi, 
2002). The overarching aim of this thesis was to improve our understanding of 
the epidemiology of brucellosis in Tanzania, with a focus on human brucellosis in 
pastoralist populations and diagnostic test performance in animal hosts. 
 
5.1 The current brucellosis prevention and control strategy 
in Tanzania 
In Tanzania, brucellosis has been recently identified by multisectoral 
collaboration as one of six national priority zoonotic diseases (Government of 
Tanzania, 2018b). In 2018, a five-year national strategy for brucellosis 
prevention and control in humans and animals was also released, which 
highlights the strengths and weakness of the situation in Tanzania with regards 
to brucellosis prevention and control (Government of Tanzania, 2018a). The 
challenges to brucellosis prevention and control in Tanzania are multifaceted, 
involving public health and animal health, as well as sociological and even 
environmental considerations. In the national strategy for brucellosis areas for 
improvement have been identified, such as the need for: detailed 
epidemiological data and a national research agenda; development of effective 
surveillance and diagnostics; consideration of community socio-cultural values; 
development of policy guidelines for control; and multi-sectoral communication 
and collaboration (Government of Tanzania, 2018a). The formulation of this 
national strategy is a fundamental step towards implementing a standardised 
and effective brucellosis prevention and control approach in Tanzania. 
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5.2 The importance and application of identified risk factors 
for human brucellosis 
Understanding the risk factors for acute human infection in pastoralist 
communities would assist in addressing the knowledge gap regarding the need 
for robust data on the transmission of brucellosis, particularly in areas suspected 
of high disease burden. These data can be used in the prioritisation of a human 
risk demographic for the implementation of a brucellosis prevention and control 
intervention. Prevention and control interventions that focus on setting-specific 
human risk activities can rapidly reduce the incidence of human brucellosis. An 
example of this is the reduction in incidence of human brucellosis in Greece, 
following milk pasteurisation and increased hygiene practices in the production 
of feta cheese (Minas et al., 2004). In Chapter 2, two risk factors were identified 
for acute brucellosis in febrile patients attending a rural hospital in Tanzania. 
This is the first study to identify risk factors for acute brucellosis in a pastoralist 
community of Tanzania, and one of few in East Africa. Being a young member of 
the community and involved in herding cattle, sheep or goats was associated 
with an increased risk of acute brucellosis. These findings provide vital 
information on who in the human population of the Ngorongoro Conservation 
Area (NCA) is at a high-risk of acute infection. If incorporated into a disease 
prevention and control strategy, these findings have the potential to 
substantially reduce the burden of acute brucellosis in the NCA. Specifically, by 
identifying and targeting young herders for communication about brucellosis 
transmission, this can address the need for better awareness of brucellosis risk 
in livestock keepers, as identified by the national brucellosis strategy 
(Government of Tanzania, 2018a). Rather than continuing with risk factor 
analyses of various strata in this community, the next step to further these 
findings would be to identify the risk behaviours being conducted by young 
members whilst herding. Following this, sensitisation of this demographic to the 
identified transmission risks for brucellosis would allow people to make informed 
decisions about brucellosis risk behaviour and could result in a substantial 
reduction in the burden of brucellosis. However, it must be recognised that an 
approach such as this to disease prevention must consider community-specific 
cultural traditions and perceptions (Marcotty et al., 2009). A successful strategy 
in these settings, particularly one based on behavioural changes, must be co-
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developed in collaboration with the community at risk including key influential 
community representatives. 
 
5.3 The importance and feasibility of active surveillance 
techniques 
In resource-limited settings, brucellosis prevention and control interventions 
have to be targeted in their approach and must identify priority areas for 
intervention. This prioritisation cannot be informed by passive surveillance data 
using healthcare facility records only. This is due to a number of reasons, 
including the lack of a standardised, consistent brucellosis reporting system for 
healthcare facilities in Tanzania (Government of Tanzania, 2018a). Additionally, 
in SSA only a proportion of the population in ill-health ever reach a healthcare 
facility (Panzner et al., 2016), meaning hospital records are not representative 
of the true brucellosis burden. There are various barriers to accessing 
healthcare. For example, approximately 25% of the total population live more 
than 2 hours travel from the nearest hospital providing emergency care in 
Tanzania (Ouma et al., 2018). Although emergency care is not directly 
comparable to healthcare facility requirements for brucellosis treatment, the 
study gives an approximation of a barrier to care faced across Tanzania. This 
barrier is likely only enhanced in geographically remote pastoralist communities. 
The use of cross-sectional community-based active surveillance also has 
disadvantages, including the high cost of collecting limited information on 
brucellosis burden due to the suspected non-uniform distribution and grouped 
nature of acute brucellosis infections. The national strategy for Tanzania 
identifies a lack of representative surveillance data that can be used to inform 
prevention and control of brucellosis (Government of Tanzania, 2018a). Chapter 
3 attempted to address the surveillance knowledge gap in order to assist in 
understanding the true burden of brucellosis in Tanzania. An adapted active 
surveillance technique was investigated to assess its ability to detect additional 
acute brucellosis cases in household members of febrile individuals reaching 
hospital. In the households of febrile patients with acute brucellosis, additional 
acute brucellosis cases were detected in household members. Yet, the study did 
not show evidence of significant grouping between febrile patients with acute 
brucellosis and household members exposed to Brucella spp. With a larger 
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sample size and longer timeframe, this study may have been sufficiently 
powered to show a significant association between febrile hospital patients with 
acute brucellosis and their household members. However, given the challenges 
of gathering these data through a well-resourced research study, this form of 
active surveillance does not appear to be a feasible, nor sustainable approach to 
additional case finding in the community and estimation of the true burden of 
brucellosis. Not only did this active case finding approach require a diverse team 
of specialists to implement, but sample size was severely limited by the high 
rate of study participation decline by the febrile patient population. 
 
There are alternative community-based approaches that may be more effective 
in obtaining accurate data on the burden of brucellosis in pastoralist 
communities and could optimise resource use and study participation rates. A 
linked hospital-based surveillance study collected data on the prevalence of 
acute brucellosis in febrile hospital patients (Bodenham et al., 2020). An 
alternative approach is to combine these prevalence data with a healthcare 
utilisation survey. A healthcare utilisation survey takes a stratified sample of 
households in the catchment area of a healthcare facility and administers a 
questionnaire at each household about household member healthcare seeking 
behaviour. Using the hospital and community-acquired data, multipliers can then 
be used to estimate the incidence of brucellosis. A community-based active 
surveillance approach such as this requires a less specialised field team. Study 
participation is also likely to be higher as only one member of the household 
need participate and no physically invasive sampling is required. This approach 
to understanding the true burden of brucellosis has already been successfully 
implemented in Moshi, Tanzania (Carugati et al., 2018) and is underway in the 
NCA. However, robust data on the prevalence of acute brucellosis in a febrile 
population attending a healthcare facility is a necessary prerequisite for this 
approach and is clearly not readily available. Another possible active 
surveillance approach for human brucellosis could be to adapt a community-
based system that is already in place. A study using a participatory approach in 
rural Nepal trained pre-existing community health workers to collect syndromic 
data using a smart phone application during their routine community visits 
(Meyers et al., 2016). In Tanzania, community health workers and also 
community outreach clinics are part of the broader healthcare system. There 
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are also at least two examples of beta smart phone applications that have been 
developed for the collection of public and animal health data, and have been 
implemented in Tanzania: AfyaData, an open source tool developed by the 
Southern African Centre for Infectious Disease Surveillance (SACIDS); and the 
Events Mobile Application (EMA-i), an animal health reporting tool developed by 
the FAO. In Tanzania, local community health workers as well as other 
healthcare facility community outreach teams could be trained to collect data in 
the community on febrile illness and healthcare seeking behaviour using an 
adaptation of an existing mobile data collection platform. This could prove to be 
a cost- and time-effective approach to active surveillance for brucellosis, when 
used alongside hospital-based passive surveillance in Tanzania. A combined 
hospital and community-based approach such as this could help address the need 
for representative brucellosis surveillance data in Tanzania (Government of 
Tanzania, 2018a). However, in order to implement such a surveillance approach, 
it is first necessary to develop a standardised brucellosis case definition and 
diagnostic testing procedure, so that brucellosis can be correctly diagnosed. An 
evaluation of the human brucellosis diagnostics available in healthcare facilities 
in Tanzania is currently underway. 
 
5.4 The importance of evaluating diagnostic test 
performance and next steps 
Evaluation of the performance of available diagnostic tools for brucellosis is 
crucial in understanding the true burden of disease in humans and animals, and 
also reliably monitoring changes in disease burden following implementation of 
prevention and control interventions. The Tanzanian national strategy for 
brucellosis prevention and control identifies a need for standardised and 
validated tests for the diagnosis of brucellosis (Government of Tanzania, 2018a). 
A linked study to the research presented in this thesis has isolated and 
characterised both B. melitensis and B. abortus in the febrile hospital 
population of the NCA (Bodenham et al., 2020). It is therefore particularly 
important to evaluate the performance of diagnostic testing protocols for cattle, 
sheep and goats in Tanzania, as each species likely has a role as a maintenance 
host for brucellosis. Chapter 4 attempted to address the knowledge gap 
regarding the need for a standardised and validated testing procedure for the 
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diagnosis of animal brucellosis in Tanzania, by evaluating the performance of the 
RBT and the cELISA as: individual tests; run in series; or run in parallel of one 
another. Diagnostic test evaluation was performed for each livestock species 
individually. This study was the first RBT and cELISA test performance evaluation 
for livestock brucellosis in Tanzania and is believed to be the first for small 
ruminants in SSA. Aside from generating sensitivity and specificity estimates for 
the RBT and cELISA individually, test performances were estimated to be 
optimal when run in-parallel for each livestock species. Applying the results of 
this study to mass animal surveillance in Tanzania is challenging as testing every 
individual animal by both diagnostic tests would require significantly more 
resources. A more practical and cost-effective approach may be to implement 
herd- or flock-level testing using a single pooled sample from each herd/flock. 
Examples of pooled testing of animal samples are infrequent (Cowling et al., 
1999), some examples include faecal samples in detection of Mycobacterium 
paratuberculosis and Salmonella spp. (Jordan, 2005; Wells et al., 2003). In order 
to consider the application of a pooled sample approach for livestock 
brucellosis, it would be necessary to conduct a sensitivity analysis in order to 
estimate the optimal pool size for detection of Brucella spp. antibodies, such as 
that conducted for pooled sera in the detection of Schistosoma japonicum (Jia 
et al., 2009). It would be equally important to generate cost estimates for a 
pooled approach under varying brucellosis prevalence estimates, such as that 
performed for pooled blood in detecting bovine viral diarrhoea virus (Muñoz-
Zanzi et al., 2000). Additionally, exploring the performance of varying 
combinations of in series and in parallel diagnostic testing during surveillance 
may be valuable in reducing resource requirements. Analyses could be 
performed in order to understand test performance using primarily series testing 
with a set proportion of parallel testing sites. 
 
5.5 Brucellosis knowledge gaps 
Overall, the three core thesis chapters have attempted to address the following 
brucellosis knowledge gaps in Tanzania: 1 – the need for more detailed 
epidemiological data, particularly in areas suspected to be at high risk of 
brucellosis; 2 – the need for surveillance approaches that can assist in providing 
a true representation of brucellosis burden; and 3- the need for a validated and 
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standardised brucellosis diagnostic test approach. With regards to these 
knowledge gaps, findings have been presented on: 1- risk factors for acute 
human infection in a high-risk community; 2 - an adapted active surveillance 
technique for the detection of acute human infections and exposure to Brucella 
spp.; and 3 - diagnostic test performance and estimation of the prevalence of 
brucellosis in different livestock species. These findings together contribute 
towards the need for robust epidemiological data in order to improve our 
understanding of the true burden of brucellosis in Tanzania and wider SSA. 
 
Following the collection of data for Chapter 2 and 3, there are features of study 
design and implementation that should be considered in future research. Risk 
factor data collection was a paper-format questionnaire and lasted 
approximately 40 minutes per participant. Forty minutes was too long, with 
some participants failing to complete all sections. Streamlining the number of 
questions would be an advantage. Also, switching to a digital format might 
increase the speed of data collection and would reduce administrator errors, 
such as skipping questions. An overlooked limitation of household member 
sampling was that more than half of households would decline participation in 
the study. This was ultimately a limiting factor to the power of the study. 
Febrile patients were informed at hospital enrolment that they may be 
contacted for a household visit. Possibly, the provision of an information leaflet 
to take away and show to other family members may have increased household 
participation. A proportion of household participation declines were due to 
absence of the head of household. The household sampling period was largely 
during the dry season. In this community, male household members (including 
the head of household) may travel for improved livestock grazing or work 
purposes during this season. Therefore, socio-cultural aspects of this community 
had a large impact on study implementation. 
 
5.6 Future research 
Some further knowledge gaps that need to be addressed in future research in 
order to implement an effective brucellosis prevention and control strategy in 
Tanzania include: identification of a rapid, standardised and validated diagnostic 
testing approach for human and animal brucellosis, and subsequently 
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identification of a national human and animal case definition; investigation into 
strengthening passive surveillance reporting channels so that more 
representative data are available; further research into appropriate community-
based active surveillance approaches; and identification of a cost-effective, 
sustainable approach to vaccination of cattle, sheep and goats. A prevention and 
control measure that can be considered for rapid implementation is 
communication about brucellosis transmission directed at high-risk individuals in 
livestock-keeping communities. As well as, the collaborative development and 
implementation of setting-specific brucellosis hygiene measures in these 
communities. 
 
5.7 Suggestions for the implementation of brucellosis 
prevention and control in Tanzania and SSA 
 
5.7.1 An ideal brucellosis prevention and control 
strategy 
There are a range of different activities that have been implemented in various 
countries around the world in order to prevent and control brucellosis. In 
Tanzania and wider SSA, it essential that the strategy implemented is 
appropriate for the setting in which it will be applied. Prevention and control 
activities routinely used in high-income settings, such as: test and slaughter; 
restricting livestock movements; and financial incentives for disease-free herd 
status, would likely prove difficult to implement, monitor and sustain in the SSA. 
Intervention using livestock vaccination could be an effective approach in the 
reduction in prevalence of brucellosis in livestock and people, and has been 
suggested as such for SSA (WHO et al., 2006). In an ideal scenario, such an 
intervention in Tanzania would include routine mass vaccination of cattle, sheep 
and goats, at a very low cost per animal to the livestock keeper. Based on 
current guidance regarding the most effective brucellosis vaccines, vaccination 
would involve the use of S19 vaccine for cattle and Rev-1 vaccine for sheep and 
goats (Corbel, 2006). The conjunctival vaccination of calves, lambs and kids only 
is suggested and would need to be conducted at less than 4 months old, with 
revaccination within 6-12 months of initial vaccination. This vaccination 
approach is advocated as it would avoid the abortifacient effect induced by 
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these vaccines in adult animals and reduces interference with serological testing 
(Godfroid et al., 2011). Vaccination would require individual animal 
identification for trace-back, potentially using ear tags. Additionally, 
appropriate training and personal protective equipment for veterinary service 
providers would be crucial in ensuring that the occupational risk of vaccine 
administration is as minimal as possible. This vaccination strategy could also be 
combined with community knowledge exchange concerning risk factors for 
animal and human brucellosis and the hygiene measures that might be feasibly 
implemented to prevent transmission. This would include food safety measures, 
such as milk boiling, that have been key in the prevention of human brucellosis 
in countries such as Greece, and are thought particularly imperative for the 
prevention and control of B. melitensis in LMICs (Godfroid et al., 2013a). 
Implementation of hygiene measures with regard to livestock-wildlife interface 
areas, such as the avoidance of shared livestock and wildlife grazing areas (Van 
Campen and Rhyan, 2010), would likely also be important. This brucellosis 
prevention and control strategy would assist in reducing brucellosis transmission 
and the burden of infection in animals and humans. However, it would require 
consideration of the most effective method of communicating and exchanging 
information for different demographic groups. This would be important in having 
the highest chance of effecting behavioural change in livestock keeper 
compliance with a vaccination strategy, and also in the avoidance of identified 
risk factors, including successful implementation of food safety measures. 
 
5.7.2 Considerations for a successful brucellosis 
prevention and control strategy 
Through the progression of this thesis research, some important points 
concerning brucellosis prevention and control in Tanzania have become 
apparent. As an NZD with very low human mortality rates, it is important to 
recognise that a brucellosis prevention and control strategy will need to be 
justifiable within the greater landscape of human disease burden in SSA. As has 
been suggested for the control of NZDs and NTDs in LMICs, one method of 
achieving the successful adoption of a brucellosis prevention and control 
strategy may be to involve the integration of several diseases (Molyneux et al., 
2005; WHO et al., 2006). This multi-disease control approach could be adapted 
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via the inclusion of other NZDs that occupy a similar ecological setting and cause 
similar syndromic presentation in humans, such as Q fever (Coxiella burnetii) 
and leptospirosis (Leptospira spp.). In Tanzania, the government has produced 
documentation identifying six priority zoonotic diseases including: brucellosis; 
rabies; avian influenza; anthrax (Bacillus anthracis); human african 
trypanosomiasis (Trypanosoma brucei spp.); and Rift Valley fever and other viral 
haemorrhagic fevers (Government of Tanzania, 2018b). For prioritised zoonoses 
involving similar host species and found in a similar geographical setting to 
brucellosis, such as anthrax, certain aspects of a disease prevention and control 
strategy could be combined into a multi-disease approach. These aspects might 
include: communication about transmission risk in livestock-keeping 
communities; or the implementation of a multi-disease mass vaccination 
campaign, if an effective vaccination strategy can be agreed for brucellosis in 
Tanzania. Additionally, communication about brucellosis transmission with 
regards to food safety measures such as boiling milk and cooking meat 
appropriately would impact on the burden of multiple zoonoses, for example: 
tuberculosis (Mycobacterium bovis); Q fever; Salmonella spp.; Escherichia coli; 
and Campylobacter spp. 
 
Secondly, as suggested in previous reports focusing on the control of NZDs, a 
strategy should be oriented around a One Health approach, which depends upon 
involvement and effective communication between public health, animal health 
and sociological sectors (Godfroid et al., 2013a; Government of Tanzania, 2018a; 
WHO et al., 2006). In pastoral settings, environmental factors may also need to 
be taken into account, with control considering impacts on issues such as: 
protection of ecosystem services; land reform; and integrated social and 
economic development (Racloz et al., 2013). The adoption of technology such as 
smart phone applications in the surveillance of brucellosis and other NZDs can 
only help to facilitate communication between multi-sectoral stakeholders. Data 
are uploaded to a central server, which would facilitate formal multi-sectoral 
reporting to stakeholders. Such surveillance data could also assist in reporting 
between bordering countries. This is important in brucellosis prevention and 
control, as bordering countries that share transhumance routes most likely also 
share brucellosis burden (Dean et al., 2013a). 
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Finally, when developing disease prevention and control strategies it is 
important that any strategy is informed by an evidence-base of robust data. 
Without this, any strategy will likely be ineffective or even harmful (Godfroid et 
al., 2013a). The study findings presented in this thesis contribute towards this 
evidence-base regarding the epidemiology of brucellosis in Tanzania and SSA. It 
is however necessary to ensure that this evidence-base is effectively translated, 
so that the core messages are accessible and clear to stakeholders without a 
scientific background. Therefore, an important next step is to develop a concise 
policy brief that summarises the key findings from the research presented here, 
as well as combining research outcomes from other available studies, such as 
data on human brucellosis incidence rates and the Brucella species causing 
human infections in Tanzania. The policy brief could suggest appropriate next 
steps in planning for the implementation of prevention and control activities, 
such as trailing livestock vaccination and investigating steps towards the 
sustainable implementation of a routine vaccination campaign through 
government collaboration with appropriate international organisations such as 
Gavi, The Vaccine Alliance. Additionally, advocating for investigation into a 
number of different costing analyses would provide important information 
regarding the feasible application of brucellosis prevention and control 
activities. These costing analyses could include: evaluation of the cost-
effectiveness of routine livestock brucellosis vaccination on human and animal 
brucellosis control, as has been conducted in Tanzania for other infectious 
diseases such as rabies, rotavirus and malaria (Fitzpatrick et al., 2014; Hutton 
and Tediosi, 2006; Ruhago et al., 2015); cost-benefit analysis of a national 
standardised livestock brucellosis diagnostic testing protocol for brucellosis 
surveillance and control; and a cost-benefit analysis evaluating a multiple 
zoonoses approach to a prevention and control strategy, particularly in the case 
of the six prioritised zoonoses for Tanzania. This communication with policy-
makers could assist in obtaining investment in essential research and generating 
momentum towards adoption of an evidence-based brucellosis prevention and 
control strategy for Tanzania. These multiple steps taken towards the successful 
prevention and control of brucellosis in Tanzania could be used to guide 
prevention and control activities in similar settings across SSA. 
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TUMAINI UNIVERSITY MAKUMIRA 
KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE 
P. O. Box 2240, Moshi   Tel. 027-27-53909 
 
Brucellosis research in northern Tanzania 
Hospital Patient-Participant Information Sheet 
 
INTRODUCTION 
You are being invited to take part in this research study because the examination at this health facility 
has shown that you have fever. Brucellosis is a disease that can cause fever and other symptoms and 
we are carrying out a research study on this disease. Before you decide if you want to take part in 
this study, it is important that you understand why the research is being done and what it will involve. 
Please read, or listen to, this information sheet and consent form carefully and take your time making 
your decision. As the study member discusses this consent form with you, please ask him/her to 
explain any words or information that you do not clearly understand. We encourage you to talk with 
your family and friends before you decide to take part in this study. The nature of the study, length 
of time it will take, risks, and other important information about the study are listed below. If you 
agree to take part in this study, you will be asked to sign or add your thumbprint to this consent form. 
You will get a copy to keep. 
 
WHO IS DOING THIS RESEARCH? 
This research will be conducted by experts in human and animal health from Tanzania and the United 
Kingdom. Dr. V Maro and Prof J. A. Crump from the Kilimanjaro Christian Medical Centre and Dr 
Gabriel Shirima from Nelson Mandela African Institute of Science and Technology, Tanzania; and 
Dr Jo Halliday from University of Glasgow will lead the field research for this project, other team 
members will also be involved. The research is funded by the Department for International 
Development (DFID) and five research councils in the UK.  
 
WHAT IS THE PURPOSE OF THIS STUDY? 
In Tanzania, data collected by other studies has shown that brucellosis occurs in different types of 
animals (e.g. cattle, sheep and goats) and that brucellosis is an important cause of disease in people. 
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Brucellosis can be caused by several different types of Brucella bacteria. Each of these types of 
Brucella has different patterns of disease in animals. Information about which Brucella types are 
present in which animals in Tanzania is not well known. To develop plans for brucellosis control that 
are most likely to be effective and affordable, it is important to understand which animals are infected 
by which Brucella types, and which transmission routes are most important in transmitting 
brucellosis from animals to people. This three-year study will help to find out which Brucella types 
are found in different animal populations and which transmission routes are important for human 
disease. The information collected will help develop control strategies and will help improve 
Brucella identification in Tanzania.  
 
WHY HAVE I BEEN CHOSEN?  
You have been invited to take part in this study because you have fever. Fever is one of the main 
signs of brucellosis. We would like to do some tests to find out if you do have brucellosis. We expect 
that about 360 people will take part in this study. 
 
DO I HAVE TO TAKE PART?  
It is up to you to decide whether you do or do not to take part in this study. Participation is voluntary. 
If you agree to take part in this study, you will be asked to sign, or add your thumbprint to this consent 
form. You will get a copy to keep. If you decide to take part, you are free to stop at any time and you 
do not need to give a reason for stopping. If you decide to stop taking part in this study your 
contributions to the study would be removed from any study outputs produced after the date that you 
stop taking part.  
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you decide to take part in this study you will be asked to allow a member of the project team to 
take blood for brucellosis testing. Up to 50cc of blood will be collected. We will use the blood sample 
you give us to do tests for brucellosis and some other diseases including malaria. We will also use 
the sample to do more tests for brucellosis and other diseases at a later date. We will give you the 
results from some of these tests when they are available, if they tell us about your current illness. We 
will not give you the results of all the tests that are done with your samples. All of these tests are 
free. You will also be asked to respond to some questions about you, your household and your health. 
It will take a few hours for us to collect samples and ask you some questions, and we will complete 
this either today or possibly in the next few days if there is not time to complete our questionnaire 
today. We will also ask you to return to a follow-up clinic in 4-6 weeks time so that we can collect 
another blood sample for testing. Or, with your permission, the project team may visit you at your 
household to collect samples later. You can choose to stop taking part at any time without any cost. 
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART IN 
THE STUDY? 
The collection of blood samples may cause some pain, bleeding or bruising where the needle enters 
the body.  A small blood clot may form where the needle enters the body or there may be swelling 
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in the area. In a small number of people lightheadedness and fainting can also happen when a blood 
sample is collected. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART IN THIS STUDY? 
Direct benefits include free tests for brucellosis, other blood infections and malaria. The project team 
will also provide you with information about brucellosis. The results of the whole project will help 
to improve medical care and identification of diseases in Tanzania. We hope that the information 
collected through this study will be used to control brucellosis and reduce the impact that this disease 
has on human and animal health in Tanzania.  
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY?  
The samples we collect will be tested at Kilimanjaro Clinical Research Institute in Moshi. After this, 
more tests may be done at one of our partner institutions including the Animal and Plant Health 
Agency of the UK and University of Glasgow. We will store leftover samples after brucellosis testing 
so that they can be used for studies in the future. This may include studies of other diseases that cause 
fever. We do not plan to contact you with the results from tests done on stored samples. This is 
because the studies will most likely be performed many months or years after the samples were 
collected and the results would no longer be important for your treatment. The results from this study 
may be used by local and international institutions, responsible ministries, individuals and scientists.  
 
WILL MY INFORMATION BE KEPT CONFIDENTIAL? 
All information which is collected about you, or responses that you provide, during the course of 
the research study will be kept strictly confidential. You will not be identified by name in the study 
records shared outside KCMC or the University of Glasgow. If study results are given to other 
researchers, you will be identified by a code number, and any information about you will have your 
name and address removed so that you cannot be recognised from it.  
 
WHAT ABOUT COMPENSATION? 
If we ask you to return to the hospital for a second blood sample in 4-6 weeks time, we will provide 
you with money to cover the cost of your transport for this visit. No other compensation will be 
provided for your participation in this study. 
 
WHAT ARE MY RIGHTS AS A RESEARCH SUBJECT? 
Taking part in this study is completely voluntary. You may choose not to take part in this study. Your 
decision will not affect your ability to take part in other studies or result in the loss of any benefits 
you are entitled to.  
 
WHO HAS REVIEWED THIS STUDY? 
This study has been approved by the Ethics Committees of KCMC, the Tanzanian National Institute 
of Medical Research (NIMR) and the University of Glasgow. 
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WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about this study contact: Dr Gabriel Shirima at 0763 973 003 or Dr Venance Maro at 
0754 581 444. For questions about this study, to discuss problems, concerns or suggestions related 
to the study or to ask for information about this study, contact the Kilimanjaro Christian Medical 
Centre Ethics Committee at 027 275 3909. You can also contact the National Health Research Ethics 
Committee at 022 212 1400. 
 
THANK YOU! 
On behalf of the project team we would like to thank you for agreeing to 
take part in this study  
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TUMAINI UNIVERSITY MAKUMIRA  
KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE 
P. O. Box 2240, Moshi   Tel. 027-27-53909 
 
Project Number: 
Participant Unique Identification Number: 
 
CONSENT FORM 
 
Brucellosis research in northern Tanzania - Participant (Adults) 
 
"The purpose of this study, what will happen to me and the risks and benefits have been explained 
to me. I have been allowed to ask questions, and I am satisfied with the answers I have received. I 
have been told who to contact if I have questions, to discuss problems, or suggestions related to the 
study, or to receive more information about the study. I have read (or had read) this information sheet 
and agree to take part in this research study, with the understanding that I may withdraw at any time. 
I have been told that I will be given a signed and dated copy of this consent form." 
Please initial or mark box 
 
I confirm that I have read (or had read) and understand the information sheet for 
________________ participants, dated __________(version _____ ) for the above study  
and have had the opportunity to ask questions. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time,  
without giving any reason, without my legal rights being affected. 
 
 
I agree to take part in the above study.       
 
 
           
Name of participant (print) Date Signature 
 
 
    
Study staff conducting consent (print) Date Signature 
 
 
   
Witness’ name (print) (As appropriate) Date Signature 
 
(1 copy for subject; 1 copy for researcher) 
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TUMAINI UNIVERSITY MAKUMIRA  
KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE 
P. O. Box 2240, Moshi   Tel. 027-27-53909 
Project Number: 
Participant Unique Identification Number: 
 
CONSENT FORM 
 
Brucellosis research in northern Tanzania – Participant (Minors) 
 
" The purpose of this study, what will happen to my child, and the risks and benefits have been 
explained to my child and me. I have been allowed to ask questions, and I am satisfied with the 
answers I have received. I have been told who to contact if I have questions, to discuss problems, or 
suggestions related to the study, or to receive more information about the study. I have read (or had 
read) this information sheet and agree for my child to take part in this research study, with the 
understanding that my child may withdraw at any time. I have been told that I will be given a signed 
and dated copy of this consent form." 
Please initial box 
I confirm that I have read (or had read) and understand the information sheet for 
________________ participants, dated __________(version _____ ) for the above study  
and have had the opportunity to ask questions. 
 
I understand that my child’s participation is voluntary and that we are free to withdraw at any time, 
without giving any reason or our legal rights being affected. 
 
 
I agree for my child to take part in the above study.       
 
 
Participant’s name (print): _________________________________ 
 
 
           
Child Assent (print) (As appropriate) Date Signature 
 
           
Parent or Legal Guardian name (print) Date Signature 
 
    
Study staff conducting consent (print) Date Signature 
 
   
Witness’ name (print) (As appropriate) Date Signature 
(1 copy for subject; 1 copy for researcher)  
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ZELS BRUCELLA - INDIVIDUAL QUESTIONNAIRE
1.3 Interviewer's initials1.1 Location ID
- -Z B L
      Sex
Male Female
1.5 Interview Date (dd/mm/yyyy)
/ /
1.7 Primary informant
Self Parent/Guardian Relative Other
1.4 Individual ID
-Z B P
     What is your marital status?
Married (Nimeolewa/oa)
Single (Sijaolewa/oa)
Divorced/separated (Nimeachika/acha)
Widowed (Miane)
      What is your tribe?
Arusha
Barabaig
Chagga
Iraqw
Maasai
Pare
Sambaa
Other (specify)
HH Q ID
1.6 Language
Kiswahili English Maasai
Reviewer's initials
Review Date (dd/mm/yyyy)
/ /
SECTION 1: INTERVIEW DETAILS
SECTION 2: INDIVIDUAL DESCRIPTION
      Date of birth (dd/mm/yyyy)
/ /
 Hali ya mahusiano ya ndoa?
Kabila lako?
ZELS Brucella - Individual Questionnaire v1.0 Page 1 of 11
      Age Class
0-5 yr 6-12 yr 13-18 yr 19-34 yr 35-54 yr > 55 yr
If only the year of birth is known, record 01 for dd and 07 for mm.
If year of birth is known, ask question 2.4.
Kama ni mwaka wa kuzaliwa pekee unajulikana jaza 01 (dd) na 07 (mm)
Kama mwaka wa kuzaliwa unajulikana, uliza swali 2.4
1.2 Enrollment Date (dd/mm/yyyy)
/ /
Nyangulo
Ilkiponi/Korrianga
Ilkumunyak/ILandis (Ilkidotu)
Ilkishumu/ Makaa (Irkishomo)
ISeuri
Ilnyankusi/Meshuki
If Maasai or Arusha ask 2.5a/2.5b, otherwise proceed to 2.6
Kama ni Mmasai au Mwarusha uliza 2.5a/2.5b, vinginevyo nenda 2.6
2.5a. What is your ageset (men)?
Wewe ni rika gani (wanaume)?
Boda boda/Ingoipila: under 20yrs
Njujulai: 20-30yrs
Maharage (Intiamaragi)/N’gali: 30-36yrs
Mosogiro: 37-46yrs
Isusan: 47-56yrs
Ingaimuk (Ingaimug): 56-65yrs
Enderito: 65+yrs
2.5b. What is your ageset (women)?
 (these are ‘unofficial’ but commonly used):
Wewe ni rika gani (wanawake)?
     Village
     Ward
       Sub-village (leave blank if none)
Arusha Rural
Arusha Urban
Longido
Monduli
Ngorongoro
Meru
Karatu
Other
2.11. How long has your boma been in your current village?
Ni kwa muda gani boma lako lipo katika kijiji hiki?
Years Months Days
Miaka Miezi Siku
       How many adults live in your boma?
       How many children live in your boma?
(age 18 years or older/ miaka 18 au zaidi)
(age less than 18 years/ chini ya miaka 18)
2.14. In the past 30 days, have you travelled outside your home region?
Katika kipindi cha siku 30 zilizopita umesha safiri nje ya mkoa
wako unaoishi?
If yes, provide details of the locations visited in the box below
Kama ndiyo, jaza katika kisanduku maeneo aliyo tembelea
Yes No
2.6
2.7 Arusha District/ Wilaya ya Arusha
Kata
Kijiji
2.8
2.9
2.10
2.12
2.13
Jinsia2.1
2.2 Tarehe ya kuzaliwa
2.3
Je, ni watu wazima wangapi wanaishi katika boma lako?
Je, ni watoto wangapi wanaishi katika boma lako?
2.4
Kitongoji
Other Region/ Mkoa mwingine
Other District/ Wilaya nyingine
5726256092
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        How many years of education have you had?
No education (Sijasoma)
Primary (1-7 years) (Msingi)
Secondary (8-11 years) (Sekondari)
High school (12-13 years) (Sekondari ya juu)
University/college (Chuo kikuu/chuo)
 Umepata elimu (darasani) kwa miaka mingapi?
2.16 What are your main work/professional activities?
Ajira yako kuu ni ipi?
livestock attendant 1
mchungi/mfugaji
butcher/abattoir worker 2
mchinjaji/mfanyakazi wa machinjioni
wildlife worker 3
mfanyakazi wa wanyamapori
milk supplier 4
msambazaji wa maziwa
crafts person 6
mhunzi
veterinarian 7
mganga wa mifugo
housewife 8
mama wa nyumbani
office worker 9
mfanyakazi wa ofisini
healthcare worker 10
mhudumu wa afya
merchant/trader 11
mjasiriamali/ mfanyabiashara
teacher 12
mwalimu
driver 13
dereva
other 18
nyingineo
Other occupation
Kazi ya ziada
(Choose many)
(Chagua yote
yanayohusika)
Primary occupation
Kazi ya kudumu
(Choose one)
(Chagua moja)
unemployed 16
sijaajiriwa
sewer worker 14
wazibua vyoo
guard/police 15
askari/ polisi
pre-working age 17
bado hajafikia umri wa kufanya kazi
Page 2 of 11
3.1 During the past two weeks, have you had any of the
following types of illness? (indicate all that apply)
Katika wiki mbili zilizopita, umewahi kupata yoyote kati
ya magonjwa yafuatayo? (ainisha yote yanayohusika)
diarrhoea: >= 3 loose stools within a 24 hours  period
kuharisha: >= choo laini 3 ndani ya muda wa saa 24
respiratory illness: cough or difficulty breathing
magonjwa ya kifua/kupumua: kuhohoa au matatizo ya kupumua
fever: report of fever
SECTION 3: CURRENT AND RECENT ILLNESS
Diarrhoea/ kuharisha
Respiratory illness/
magonjwa ya kifua/ kupumua
Fever/ homa
Yes No
Yes No
Yes No
Continual Intermittent
3.2  Is your fever continual or intermittent?
Je, homa yako ni ya mfululizo au ya vipindi?
 If yes to fever in 3.1,ask questions 3.2 - 3.5
Kama jibu la homa ni ndio kwa swali 3.1, tafadhali uliza maswali 3.2 - 3.5
Days Months Years
3.3  How long ago did the fever start?
Je, ni muda gani tangu kuanza kwa homa?
3.4  How long ago did your illness start?
Je, ni muda gani ugonjwa wako ulikuanza?
Days Months Years
ZELS Brucella - Individual Questionnaire v1.0
2.15
student 5
mwanafunzi
mfululizo vipindi
siku miezi miaka
siku miezi miaka
1478256092
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3.5 Have you had any of the following signs or symptoms of illness
during this current illness?
Umepata yoyote kati ya dalili zifuatazo za ugonjwa katika kipindi
hiki cha kuugua kwako?
If not currently febrile, please ask for past 2 weeks and past 12 months only
Kama hana homa kwa sasa, uliza katika kipindi cha majuma mawili yaliyopita na miezi
12 iliyopita tu
night sweats
jasho la usiku
joint pain
maumivu ya viungo
Yes
DK
No
Past 12
months
Current
Illness
abdominal pain
maumivu ya tumbo
convulsions
degedege
rigors
kutetemeka baridi
jaundice/yellow eyes
manjano/macho ya
njano
fatigue
uchovu wa mwili
muscle pain
maumivu ya misuli
back pain
maumivu ya mgongo
vomiting
tapika
swollen joints
kuvimba kwa viungo
headache
kuumwa kichwa
stiff neck
shingo kukakamaa
conjunctival suffussion
macho kua mekundu
_______ear pain or drainage
maumivu ya sikio
sore throat
kuumwa koo
loss of appetite
kupoteza hamu ya kula
constipation
kuvimbiwa
bloody stool
choo chenye damu
dysuria
unapata maumivu
unapokojoa
swollen painful testicles
(male only)
Kuvimba korodani/
makende (wanaume)
rash
upele
eschar
kovu
3.6a Have you sought care for this illness at another location prior to
presentation at Endulen?
Je, ulishatafuta tiba ya ugonjwa huu sehemu nyingine kabla ya
Endulen?
Yes No
Yes
DK
No
Past 2
weeks
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
Yes
DK
No
3.7a Have you sought care for your illness with a healthcare provider?
Je, umesha tafuta tiba ya ugonjwa wako kwa mtoa huduma ya
afya? Yes No
3.6b Which type of Healthcare facilities were visited?
Ni aina gani ya vituo vya afya ulivyohudhuria?
Pharmacy
Dispensary
Traditional healer
Health center
Other Hospital
Other
(Duka la dawa)
(Zahanati)
(Mganga wa jadi)
(Kituo cha afya)
3.8 Have you taken any medicines over the past 2 weeks?
Umetumia dawa yoyote katika kipindi cha majuma 2 yaliyopita?
Yes No DK  If yes, what was the medication(s) for?
Kama ndio, dawa zilikua kwa ajili gani?
 A.
B.
 C.
 D.
 A.
B.
 C.
 D.
For febrile participants in the household only. Kwa
wagonjwa wa homa katika kaya tu.
3.7b Which type of Healthcare facilities were visited?
Ni aina gani ya vituo vya afya ulivyohudhuria?
 If yes for question 3.6a ask 3.6b/  Kama ndio kwa sawali 3.6a, uliza 3.6b
 If yes, how many locations
Kama ndio, sehemu ngapi?
Page 3 of 11ZELS Brucella - Individual Questionnaire v1.0
For the next question:
Hospital participants should complete question.3.6a (and 3.6b if appropriate) but not
3.7a /3.7b.
Households participants should complete question 3.7a (and 3.7b if appropriate) but
not 3.6a/ 3.6b
All participants should complete questions 3.8 onwards
 If yes, how many
Kama ndio, wangapi?
 If yes for question 3.7a ask 3.7b/ Kama ndio kwa sawali 3.7a, uliza 3.7b
 If yes, what was the medication(s) name(s)?
Kama ndio, dawa hizo zinaitwaje?
Pharmacy
Dispensary
Traditional healer
Health center
Other Hospital
Other
(Duka la dawa)
(Zahanati)
(Mganga wa jadi)
(Kituo cha afya)
3934256091
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3.9 Have you taken any other medications over the past 2 weeks?
Umetumia dawa nyingine zozote katika kipindi cha majuma 2
yaliyopita?
Tuberculosis drugs/
Dawa za kifua kikuu Yes No DK
Yes No DK
Yes No DK
Yes No DK
Analgesics/
Dawa za kupunguza maumivu
Antiretrovirals/
Dawa za ARV
Other/
Nyinginezo
5.1 Before we talked to you about this study, had you heard of a
disease called brucellosis/ brucella?
Kabla ya kuzungumza na wewe kuhusu huu utafiti, je uliwahi
kusikia ugonjwa unaoitwa brucellosis/ brusela? Yes No
SECTION 5: BRUCELLOSIS HISTORY
5.2 Can you tell us what are the usual symptoms of brucellosis in people?
Unaweza kutuambia dalili za mtu mwenye brucellosis?
 If no to 5.1, skip to 5.9 / Kama hapana kwa swali 5.1, nenda swali la 5.9
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SECTION 4: PREGNANCY HISTORY (females only)
4.2 Have you started menstruating?
Umeanza kupata siku za mwezi/ hedhi
(umefikia kuvunja ungo)? Yes No
4.3 Have you ever been pregnant?
Umewahi kupata ujauzito? Yes No
4.4 How  many times have you been pregnant (including
abortions, miscarriages, stillbirths and live births)?
Ni mara ngapi umepata ujauzito (ikihusisha mimba
zilizotolewa zilizoharibika, kuzaa watoto wafu na
watoto hai)?
4.5 How many live births have you had?
Umejifungua mara ngapi watoto wakiwa hai?
If no, skip to SECTION 5./
Kama hapana, nenda SEHEMU ya 5
If no, skip to SECTION 5/
Kama ni hapana nenda SEHEMU ya 5.
4.6 Have you ever had a miscarriage or stillbirth?
Je, umewahi kupata mimba ikaharibika au kutoka yenyewe
au kichanga kuzaliwa mfu? 
                             If yes, how many?
                                    Kama ndio, mara ngapi?
Yes No
Miscarriage or spontaneous abortion (<28 weeks)
Fetal death or stillbirth (after 28 weeks)
Live birth
NA- first pregnancy ongoing
Other
Mtoto kufia tumboni au mimba kuharibika (kabla ya wiki 28 za ujauzito)
Mtoto kufia tumboni/kuzaliwa mfu (baada ya wiki 28 za ujauzito)
Mtoto aliye hai
Nyingine
Bado ni mjamzito
We would now like to ask you some questions about your
pregnancy history/
Tungependa sasa kukuuliza baadhi ya maswali kuhusu
historia yako ya ujauzito
4.1 Are you comfortable answering questions about this?
Je, unajisikia vizuri kujibu maswali kuhusiana na hili?
Yes No
 If yes, proceed to next questions. If no, skip to SECTION 5
Kama ndio, endelea na maswali yafuatayo. Kama hapana, nenda
SEHEMU ya 5
sweats/ kutokwa na jasho
malaise/ uchovu
joint pain/ maumivu ya viungo
abdominal pain/ maumivu ya tumbo
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
headache/ maumivu ya kichwa
fever/ homa
Yes No
Yes No
Yes No
anorexia/ kushindwa kula
back pain/ maumivu ya mgongo
chills/ kutetemeka baridi
chest pain/ maumivu ya kifua
muscle aches/ kuumwa kwa misuli
cough/ kukohoa
constipation/ kufunga choo au kuvimbiwa
neck pain/ maumivu ya shingo
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
diarrhoea/ kuharisha
vomiting/ kutapika
breathlessness/ kupumua kwa shida
weight loss/ kupungua kwa uzito
joint swelling/ kuvimba kwa viungo
rash/ upele
orchitis (in males)/ kuvimba korodani
I don't know/ sijui
Yes No
Go through the list of symptoms/ signs and prompt the respondent to find out if they
think each is associated with brucellosis. Record a Yes (Y) or No (N) response after
prompting. record any additional reported signs or symptoms in the text box.
Pitia orodha ya dalili/ viashiria na muulize mshiriki kama dalili/ viashiria hivi vina
uhusiano na brucellosis. Jaza jibu la Yes (Y) au No (N)  baada ya kuuliza na jaza
dalili zozote nyingine kwenye kisanduku mwishoni mwa jedwali.
DK
4.7 What was the outcome of your last pregnancy?
Je, yapi yalikua matokeo ya ujauzito wako wa mwisho?
Other signs/ symptoms/ Dalili/ viashiria vingine:
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5.3 Have you ever been diagnosed with brucellosis?
Je, ulishawahi kugundulika una brucellosis?
Yes No
5.4 When was the diagnosis made? / Je, uligundulika lini?
 If no to 5.3, skip to 5.8/ Kama hapana kwa  5.3, nenda 5.8
5.5 Where was the diagnosis made? / Je, uligundulika wapi?
5.6 Did you receive treatment? /Je, ulipatiwa matibabu?
Yes No
5.7 What was your treatment? / Ulipatiwa tiba ipi?
5.8 Have any other members of your family ever been
diagnosed with brucellosis?
Je, kuna mtu yeyote katika kaya yako aliwahi
kugundulika ana brucellosis? Yes No
 If yes, record who in the family, where and by who the diagnosis was made?
Kama ndio, jaza ni nani aliyegundulika katika familia na ni wapi na ni  nani
aliye gundua?
If participant is febrile.
Kama mshiriki ana homa.
5.9 Do you know anyone in your boma or village who has current
symptoms similar to yours?
Je, unamjua mtu yeyote katika boma au kijiji chako mwenye
dalili sawa na za kwako?
If yes, fill out "contact screening form"./
Kama ndio, jaza fomu ya "contact screening"
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Number
of people
Idadi ya watu
Boma member
Mwanaboma
Village member
Mwanakijiji
Yes No DK
Yes No DK
 If no to 5.6, skip to 5.8/ Kama hapana kwa swali la 5.6, nenda 5.8
Yes No
Month/ Mwezi Year/ Mwaka
SECTION 6: FOOD
6.1 In the past 30 days, have you consumed the following types of
boiled or pasteurised dairy products?
Katika siku 30 zilizopita, umetumia/ kula aina za mazao ya
maziwa zilizochemshwa au za viwandani?
If yes, include how many days per week (in a typical week).
If no, ask if the dairy product has been consumed in the past 12 months
Kama  ndiyo, jaza ni siku ngapi katika juma (juma la kawaida)
Kama hapana, uliza kama aina hiyo ya mazao ya maziwa alitumia katika kipindi cha
miezi 12 iliyopita
cheese, butter, cream or yogurt but unsure
whether milk raw or boiled/ pasteurised
Jibini, siagi, mafuta au mgando/mtindi
lakini hakuna uhakika kama maziwa
yalikuwa mabichi, yaliyochemshwa au ya
kiwandani
Milk
Maziwa
Yes
No
Yogurt
Maziwa mtindi
Yes
No
Cheese
Jibini
Yes
No
Butter
Siagi
Yes
No
Cream
Mafuta ya maziwa
Yes
No
Yes
No
Past
30 days
Past 12
months
Number of
 days (1-7)
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Other food (e.g. uji, ndizi) prepared by adding
dairy products before or during cooking
Vyakula vingine (mfano uji, ndizi)  kwa
kuviongezea mazao ya maziwa kabla au
wakati wakupikwa
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Other products made from  boiled or
pasteurised dairy products
Mazao mengine yatokanayo na  maziwa
ya viwandani au maziwa yaliyochemshwa
Other food (e.g. uji, ndizi) prepared by
adding pasteurised or boiled dairy products
after cooking
Vyakula vingine (mfano uji, ndizi) kwa
kuviongezea mazao ya maziwa
yaliyochemshwa baada ya kupika
goat/ mbuzi wako Yes No
Yes Nocow/ ng'ombe wako
sheep/ kondoo wako Yes No
other animal/ wengine Yes No
6.2 Which animals did the boiled or pasteurised milk products come
from? (Choose all that apply and prompt all options)
Je, ni kutoka kwa wanyama wepi maziwa yaliyochemshwa au
bidhaa za maziwa ya kiwandani yamepatikana?
(Chagua yote yanayohusika)
/
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6.3 In the past 30 days, have you consumed any of the following
types of raw meat or offal or raw animal blood?
Katika kipindi cha siku 30 zilizopita, je wewe umetumia/kula
yoyote kati ya aina ya nyama mbichi au nyama za ndani, au
damu mbichi ya mnyama?
If yes, include how many days per week (in a typical week).
If no, ask if the meat/offal/blood has been consumed in the past 12 months.
Kama ndio, uliza ni siku ngapi katika juma (juma la kawaida)
Kama hapana, uliza kama nyama mbichi/nyama za ndani/ damu mbichi
ilitumika miezi 12 iliyopita
raw goat blood
damu mbichi ya mbuzi
raw blood from other animal
damu mbichi ya mnyama mwingine
raw cow blood
damu mbichi ya ng'ombe
raw meat or offal from cow
nyama mbichi au nyama za
ndani kutoka kwa ng'ombe
raw meat or offal from goat
nyama mbichi au za ndani kutoka
kwa mbuzi
raw meat or offal from another animal
nyama mbichi au za ndani kutoka
kwa mnyama mwingine
raw sheep blood
damu mbichi ya kondoo
raw meat or offal from sheep
nyama mbichi au za ndani
kutoka kwa kondoo
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Past 30
days
Number of
 days (1-7)
Past 12
months
6.4 In the past 30 days have you consumed soup with blood?
Je, katika kipindi cha siku 30 zilizopita uliwahi kunywa
supu yenye damu (kisusio)?
6.5 In the past 30 days have you consumed blood mixed
with milk?
Je, katika kipindi cha siku 30 zilizopita uliwahi kunywa
maziwa yaliyochanganywa na damu (mlaso)?
Cow/ Ng'ombe
Sheep/ Kondoo
Goat/ Mbuzi
Other/ Wengine
6.6 In the past 12 months, have you consumed meat or offal
from an aborted animal or the placenta of an aborted animal?
Katika miezi 12 iliyopita, umetumia/kula nyama au nyama
za ndani kutoka kwa kichanga cha mnyama au kondo la
nyuma? Yes No
Yes No
 If yes, blood from which animal?
 Kama ndio, ni damu kutoka kwa mnyama yupi?
Yes No
 If yes, blood from which animal?
 Kama ndio, ni damu kutoka kwa mnyama yupi?
 If yes, milk from which animal?
Kama ndio, ni maziwa kutoka kwa mnyama yupi?
Another animal
Mnyama mwingine
Sheep/ Kondoo
Goat/ Mbuzi
If no, skip to 6.7
If yes, complete table below. If activity was performed in past 30 days,
include how many days per week (in a typical week).
Kama hapana, nenda swali 6.7
Kama ndio, kamilisha jedwali lifuatalo. Kama shughuli ilifanyika katika
siku 30 zilizopita jaza ni siku ngapi katika juma (juma la kawaida)
Number of
 days (1-7)
Cow / Ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12
months
Past 30
days
6.7 Was the meat or offal raw?
Je, nyama/ nyama za ndani zilikua mbichi? Yes No
Yes No
Yes No
Yes No
Yes No
Cow/ Ng'ombe
Sheep/ Kondoo
Goat/ Mbuzi
Other/ Wengine
Yes No
Yes No
Yes No
Yes No
Cow/ Ng'ombe
Sheep/ Kondoo
Goat/ Mbuzi
Other/ Wengine
Yes No
Yes No
Yes No
Yes No
5410256092
  177 
 
 
 
 
 
Other products made from  other raw
dairy products
Mazao mengine yatokanayo  katika
mazao mengine ya maziwa mabichi
Other food (e.g. uji, ndizi) prepared by
adding raw dairy products after cooking
Vyakula vingine (mfano uji, ndizi)  kwa
kuongeza mazao ya maziwa mabichi
baada ya kupika
6.8 In the past 30 days, have you consumed the following types of
raw dairy products?
Katika siku 30 zilizopita, umetumia/ kula aina za mazao ya
maziwa mabichi zifuatazo?
If yes, include how many days per week (in a typical week).
If no, ask if the raw dairy product has been consumed in the past 12 months
Kama  ndiyo, jaza ni siku ngapi katika juma (juma la kawaida)
Kama hapana, uliza kama aina hiyo ya mazao ya maziwa mabichi yalitumika katika
kipindi cha miezi 12 iliyopita
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Past
30 days
Past 12
months
Number of
 days (1-7)
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Milk
Maziwa
Yogurt
Maziwa mtindi
Cheese
Jibini
Butter
Siagi
Cream
Mafuta ya maziwa
Other food (e.g. uji, ndizi) prepared by adding
raw dairy products before or during cooking
Vyakula vingine (mfano uji, ndizi)  kwa
kuongeza mazao ya maziwa mabichi
kabla au wakati unapika
7.1 Have you milked any animals in the past 12 months?
Je wewe umekamua wanyama wowote katika kipindi cha
miezi 12 iliyopita?
If no, skip to 7.2
If yes, complete the following table. If activity was performed in past 30 days,
include how many days per week (in a typical week).
Kama hapana nenda swali 7.2
Kama ndio, kamilisha jedwali lifuatalo. Kama shughuli ilifanyika katika siku
30 zilizopita jaza ni siku ngapi katika juma (juma la kawaida)
Yes No
SECTION 7:ANIMAL RELATED ACTIVITIES
6.9 If you do not tend to drink raw milk, or consume it in other dairy or
food products, are there any particular circumstances where you might
consume raw milk or it’s products?
Kama huna nia ya kunywa maziwa mabichi au kuyatumia katika
mazao yoyote ya maziwa au vyakula, je kuna mazingira yoyote
huenda yakasababisha kunywa maziwa mabichi au mazao yake?
Yes No If yes, under what circumstances?Kama ndio, ni katika mazingira gani?
another animal
wengineo
sheep
kondoo
goats
mbuzi
Number of
 days (1-7)
cattle
ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12
monthsPast 30 days
7.2 In the past 12 months, have you slept in the same room
or enclosure as any animals?
Katika miezi 12 iliyopita, umelala usiku kucha katika
chumba kimoja au sehemu moja na wanyama wowote?
If no, skip to 7.3
If yes, complete table below. If activity was performed in past 30 days,
include how many days per week (in a typical week).
Kama hapana nenda swali 7.3
Kama ndio, kamilisha jedwali lifuatalo. Kama shughuli ilifanyika katika siku
30 zilizopita jaza ni siku ngapi katika juma (juma la kawaida)
7.3 In the past 12 months have you handled the waste
(manure) of any animals, including during building
construction, cleaning animal pens, use as fertiliser etc.?
Katika kipindi cha miezi 12 iliyopita umeshashika samadi
ya mnyama yeyote ikiwemo katika ujenzi, usafi wa zizi,
matumizi ya mbolea n.k? Yes No
Yes No
Number of
 days (1-7)
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12
months
Past 30
days
cattle
ng'ombe
goats
mbuzi
sheep
kondoo
another animal
wengineo
sheep
kondoo
goats
mbuzi
Number of
 days (1-7)
cattle
ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12
months
Past 30
days
If no, skip to7.4
If yes, complete table below. If activity was performed in past 30 days,
include how many days per week (in a typical week).
Kama hapana nenda swali 7.4
Kama ndio, kamilisha jedwali lifuatalo. Kama shughuli ilifanyika katika siku
30 zilizopita jaza ni siku ngapi katika juma (juma la kawaida)
7.4 Have you herded or used any animals for herding in the
past 12 months?
Je, wewe umechunga au kumtumia yoyote kati ya
wanyama kwa ajili ya kuchungia katika miezi 12 iliyopita?
Yes No
ZELS Brucella - Individual Questionnaire v1.0 Page 7 of 11
another animal
wengineo
Yes No Yes No
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If no, skip to 7.5
If yes, complete table below. If activity was performed in past 30 days, include
how many days per week (in a typical week).
Kama hapana nenda swali 7.5
Kama ndio, kamilisha jedwali lifuatalo. Kama shughuli ilifanyika katika siku 30
zilizopita jaza ni siku ngapi katika juma (juma la kawaida)
sheep
kondoo
goats
mbuzi
Number of
 days (1-7)
cattle
ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12
monthsPast 30 days
dogs
mbwa Yes No Yes No
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7.5 Have you assisted with the birthing of any animals in the past
12 months?
Je, ulisaidia kuzalisha mnyama yeyote katika miezi 12 iliyopita?
If yes, number of animals in past 30 days
If no, ask if they have assisted with birthing of any of these animals in the past 12 months
Kama ndio, idadi ya wanyama katika kipindi cha siku 30 zilizopita
Kama hapana, uliza kama walisaidia kuzalisha wanyama wowote katika miezi 12 iliyopita
another animal
mnyama mwingine
sheep
kondoo
goats
mbuzi
cattle
ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12 monthsPast 30 days
Yes No
Number of
 animals
donkeys
punda Yes No Yes No
7.6 Have you handled/had contact with any placental or birth
material of any animals in the past 12 months?
Je, umewahi kushika/kugusa kondo la nyuma au vitu vya
uzazi vya mnyama yeyote katika miezi 12 iliyopita?
If no, skip to 7.7 If yes, complete table below.
Kama hapana, nenda swali 7.7
Kama ndio,kamilisha jedwali lifuatalo
sheep
kondoo
goats
mbuzi
cattle
ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12 monthsPast 30 days
dogs
mbwa Yes No Yes No
7.7 Have you handled/had contact with any aborted birth
products from any animals in the past 12 months, including dead
young/ offspring, animal fluid, placenta or blood?
Je, umewahi kushika/ kugusa vitu vyovyote vya mimba
iliyotoka/ haribika ikiwemo kichanga mfu, maji maji ya
mnyama, kondo la nyuma au damu kutoka kwa mnyama
yoyote katika miezi 12 iliyopita?
If no, skip to 7.8 .If yes, complete table below.
Kama hapana, nenda swali 7.8 Kama ndio, kamilisha jedwali lifuatalo
sheep/ kondoo
goats/ mbuzi
cattle/ ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12 monthsPast 30 days
another animal/ wengineo Yes No Yes No
7.8 Have you slaughthered or butchered (or assisted in butchering)
any livestock or domestic animals in the past 12 months?
Je wewe ulichinja au kukatakata (au kusaidia kuchinja au
kukatakata) yeyote kati ya mifugo au wanyama wanaofugwa
katika miezi 12 iliyopita?
If no, skip to 7.9. If yes, complete table below.
Kama hapana, nenda swali 7.9 Kama ndio, kamilisha jedwali lifuatalo
another animal/ mwingine
sheep/ kondoo
goats/ mbuzi
cattle/ ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Past 12 monthsPast 30 days
Yes No Yes Nopigs/ nguruwe
Yes No
Yes No
Yes No
Number of
 animals
7.9 Have you handled/had contact with the carcass/ carcasses of
any livestock or domestic animals in the past 12 months?
Je, umewahi kushika/ kugusa mzoga/ mizoga ya mifugo au
wanyama wanaofugwa katika kipindi cha miezi 12 iliyopita?
If no, skip to 7.10 .If yes, complete table below.
Kama hapana, nenda swali 7.10. Kama ndio, kamilisha jedwali lifuatalo
Past 12 monthsPast 30 days
sheep
kondoo
goats
mbuzi
cattle
ng'ombe Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No Yes Nopigsnguruwe
dogs
mbwa Yes No Yes No
donkeys
punda Yes No Yes No
Yes No
Number of
 animals
another animal
mnyama mwingine
another animal
mnyama
mwingine
another animal
mnyama mwingine
6067256091
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7.10 Have you handled/had contact with the carcass/
carcasses of any wild animals in the past 12 months?
Je, umewahi kushika/ kugusa mzoga/ mizoga ya
wanyama wa wowote wa mwituni katika kipindi cha miezi
12 iliyopita?
If no, skip to 7.11 .If yes, complete table below.
Kama hapana, nenda swali 7.11.Kama ndio, kamilisha jedwali lifuatalo
Yes No
Past 12 monthsPast 30 days
another animal
wengineo
buffalo
nyati
wildebeest
nyumbu
zebra
pundamilia Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No Yes Noantelopeswala
Number of
 animals
7.11 Have you handled/prepared raw animal blood, meat or
offal in the past 12 months?
Katika kipindi cha miezi 12 iliyopita umeshika/ andaa
damu mbichi, nyama au nyama za ndani za wanyama?
Yes No
Yes No Yes No
Yes No Yes No
Yes No Yes No
Yes No Yes No
Past 30 days
Number of
 days (1-7)
Past 12
months
Cow
Ng'ombe
Goat
Mbuzi
Sheep
Kondoo
Another animal
Mnyama mwingine
If yes, complete the following table.If no, skip to next question.
Kama ndio, kamilisha jedwali lifuatalo. Kama hapana nenda swali linalofuata
7.12 Have you handled or prepared animal hides from any
animal in the past 12 months?
Katika kipindi cha miezi 12 iliyopita umeshika au kuandaa
ngozi za mnyama au wanyama wowote?
If yes, complete table below. If no, skip to next question.
Kama ndio, kamilisha jedwali lifuatalo. Kama hapana, uliza swali linalofuata.
Yes No
Yes No Yes No
Yes No Yes No
Yes No Yes No
Yes No Yes No
Past 30 days
Number of
 days (1-7)
Past 12
months
cow
ng'ombe
goat
mbuzi
sheep
kondoo
another animal
mwingineo
Yes No DK NA
Yes No DK NA
Yes No DK NA
If yes how many
Kama ndio, wangapi?
If yes how many
Kama ndio, wangapi?
If yes how many
Kama ndio, wangapi?
Sheep (Kondoo)
Goats (Mbuzi)
Cattle (Ng'ombe)
7.13 Have any of your family's livestock kept at your boma,
aborted or delivered still-born offspring in the last 12 months?
Kuna mfugo yoyote (ng’ombe, kondoo au mbuzi)
anayefugwa katika boma hili,ametoa/ameharibu mimba
au amezaa mtoto mfu katika miezi 12 iliopita?
If yes, indicate the number of abortions/ stillbirths in the last 12 months.
Record NA if that species is not kept at this boma
Kama ndio, ainisha idadi ya mimba zilizoharibika/ watoto waliozaliwa wafu
katika miezi 12 iliopita.
Jaza NA kama mnyama hafugwi katika boma hili
Yes No DK NA
If yes how many
Kama ndio, wangapi?
Other Animal (Mnyama mwingine)
7.14 Have any of your family's animals died in the past 30 days?
(do not include animals intentionally slaughtered)
Kuna yoyote kati ya mifugo ya familia yako imekufa katika
kipindi cha siku 30 zilizopita?
(usihusishe wanyama waliochinjwa)
Number adult
Idadi ya
wanyama
wakubwa
Number young
Idadi ya
wanyama
watoto
Yes No DK
Donkeys
Punda
Other specify/
Wengineo
Yes No DK
Yes No DK
Yes No DK
Yes No DK
Yes No DK
If yes, which animals and how many?
Kama ndio, wanyama wepi na wangapi?
If yes to 7.14, proceed to 7.15. If no, skip to SECTION 8
Kama ndio kwa swali 7.14, uliza 7.15. Kama hapana endelea
SEHEMU ya 8
Cow
Ng'ombe
Goat
Mbuzi
Sheep
Kondoo
2638256091
  180 
 
 
 
 
 
Page 10 of 11ZELS Brucella - Individual Questionnaire v1.0
SECTION 8: WATER USAGE
8.1 What is your primary source of drinking water in the dry & wet
seasons?
Chanzo kikuu cha maji ya kunywa kwa wanakaya katika kipindi
cha ukame na masika ni kipi?
Piped water into the home
Maji ya bomba nyumbani
Public/ communal well or standpipe
Kisima cha umma, bomba ya umma
River or creek (moving water) directly
Moja kwa moja kutoka katika mto au mfereji (maji yanayotembea)
Lake, pond, dam (standing water) directly
Moja kwa moja kutoka katika ziwa, dimbwi, au bwawa
 (maji yaliyosimama)
Private well or pump
Kisima au pampu binafsi
From a spring
Moja kwa moja kutoka katika chemchem
Rainwater
Maji ya mvua
Other (specify)
Vinginevyo (ainisha)
Dry season primary
source (select one)
Kiangazi, chanzo
kikuu
(chagua moja tu)
Wet season
primary source
Masika, chanzo
kikuu
(chagua moja tu)
Wet season, other
sources
Msimu wa mvua,
vyanzo vingine
Tanker truck
Gari la kubebea maji (boza)
Dry season, other
sources
Msimu wa ukame,
vyanzo vingine
Piped water near the home
Bomba ndani karibu na boma
8.2 Is your drinking water treated
(by filtering, boiling, chlorinating, straining, etc.)?
Huwa una tibu maji ya kunywa (kwa kuchuja, kuchemsha,
kuweka dawa ya klorine, kuchuja kwa nguo, nk)?
If yes, how frequently do you treat your household drinking water?
Kama ndio, mara ngapi una tibu maji ya kunywa katika kaya yako?
Always Sometimes Never DK
If always or sometimes, answer 8.3, otherwise skip to SECTION 9
Kama ni "kila wakati" au "muda kwa muda", jibu swali 8.3, vinginevyo
nenda SEHEMU ya 9.
Kila wakati Hatujafanya
chochote
Muda kwa muda Adding disinfectant, such
as chlorine or bleach
Kuweka dawa kama klorine/
bleach/water guard
8.3 How do you treat it? (choose all that apply)
Kama ndio, unatibu vipi ? (chagua yote yanayohusika)
Yes No
Other, specify/
Nyinginezo,
ainisha
Sedimentation and decant/
Kuacha kwa muda
yatwae/uchafu uende
chini
Filtering/
Kuchuja
Solar disinfection/
Kuweka juani
Strain it through a cloth/
Kuchuja kwa nguo
Boiling/ Kuchemsha
Sijui
7.15 Can you list the causes of death for your animals?
Unaweza kuorodhesha sababu ya vifo kwa wanyama wako?
0060256098
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SECTION 9: HOME
Hakuna choo wala kwenda porini
Flush or pour toilet with septic tank, including squat toilet
Flush or pour toilet connected to sewer pipe
Pit latrine with covering slab
Pit latrine without covering slab
Ventilated improved pit latrine (VIP)
Bucket or plastic bags
No facilites or field or bush
9.1 What type of toilet system do members of your home normally
use? (choose only one)
Ni aina gani ya mfumo wa choo ambao kwa kawaida unatumika
na wakazi wa nyumbani kwako? (chagua moja tu)
Choo cha kuchuchumaa, cha kumwaga maji na mfumo wa shimo la maji taka
Choo cha maji kilichounganishwa na bomba la maji taka
Choo cha shimo kilichosakafiwa
Choo cha shimo ambacho hakijasakafiwa (kisichosakafiwa)
Choo cha shimo bora chenye bomba la kutoa hewa chafu (VIP)
Ndoo au mifuko
9.2 Do you have electricity in your home?
Una umeme wowote nyumbani kwako?
If yes, ask question 9.3.  If no, skip to 9.4
Kama ndio, uliza swali 9.3. Kama hapana uliza swali 9.4
Yes No
Grid (Gridi)
Solar (Solar)
Generator (Jenerata)
Other (Mwingineo)
9.4 What type of energy sources are used for cooking in your home?
(primary and secondary sources)
Aina gani kuu (ya msingi) ya nishati inatumika kwa kupikia
nyumbani kwako?
Electricity/ Umeme
Gas/ Gesi
Kerosene/ Mafuta taa
Cow dung/
Kinyesi cha ng'ombe
Charcoal/ Mkaa
Other/ Nyinginezo
Other source (choose
all that apply)
Vyanzo vingine
(chagua yote
yanoyohusika)
Primary source
(choose one)
Chanzo cha
kudumu
(Chagua moja)
Firewood/ Kuni
9.3 What kind of electricity do you have?
Unatumia umeme wa aina gani?
Ox plough (Jembe la ng'ombe) Yes No
Ox cart (Mkokoteni wa ng'ombe) Yes No
Bicycle (Baiskeli) Yes No
Motorbike (Pikipiki) Yes No
Car (Gari) Yes No
Tractor (Trekta) Yes No
Mobile phone(Simu ya mkononi) Yes No
Radio (Redio) Yes No
Television (Luninga) Yes No
Sofa (Makochi) Yes No
Refrigerator (Jokofu au friji) Yes No
Bed net (Chandarua) Yes No
9.5 Do the members of this home (all combined) own any of the
following items? (choose all that apply)
Je, wakazi wa nyumba hii (wote pamoja) wanamiliki chochote
kati ya vitu vifuatavyo? (chagua yote yanayohusika)
Please enter 00 in the Number of units field for items that are not owned at this home
Tafadhali jaza 00 katika sehemu ya idadi ya namba kwenye sehemu ambayo vitu
hivyo havimilikiwi katika nyumba hii.
Number of
Unit
Ngapi?
If respondent is
Female:
Kama mhojiwa ni
mwanamke:
Are any of these items
yours personally?
Vitu vyote vyako?
Yes NoA Business (Biashara)
9.6 How many structures/ buildings including livestock bomas and
homes in total are in your boma?
Kuna idadi gani ya mifumo/ majengo, ikiwemo maboma ya mifugo
pamoja na idadi ya nyumba kwa ujumla katika boma lako?
Comments/ Maelezo:
5363256099
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TUMAINI UNIVERSITY MAKUMIRA 
KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE 
P. O. Box 2240, Moshi   Tel. 027-27-53909 
 
Brucellosis research in northern Tanzania 
Patient contact - Participant Information Sheet 
 
INTRODUCTION 
You are being invited to take part in this research study because a member of your household or 
village has been shown to have fever or a recent history of fever. Brucellosis is a disease that can 
cause fever and other symptoms and we are carrying out a research study on this disease. Before you 
decide if you want to take part in this study, it is important that you understand why the research is 
being done and what it will involve. Please read, or listen to, this information sheet and consent form 
carefully and take your time making your decision. As the study member discusses this consent form 
with you, please ask him/her to explain any words or information that you do not clearly understand. 
We encourage you to talk with your family and friends before you decide to take part in this study. 
The nature of the study, length of time it will take, risks and other important information about the 
study are listed below. If you agree to take part in this study, you will be asked to sign or add your 
thumbprint to this consent form. You will get a copy to keep. 
 
WHO IS DOING THIS RESEARCH? 
This research will be conducted by experts in human and animal health from Tanzania and the United 
Kingdom. Dr. V Maro and Prof J. A. Crump from the Kilimanjaro Christian Medical Centre; Dr 
Gabriel Shirima from Nelson Mandela African Institute of Science and Technology; and Dr Jo 
Halliday from University of Glasgow will lead the field research for this project, other team members 
will also be involved. The research is funded by the Department for International Development 
(DFID) and five research councils in the UK.  
 
WHAT IS THE PURPOSE OF THIS STUDY? 
You are being invited to take part in a research study to find out if animals in this area are carrying 
diseases that can also cause illness in people. In Tanzania, data collected by other studies has shown 
that brucellosis occurs in different types of animals (e.g., cattle, sheep and goats) and that brucellosis 
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is an important cause of disease in people. Brucellosis can be caused by several different types of 
Brucella bacteria. Each of these types of Brucella has different patterns of disease in animals. 
Information about which Brucella types are present in which animals in Tanzania is not well known. 
To develop plans for brucellosis control that are most likely to be effective and affordable, it is 
important to understand which animals are infected by which Brucella types, and which transmission 
routes are most important in transmitting brucellosis from animals to people. This three-year study 
will help to find out which Brucella types are found in different animal populations and what are the 
most important ways people become infected. The information collected will help develop control 
strategies and will help improve Brucella identification in Tanzania.  
 
WHY HAVE I BEEN CHOSEN?  
You have been invited to take part in this study because you or someone that you know has fever.  
Fever is one of the main signs of brucellosis. We would like to do some tests to find out if you do 
have or have ever had brucellosis. We expect that about 360 people will take part in this study. 
 
DO I HAVE TO TAKE PART?  
It is up to you to decide whether you do or do not take part in this study. Participation is voluntary. 
If you agree to take part in this study, you will be asked to sign, or add your thumbprint to this consent 
form. You will get a copy to keep. If you decide to take part, you are free to stop at any time and you 
do not need to give a reason for stopping. If you decide to stop taking part in this study your 
contributions to the study would be removed from any study outputs produced after the date that you 
stop taking part.  
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you decide to take part in this study you will be asked to allow a member of the project team to 
take blood for brucellosis testing. Up to 50cc of blood will be collected. The samples we collect, and 
tests we do, depend on whether you have fever currently. We will use the blood sample you give us 
to do tests for brucellosis and some other diseases including malaria. We will also use the sample to 
do more tests for brucellosis and other diseases at a later date. We will give you the results from 
some of these tests when they are available, if they tell us about current illness. We will not give you 
the results of all the tests that are done with your samples. All of these tests are free. You will also 
be asked to respond to some questions about you, your household and your health. It will take a few 
hours for us to collect samples and ask you some questions, and we will complete this either today 
or possibly in the next few days if there is not time to complete our questionnaire survey today. We 
would also like to return to your household in 4-6 weeks time so that we can collect a final blood 
sample for testing. You can choose to stop taking part at any time without any cost. 
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART IN 
THE STUDY? 
The collection of blood samples may cause some pain, bleeding or bruising where the needle enters 
the body. A small blood clot may form where the needle enters the body or there may be swelling in 
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the area. In a small number of people lightheadedness and fainting can also happen when a blood 
sample is collected.  
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART IN THIS STUDY? 
The study team will also provide you with information about brucellosis. The results of the whole 
project will help to improve medical care and identification of diseases in Tanzania. We hope that 
the information collected through this study will be used to control brucellosis and reduce the impact 
that this disease has on human and animal health in Tanzania.  
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY?  
The samples we collect will firstly be tested at Kilimanjaro Clinical Research Institute in Moshi. 
After this, more tests may be done at one of our partner institutions including the Animal and Plant 
Health Agency of the UK and University of Glasgow. We will store leftover samples after brucellosis 
testing so that they can be used for studies in the future. This may include studies of other diseases 
that cause fever. We do not plan to contact you with the results from tests done on stored samples. 
This is because the studies will most likely be performed many months or years after the samples 
were collected and the results would no longer be important for your treatment. The results from this 
study may be used by local and international institutions, responsible ministries, individuals and 
scientists.  
 
WILL MY INFORMATION BE KEPT CONFIDENTIAL? 
All information which is collected about you, or responses that you provide during the course of 
the research study will be kept strictly confidential. You will not be identified by name in the study 
records shared outside KCMC or the University of Glasgow. If study results are given to other 
researchers, you will be identified by a code number, and any information about you will have your 
name and address removed so that you cannot be recognised from it.  
 
WHAT ABOUT COMPENSATION? 
No compensation will be provided for your participation in this study. 
 
WHAT ARE MY RIGHTS AS A RESEARCH SUBJECT? 
Taking part in this study is completely voluntary. You may choose not to take part in this study. Your 
decision will not affect your ability to take part in other studies or result in the loss of any benefits 
that you are entitled to. 
 
WHO HAS REVIEWED THIS STUDY? 
This study has been approved by the Ethics Committees of KCMC, the Tanzanian National Institute 
of Medical Research (NIMR) and the University of Glasgow. 
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WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about this study contact: Dr Gabriel Shirima at 0763 973 003 or Dr Venance Maro at 
0754 581 444. For questions about this study, to discuss problems, concerns or suggestions related 
to the study or to ask for information about this study, contact the Kilimanjaro Christian Medical 
Centre Ethics Committee at 027 275 3909. You can also contact the National Health Research Ethics 
Committee at 022 212 1400. 
 
THANK YOU! 
On behalf of the project team we would like to thank you for agreeing to 
take part in this study 
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TUMAINI UNIVERSITY MAKUMIRA  
KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE 
P. O. Box 2240, Moshi   Tel. 027-27-53909 
Project Number: 
Participant Unique Identification Number: 
 
CONSENT FORM 
 
Brucellosis research in northern Tanzania - Participant (Adults) 
 
"The purpose of this study, what will happen to me and the risks and benefits have been explained 
to me. I have been allowed to ask questions, and I am satisfied with the answers I have received. I 
have been told who to contact if I have questions, to discuss problems, or suggestions related to the 
study, or to receive more information about the study. I have read (or had read) this information sheet 
and agree to take part in this research study, with the understanding that I may withdraw at any time. 
I have been told that I will be given a signed and dated copy of this consent form." 
Please initial or mark box 
 
I confirm that I have read (or had read) and understand the information sheet for 
________________ participants, dated __________(version _____ ) for the above study  
and have had the opportunity to ask questions. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time,  
without giving any reason, without my legal rights being affected. 
 
 
I agree to take part in the above study.       
 
 
           
Name of participant (print) Date Signature 
 
 
    
Study staff conducting consent (print) Date Signature 
 
 
   
Witness’ name (print) (As appropriate) Date Signature 
 
(1 copy for subject; 1 copy for researcher) 
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TUMAINI UNIVERSITY MAKUMIRA  
KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE 
P. O. Box 2240, Moshi   Tel. 027-27-53909 
Project Number: 
Participant Unique Identification Number: 
 
CONSENT FORM 
 
Brucellosis research in northern Tanzania – Participant (Minors) 
 
" The purpose of this study, what will happen to my child, and the risks and benefits have been 
explained to my child and me. I have been allowed to ask questions, and I am satisfied with the 
answers I have received. I have been told who to contact if I have questions, to discuss problems, or 
suggestions related to the study, or to receive more information about the study. I have read (or had 
read) this information sheet and agree for my child to take part in this research study, with the 
understanding that my child may withdraw at any time. I have been told that I will be given a signed 
and dated copy of this consent form." 
Please initial box 
I confirm that I have read (or had read) and understand the information sheet for 
________________ participants, dated __________(version _____ ) for the above study  
and have had the opportunity to ask questions. 
 
I understand that my child’s participation is voluntary and that we are free to withdraw at any time, 
without giving any reason or our legal rights being affected. 
 
 
I agree for my child to take part in the above study.       
 
 
Participant’s name (print): _________________________________ 
 
 
           
Child Assent (print) (As appropriate) Date Signature 
 
           
Parent or Legal Guardian name (print) Date Signature 
 
    
Study staff conducting consent (print) Date Signature 
 
   
Witness’ name (print) (As appropriate) Date Signature 
(1 copy for subject; 1 copy for researcher)  
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Appendix 4: Bovine brucellosis Bayesian latent class model 
sensitivity analysis diagnostic plots 
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Bovine model: Model with uniform prior set and 
conditional dependence 
 
 
Figure S4.1: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a bovine model under conditional 
dependence showing a uniform prior set* (grey bars) and posterior estimates 
(red bars) 
*uniform prior set: 
Se RBT ~ dbeta(1,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(1,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S4.2: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the bovine model with a uniform prior set and under 
conditional dependence, Se[1] is sensitivity of the Rose Bengal plate test 
(RBT), Se[2] is sensitivity of the competitive enzyme-linked immunosorbent 
assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, 
Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is specificity of 
RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and cELISA run in-
parallel, Sp_parallel is specificity of RBT and cELISA run in-parallel, covDn is 
covariance when animal is disease negative, covDp is covariance when animal is 
disease positive, p[1] is prevalence in a non-exclusive pastoralist population and 
p[2] is prevalence in an exclusive pastoralist population  
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Bovine model: Model with uniform prior set and 
conditional independence 
 
 
Figure S4.3: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a bovine model under conditional 
independence showing a uniform prior set* (grey bars) and posterior 
estimates (red bars) 
*uniform prior set: 
Se RBT ~ dbeta(1,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(1,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S4.4: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the bovine model with a uniform prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in aan exclusive 
pastoralist population 
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Bovine model: Model with relaxed prior set and 
conditional dependence 
 
Figure S4.5: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a bovine model under conditional 
dependence showing a relaxed prior set* (grey bars) and posterior estimates 
(red bars) 
*relaxed prior set: 
Se RBT ~ dbeta(7,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(30,2) 
Sp cELISA ~ dbeta(1,1) 
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Figure S4.6: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the bovine model with a relaxed prior set and under conditional 
dependence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, covDn is covariance when animal is 
disease negative, covDp is covariance when animal is disease positive, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population  
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Bovine model: Model with relaxed prior set and 
conditional independence 
  
Figure S4.7: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a bovine model under conditional 
independence showing a relaxed prior set* (grey bars) and posterior 
estimates (red bars) 
*relaxed prior set: 
Se RBT ~ dbeta(7,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(30,2) 
Sp cELISA ~ dbeta(1,1) 
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Figure S4.8: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the bovine model with a relaxed prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population 
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Bovine model: Model with strict prior set and 
conditional dependence 
 
Figure S4.9: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a bovine model under conditional 
dependence showing a strict prior set* (grey bars) and posterior estimates 
(red bars) 
*strict prior set: 
Se RBT ~ dbeta(8,1) 
Sp RBT ~ dbeta(7,1) 
Se cELISA ~ dbeta(102,3) 
Sp cELISA ~ dbeta(4,1) 
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Figure S4.10: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the bovine model with a strict prior set and under conditional 
dependence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, covDn is covariance when animal is 
disease negative, covDp is covariance when animal is disease positive, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population 
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Bovine model: Model with strict prior set and 
conditional independence 
 
Figure S4.11: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a bovine model under conditional 
independence showing a strict prior set* (grey bars) and posterior estimates 
(red bars) 
*strict prior set: 
Se RBT ~ dbeta(8,1) 
Sp RBT ~ dbeta(7,1) 
Se cELISA ~ dbeta(102,3) 
Sp cELISA ~ dbeta(4,1) 
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Figure S4.12: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the bovine model with a strict prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population 
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Appendix 5: Bayesian latent class model code: Bovine final 
model with conditional independence 
 
# Set up data for JAGS 
pop <- t(matrix(with(data, table(rbt, celisa, population), 
                     dnn=c("rbt", "celisa", "population")), 4,2)) 
n.pop = 2 
n = apply(pop,1,sum) 
 
# JAGS model 
# [1] is RBT 
# [2] is cELISA 
# Tests in order  -- / +- / -+ / ++ 
 
cat("model{ 
    for (i in 1:n.pop){ 
    pop[i, 1:4] ~ dmulti(par[i, 1:4], n[i]) 
    p[i] ~ dunif(0, 0.49) 
    par[i,4] <- p[i]*   Se[2] * Se[1] + (1-p[i])*(1-Sp[2])*(1-Sp[1]) #11 
    par[i,3] <- p[i]*(1-Se[2])* Se[1] + (1-p[i])*  (Sp[2])*(1-Sp[1]) #01 
    par[i,2] <- p[i]*   Se[2] * (1-Se[1]) + (1-p[i])*(1-Sp[2])*(Sp[1]) #10 
    par[i,1] <- p[i]*(1-Se[2])* (1-Se[1]) + (1-p[i])*  (Sp[2])*(Sp[1]) #00 
    } 
 
    Se[1] ~ dbeta(7,1) 
    Sp[1] ~ dbeta(1,1) 
    Se[2] ~ dbeta(30,2) 
    Sp[2] ~ dbeta(1,1) 
     
    # To get in-series and in-parallel Se and Sp 
    Se_series <- Se[1] * Se[2]  
    Se_parallel <- 1 - (1 - Se[1]) * (1 - Se[2])   
    Sp_series <- 1 - (1 - Sp[1]) * (1 - Sp[2])   
    Sp_parallel <- Sp[1] * Sp[2] 
     
    }", file="mod.jag") 
 
# Initial values for the three chains 
modelInit1 <- list(Se=c(0.4,0.99),  Sp=c(0.7,0.95),  p=c(0,0.1)) 
modelInit2 <- list(Se=c(0.3,0.98), Sp=c(0.5,0.9),  p=c(0.01,0.25)) 
modelInit3 <- list(Se=c(0.2,0.8),  Sp=c(0.3,0.99),  p=c(0.02,0.49)) 
INI <- list(modelInit1, modelInit2,modelInit3) 
 
# Compile model components 
  203 
M <- jags.model(data=list(pop=pop,n=n, n.pop=n.pop), inits=INI, n.chains=3, 
n.adapt= 50000, file="mod.jag") 
 
# Run the model with 50,000 burn-in and a further 250,000 iterations and 
thinning every 100th iteration 
R <- coda.samples(M, c("Se", "Sp", "p", "Se_series", "Se_parallel", "Sp_series", 
"Sp_parallel"), n.iter=250000, n.thin=100) 
 
# Check model deviance information criterion (DIC) 
dic.samples(M, n.iter=250000, n.thin=100, type="pD") 
 
# Check model convergence 
densityplot(R) 
gelman.diag(R, multivariate = FALSE) 
gelman.plot(R) 
traceplot(R) 
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Appendix 6: Ovine brucellosis Bayesian latent class model 
sensitivity analysis diagnostic plots 
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Ovine model: Model with uniform prior set and 
conditional dependence 
Figure S6.1: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a ovine model under conditional 
dependence showing a uniform prior set* (grey bars) and posterior estimates 
(red bars) 
*uniform prior set: 
Se RBT ~ dbeta(1,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(1,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S6.2: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the ovine model with a uniform prior set and under conditional 
dependence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, covDn is covariance when animal is 
disease negative, covDp is covariance when animal is disease positive, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population  
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Ovine model: Model with uniform prior set and 
conditional independence 
 
Figure S6.3: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a ovine model under conditional 
independence showing a uniform prior set* (grey bars) and posterior 
estimates (red bars) 
*uniform prior set: 
Se RBT ~ dbeta(1,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(1,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S6.4: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the ovine model with a uniform prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population  
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Ovine model: Model with relaxed prior set and 
conditional dependence 
  
Figure S6.5: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a ovine model under conditional 
dependence showing a relaxed prior set* (grey bars) and posterior estimates 
(red bars) 
*relaxed prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S6.6: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the ovine model with a relaxed prior set and under conditional 
dependence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, covDn is covariance when animal is 
disease negative, covDp is covariance when animal is disease positive, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population  
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Ovine model: Model with relaxed prior set and 
conditional independence 
 
Figure S6.7: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a ovine model under conditional 
independence showing a relaxed prior set* (grey bars) and posterior 
estimates (red bars) 
*relaxed prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(1,1) 
 
 
 
Se RBT
Fr
eq
ue
nc
y
0.0 0.2 0.4 0.6 0.8 1.0
0
50
15
0
25
0
35
0
Sp RBT
Fr
eq
ue
nc
y
0.0 0.2 0.4 0.6 0.8 1.0
0
50
15
0
25
0
35
0
Se cELISA
Fr
eq
ue
nc
y
0.0 0.2 0.4 0.6 0.8 1.0
0
50
15
0
25
0
35
0
Sp cELISA
Fr
eq
ue
nc
y
0.0 0.2 0.4 0.6 0.8 1.0
0
50
15
0
25
0
35
0
  212 
 
 
Figure S6.8: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the ovine model with a relaxed prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population  
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Ovine model: Model with strict prior set and 
conditional dependence 
 
Figure S6.9: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a ovine model under conditional 
dependence showing a strict prior set* (grey bars) and posterior estimates 
(red bars) 
*strict prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(2,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(104,1) 
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Figure S6.10: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the ovine model with a strict prior set and under conditional 
dependence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, covDn is covariance when animal is 
disease negative, covDp is covariance when animal is disease positive, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population  
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Ovine model: Model with strict prior set and 
conditional independence 
 
Figure S6.11: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a ovine model under conditional 
independence showing a strict prior set* (grey bars) and posterior estimates 
(red bars) 
*strict prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(2,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(104,1) 
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Figure S6.12: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the ovine model with a strict prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive pastoralist 
population  
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Appendix 7: Ovine final model diagnostic plots 
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Figure S7.1: Density plots for each parameter of the final ovine model, Se[1] 
is sensitivity of the Rose Bengal plate test (RBT), Se[2] is sensitivity of the 
competitive enzyme-linked immunosorbent assay (cELISA), Sp[1] is specificity of 
RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity of RBT and cELISA run 
in-series, Sp_series is specificity of RBT and cELISA run in-series, Se_parallel is 
sensitivity of RBT and cELISA run in-parallel, Sp_parallel is specificity of RBT 
and cELISA run in-parallel, covDn is covariance when animal is disease negative, 
covDp is covariance when animal is disease positive, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population 
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Figure S7.2: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the final ovine model, Se[1] is sensitivity of the Rose Bengal 
plate test (RBT), Se[2] is sensitivity of the competitive enzyme-linked 
immunosorbent assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of 
cELISA, Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is 
specificity of RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and 
cELISA run in-parallel, Sp_parallel is specificity of RBT and cELISA run in-
parallel, covDn is covariance when animal is disease negative, covDp is 
covariance when animal is disease positive, p[1] is prevalence in a non-exclusive 
pastoralist population and p[2] is prevalence in an exclusive pastoralist 
population
 220  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7.3: Trace plots showing MCMC chain convergence for each 
parameter of the final ovine model, Se[1] is sensitivity of the Rose Bengal 
plate test (RBT), Se[2] is sensitivity of the competitive enzyme-linked 
immunosorbent assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of 
cELISA, Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is 
specificity of RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and 
cELISA run in-parallel, Sp_parallel is specificity of RBT and cELISA run in-
parallel, covDn is covariance when animal is disease negative, covDp is 
covariance when animal is disease positive, p[1] is prevalence in a non-exclusive 
pastoralist population and p[2] is prevalence in an exclusive pastoralist 
population  
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Appendix 8: Bayesian latent class model code: Ovine final 
model with conditional dependence 
 
# Set up data for JAGS 
pop <- t(matrix(with(data, table(rbt, celisa, population), 
                     dnn=c("rbt", "celisa", "population")), 4,2)) 
n.pop = 2 
n = apply(pop,1,sum) 
 
# JAGS model 
# [1] is RBT 
# [2] is cELISA 
# Tests in order  -- / +- / -+ / ++ 
 
cat("model{ 
    for (i in 1:n.pop){ 
    pop[i, 1:4] ~ dmulti(par[i, 1:4], n[i]) 
    p[i] ~ dunif(0, 0.49) 
    par[i,4] <- p[i]*   (Se[2] * Se[1] + covDp) + (1-p[i])*((1-Sp[2])*(1-Sp[1]) + covDn)  
    par[i,3] <- p[i]* ((1-Se[2])* Se[1] - covDp) + (1-p[i])*((Sp[2])*(1-Sp[1]) - covDn)  
    par[i,2] <- p[i]*   (Se[2] * (1-Se[1]) - covDp) + (1-p[i])*((1-Sp[2])*(Sp[1]) - 
covDn) 
    par[i,1] <- p[i]* ((1-Se[2])* (1-Se[1]) + covDp) + (1-p[i])*((Sp[2])*(Sp[1]) + 
covDn) 
    } 
     
    ls <- (Se[1]-1)*(1-Se[2]) 
    us <- min(Se[1],Se[2]) - Se[1]*Se[2] 
    lc <- (Sp[1]-1)*(1-Sp[2]) 
    uc <- min(Sp[1],Sp[2]) - Sp[1]*Sp[2] 
    rhoD <- covDp / sqrt(Se[1]*(1-Se[1])*Se[2]*(1-Se[2])) 
    rhoDc <- covDn / sqrt(Sp[1]*(1-Sp[1])*Sp[2]*(1-Sp[2])) 
     
    Se[1] ~ dbeta(4,1) 
    Sp[1] ~ dbeta(1,1) 
    Se[2] ~ dbeta(7,1) 
    Sp[2] ~ dbeta(1,1) 
     
    # To get Serial and Parallel Ses and Sps 
    Se_series <- Se[1] * Se[2]  
    Se_parallel <- 1 - (1 - Se[1]) * (1 - Se[2])   
    Sp_series <- 1 - (1 - Sp[1]) * (1 - Sp[2])   
    Sp_parallel <- Sp[1] * Sp[2] 
    covDn ~ dunif(lc, uc) 
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    covDp ~ dunif(ls, us) 
     
    }", file="mod.jag") 
 
# Initial values for the three chains 
modelInit1 <- list(Se=c(0.7,0.99),  Sp=c(0.3,0.99),  p=c(0,0.1)) 
modelInit2 <- list(Se=c(0.3,0.8), Sp=c(0.15,0.7),  p=c(0.01,0.25)) 
modelInit3 <- list(Se=c(0.6,0.95),  Sp=c(0.4,0.90),  p=c(0.02,0.49)) 
INI <- list(modelInit1, modelInit2,modelInit3) 
 
# Compile model components 
M <- jags.model(data=list(pop=pop,n=n, n.pop=n.pop), inits=INI, n.chains=3, 
n.adapt= 50000, file="mod.jag") 
 
# Run the model with 50,000 burn-in and a further 250,000 iterations and 
thinning every 100th iteration 
R <- coda.samples(M, c("Se", "Sp", "p", "Se_series", "Se_parallel", "Sp_series", 
"Sp_parallel"), n.iter=250000, n.thin=100) 
 
# Check model deviance information criterion (DIC) 
dic.samples(M, n.iter=250000, n.thin=100, type="pD") 
 
# Check model convergence 
densityplot(R) 
gelman.diag(R, multivariate = FALSE) 
gelman.plot(R) 
traceplot(R) 
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Appendix 9: Caprine brucellosis Bayesian latent class model 
sensitivity analysis diagnostic plots 
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Caprine model: Model with uniform prior set and 
conditional dependence 
 
Figure S9.1: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a caprine model under conditional 
dependence showing a uniform prior set* (grey bars) and posterior estimates 
(red bars) 
*uniform prior set: 
Se RBT ~ dbeta(1,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(1,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S9.2: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the caprine model with a uniform prior set and under 
conditional dependence, Se[1] is sensitivity of the Rose Bengal plate test 
(RBT), Se[2] is sensitivity of the competitive enzyme-linked immunosorbent 
assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, 
Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is specificity of 
RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and cELISA run in-
parallel, Sp_parallel is specificity of RBT and cELISA run in-parallel, covDn is 
covariance when animal is disease negative, covDp is covariance when animal is 
disease positive, p[1] is prevalence in a non-exclusive pastoralist population and 
p[2] is prevalence in an exclusive pastoralist population  
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Caprine model: Model with uniform prior set and 
conditional independence 
 
Figure S9.3: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a caprine model under conditional 
independence showing a uniform prior set* (grey bars) and posterior 
estimates (red bars) 
*uniform prior set: 
Se RBT ~ dbeta(1,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(1,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S9.4: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the caprine model with a uniform prior set and under 
conditional independence, Se[1] is sensitivity of the Rose Bengal plate test 
(RBT), Se[2] is sensitivity of the competitive enzyme-linked immunosorbent 
assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, 
Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is specificity of 
RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and cELISA run in-
parallel, Sp_parallel is specificity of RBT and cELISA run in-parallel, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population  
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Caprine model: Model with relaxed prior set and 
conditional dependence 
  
Figure S9.5: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a caprine model under conditional 
dependence showing a relaxed prior set* (grey bars) and posterior estimates 
(red bars) 
*relaxed prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S9.6: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the caprine model with a relaxed prior set and under 
conditional dependence, Se[1] is sensitivity of the Rose Bengal plate test 
(RBT), Se[2] is sensitivity of the competitive enzyme-linked immunosorbent 
assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, 
Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is specificity of 
RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and cELISA run in-
parallel, Sp_parallel is specificity of RBT and cELISA run in-parallel, covDn is 
covariance when animal is disease negative, covDp is covariance when animal is 
disease positive, p[1] is prevalence in a non-exclusive pastoralist population and 
p[2] is prevalence in an exclusive pastoralist population 
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Caprine model: Model with relaxed prior set and 
conditional independence 
 
Figure S9.7: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a caprine model under conditional 
independence showing a relaxed prior set* (grey bars) and posterior 
estimates (red bars) 
*relaxed prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(1,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(1,1) 
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Figure S9.8: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the caprine model with a relaxed prior set and under 
conditional independence, Se[1] is sensitivity of the Rose Bengal plate test 
(RBT), Se[2] is sensitivity of the competitive enzyme-linked immunosorbent 
assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, 
Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is specificity of 
RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and cELISA run in-
parallel, Sp_parallel is specificity of RBT and cELISA run in-parallel, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population   
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Caprine model: Model with strict prior set and 
conditional dependence 
 
Figure S9.9: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a caprine model under conditional 
dependence showing a strict prior set* (grey bars) and posterior estimates 
(red bars) 
*strict prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(2,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(104,1) 
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Figure S9.10: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the caprine model with a strict prior set and under conditional 
dependence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, covDn is covariance when animal is 
disease negative, covDp is covariance when animal is disease positive, p[1] is 
prevalence in a non-exclusive pastoralist population and p[2] is prevalence in an 
exclusive pastoralist population  
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Caprine model: Model with strict prior set and 
conditional independence 
 
Figure S9.11: Frequency plots for sensitivity (Se) and specificity (Sp) 
parameters of the Rose Bengal plate test (RBT) and competitive enzyme-
linked immunosorbent assay (cELISA) for a caprine model under conditional 
independence showing a strict prior set* (grey bars) and posterior estimates 
(red bars) 
*strict prior set: 
Se RBT ~ dbeta(4,1) 
Sp RBT ~ dbeta(2,1) 
Se cELISA ~ dbeta(7,1) 
Sp cELISA ~ dbeta(104,1) 
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Figure S9.12: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the caprine model with a strict prior set and under conditional 
independence, Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is 
sensitivity of the competitive enzyme-linked immunosorbent assay (cELISA), 
Sp[1] is specificity of RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity 
of RBT and cELISA run in-series, Sp_series is specificity of RBT and cELISA run in-
series, Se_parallel is sensitivity of RBT and cELISA run in-parallel, Sp_parallel is 
specificity of RBT and cELISA run in-parallel, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population  
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Appendix 10: Caprine final model diagnostic plots 
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Figure S10.1: Density plots for each parameter of the final caprine model, 
Se[1] is sensitivity of the Rose Bengal plate test (RBT), Se[2] is sensitivity of the 
competitive enzyme-linked immunosorbent assay (cELISA), Sp[1] is specificity of 
RBT, Sp[2] is specificity of cELISA, Se_series is sensitivity of RBT and cELISA run 
in-series, Sp_series is specificity of RBT and cELISA run in-series, Se_parallel is 
sensitivity of RBT and cELISA run in-parallel, Sp_parallel is specificity of RBT 
and cELISA run in-parallel, covDn is covariance when animal is disease negative, 
covDp is covariance when animal is disease positive, p[1] is prevalence in a non-
exclusive pastoralist population and p[2] is prevalence in an exclusive 
pastoralist population 
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Figure S10.2: Gelman-Rubin diagnostic plots showing convergence for each 
parameter of the final caprine model, Se[1] is sensitivity of the Rose Bengal 
plate test (RBT), Se[2] is sensitivity of the competitive enzyme-linked 
immunosorbent assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of 
cELISA, Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is 
specificity of RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and 
cELISA run in-parallel, Sp_parallel is specificity of RBT and cELISA run in-
parallel, covDn is covariance when animal is disease negative, covDp is 
covariance when animal is disease positive, p[1] is prevalence in a non-exclusive 
pastoralist population and p[2] is prevalence in an exclusive pastoralist 
population 
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Figure S10.3: Trace plots showing MCMC chain convergence for each 
parameter of the final caprine model, Se[1] is sensitivity of the Rose Bengal 
plate test (RBT), Se[2] is sensitivity of the competitive enzyme-linked 
immunosorbent assay (cELISA), Sp[1] is specificity of RBT, Sp[2] is specificity of 
cELISA, Se_series is sensitivity of RBT and cELISA run in-series, Sp_series is 
specificity of RBT and cELISA run in-series, Se_parallel is sensitivity of RBT and 
cELISA run in-parallel, Sp_parallel is specificity of RBT and cELISA run in-
parallel, covDn is covariance when animal is disease negative, covDp is 
covariance when animal is disease positive, p[1] is prevalence in a non-exclusive 
pastoralist population and p[2] is prevalence in an exclusive pastoralist 
population 
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Appendix 11: Bayesian latent class model code: Caprine final 
model with conditional dependence 
 
# Set up data for JAGS 
pop <- t(matrix(with(data, table(rbt, celisa, population), 
                     dnn=c("rbt", "celisa", "population")), 4,2)) 
n.pop = 2 
n = apply(pop,1,sum) 
 
# JAGS model 
# [1] is RBT 
# [2] is cELISA 
# Tests in order  -- / +- / -+ / ++ 
 
cat("model{ 
    for (i in 1:n.pop){ 
    pop[i, 1:4] ~ dmulti(par[i, 1:4], n[i]) 
    p[i] ~ dunif(0, 0.49) 
    par[i,4] <- p[i]*   (Se[2] * Se[1] + covDp) + (1-p[i])*((1-Sp[2])*(1-Sp[1]) + covDn)  
    par[i,3] <- p[i]* ((1-Se[2])* Se[1] - covDp) + (1-p[i])*((Sp[2])*(1-Sp[1]) - covDn)  
    par[i,2] <- p[i]*   (Se[2] * (1-Se[1]) - covDp) + (1-p[i])*((1-Sp[2])*(Sp[1]) - 
covDn) 
    par[i,1] <- p[i]* ((1-Se[2])* (1-Se[1]) + covDp) + (1-p[i])*((Sp[2])*(Sp[1]) + 
covDn) 
    } 
     
    ls <- (Se[1]-1)*(1-Se[2]) 
    us <- min(Se[1],Se[2]) - Se[1]*Se[2] 
    lc <- (Sp[1]-1)*(1-Sp[2]) 
    uc <- min(Sp[1],Sp[2]) - Sp[1]*Sp[2] 
    rhoD <- covDp / sqrt(Se[1]*(1-Se[1])*Se[2]*(1-Se[2])) 
    rhoDc <- covDn / sqrt(Sp[1]*(1-Sp[1])*Sp[2]*(1-Sp[2])) 
     
    Se[1] ~ dbeta(4,1) 
    Sp[1] ~ dbeta(1,1) 
    Se[2] ~ dbeta(7,1) 
    Sp[2] ~ dbeta(1,1) 
     
    # To get Serial and Parallel Ses and Sps 
    Se_series <- Se[1] * Se[2]  
    Se_parallel <- 1 - (1 - Se[1]) * (1 - Se[2])   
    Sp_series <- 1 - (1 - Sp[1]) * (1 - Sp[2])   
    Sp_parallel <- Sp[1] * Sp[2] 
    covDn ~ dunif(lc, uc)  
  241 
    covDp ~ dunif(ls, us) 
     
    }", file="mod.jag") 
 
# Initial values for the three chains 
modelInit1 <- list(Se=c(0.7,0.99),  Sp=c(0.3,0.99),  p=c(0,0.1)) 
modelInit2 <- list(Se=c(0.3,0.8), Sp=c(0.15,0.7),  p=c(0.01,0.25)) 
modelInit3 <- list(Se=c(0.6,0.95),  Sp=c(0.4,0.90),  p=c(0.02,0.49)) 
INI <- list(modelInit1, modelInit2,modelInit3) 
 
# Compile model components 
M <- jags.model(data=list(pop=pop,n=n, n.pop=n.pop), inits=INI, n.chains=3, 
n.adapt= 50000, file="mod.jag") 
 
# Run the model with 50,000 burn-in and a further 250,000 iterations and 
thinning every 100th iteration 
R <- coda.samples(M, c("Se", "Sp", "p", "Se_series", "Se_parallel", "Sp_series", 
"Sp_parallel"), n.iter=250000, n.thin=100) 
 
# Check model deviance information criterion (DIC) 
dic.samples(M, n.iter=250000, n.thin=100, type="pD") 
 
# Check model convergence 
densityplot(R) 
gelman.diag(R, multivariate = FALSE) 
gelman.plot(R) 
traceplot(R) 
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